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Abstract 
The total synthesis of analogues of withanolide F I, a highly oxygenated C-28 steroidal 
lactone natural product isolated from the leaves of the plant Withania adpressa is discussed 
herein. Chapter 1 describes the classification of the withanolides, their biological activity 
and previous studies towards the synthesis of the withanolides. Based on well-established 
chemistry, commercially available pregnenolone II was transformed into the key aldehyde 
III in nine steps, two steps fewer than previously published routes, with an optimised 14% 
yield as summarised in Chapter 2 
 
Chapter 3 outlines the synthetic efforts towards the construction of the δ-lactone side chain 
in compound IV. The synthesis of 14,17-dideoxy-17-epi-withanolide F V was then 
completed via a straightforward acetylation-oxidation-elimination sequence from triol IV. 
Isomerisation of the 2,3-double bond delivered a novel analogue of withanolide F I,  
3,4-dihydro-Δ3,4-14,17-dideoxy-17-epi- withanolide F VI, as reported in Chapter 4. 
 
The development of new methodology to form δ-lactone side chain IX, a key structural 
feature of natural products I, V and VI, from cyclic sulfone VII via the heterocyclic 
lactone VIII based on the Dreiding-Schmidt reaction was investigated. Chapter 5 discusses 
the studies towards the synthesis of strategic sulfone VII. 
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Chapter 1. Introduction: Withanolide Natural 
Products. 
 
1.1. Withanolide F (1) 
1.1.1. Isolation and biological activity 
Withanolide F (1) (Figure 1i) is a natural compound first extracted in 1977 by Glotter and 
co-workers as a minor component of  Withania somnifera Dunal.
1 
It has also been 
extracted from other Withania species such as the aerial parts of Withania coagulans,
2 
and 
the leaves of Withania adpressa (Figure 1ii).
3 
This molecule presents interesting biological 
properties including strong immunosuppressive activity expressed as the inhibition of  
B- and T-cell proliferation on murine spleen cells (1.66 μM).4 Furthermore, withanolide F 
(1) exhibits potent cytotoxicity against Hep2 human cancer cell lines (4.4 μg/mL) 
reinforcing its potential as an antiproliferative agent and thus, its great interest in cancer 
chemotherapy.
5 
 
                                         
                                        i                                                                        ii 
Figure 1 i. Structure of withanolide F (1), ii. Withania species. 
 
1.1.2. Structural features and assignment 
The structural features and assignments of withanolide F (1) have been determined through 
1
H-NMR and 
13
C-NMR spectroscopy (in conjunction with COSY and HMBC 
experiments) together with IR, UV and mass spectrometry. This compound was described 
as a colourless solid with a melting point of 159-160 °C and UV (MeOH) maximum at  
226 nm which is characteristic for an α,β-unsaturated carbonyl chromophore. The 1H-NMR 
spectrum of withanolide F (1) showed three downfield signals at δ 5.79-5.74 (m), δ 6.88 
 2 
 
(ddd, J3,2 = 9.8 Hz, J3,4β = 4.9 Hz, J3,4α = 2.2 Hz) and δ 5.60-5.56 (m) representative of 
protons H-2, H-3 and H-6, respectively, and a downfield methine signal at δ 4.65 (dd,  
J22,23α  = 12.7 Hz, J22,23β = 3.6 Hz) representative of proton H-22 characteristic of the  
δ-lactone side chain.3 
 
1.2. Structurally Related Natural Products 
1.2.1. General overview of withanolides 
Withanolides are a class of natural compounds isolated from plants of the family 
Solanaceae which show a rich array of biological properties. More specifically, they are 
secondary metabolites of the genus Withania. From a structural point of view, the 
withanolides are characterised by a highly oxygenated A/B-ring system of a steroid 
skeleton which is based on an ergostane core structure. They are also distinguished by the 
presence of a δ-lactone side chain (Figure 2).6 
 
 
  Figure 2. Withanolide skeleton. 
 
1.2.2. Withanolide classification 
The core of these interesting molecules can occur in several modifications and 
withanolides extracted from different species present diverse differences, albeit some of 
them seem to follow common patterns for the A/B-ring substitution (Figure 3).
6
 
 3 
 
 
Figure 3. Common substitution patterns of the A/B-ring in withanolides. 
 
From the discovery of the first withanolide, isolated in 1965,
7
 to the end of 1989, almost 
170 different compounds were isolated and characterised.
8
 More recently, between 1996 
and 2010 another major investigation campaign was conducted during which over 360 new 
withanolides were identified.
8
 Considering the large number of molecules, it became 
necessary to establish an accurate classification of these compounds. Investigations on 
compounds extracted from Withania somnifera Dunal growing in Israel in 1968 by Glotter 
and Lavie led to the identification of three chemotypes, a chemically distinct entity within 
the same species, that helped classify the withanolides.
9
 The common structural features of 
these three new chemotypes are shown in Figure 4: 
- Chemotype I: 20-H withanolides (e.g.: Nic-11 (2)
10
). 
- Chemotype II: 20-OH and -oriented side chain withanolides (e.g.: withanolide G (3)11). 
- Chemotype III: 20-OH and α-oriented side chain withanolides (e.g.: withanolide S (4)1). 
 
 
Figure 4. Chemotype classification of withanolides. 
 
 
 4 
 
1.2.3. Withanolide bioactivity 
Recent studies have showed that embryonic patterning pathways, such as Wnt, Hh 
(Hedgehog) and Notch, play critical roles in human cancer. Inhibition of these pathways 
can lead to tumour cell proliferative arrest and death.
12
 Therefore, the investigation of 
natural small molecules that have anti-tumoural effects in vitro would be a promising 
therapeutic strategy in cancer treatment. Many natural compounds extracted from 
medicinal plants are an invaluable source of complex molecules with a number of 
pharmacological properties. Amongst them are withanolides which have been thoroughly 
studied since 1965 and highly appreciated for their biological activities including 
anticancer activity in vitro, antifeedant, immunosuppressive, antimicrobial and  
anti-inflammatory activities.
13
 Figure 5 shows a selection of structurally different 
withanolides exhibiting these diverse biological activities. 
 
 5 
 
 
Figure 5.  Examples of well-known withanolides and their biological properties. 
 
Furthermore, in vitro screening of cardiac glycosides, natural compounds that belong to the 
same plant steroids as withanolides, has produced strong inhibitors of Hh/Gli signalling 
pathway expressed in human pancreatic cancer cells (Figure 6).
12
 Interestingly, these two 
families of natural products present structural similarities, including a lactone side chain 
and the aglycone functionality, which might be helpful in future SAR studies. 
 6 
 
 
Figure 6.  Structure of cardiac glycoside 17 (14). 
 
Due to this broad spectrum of biological activity and their intriguing structural features, the 
investigation of withanolides would be a promising starting point in the development of 
new therapeutic agents. 
 
1.3. Biosynthesis 
The biogenetic aspects of withanolides have not been studied in detail and there is very 
little information on their biosynthesis. In 1976, Goodwin et al. suggested that  
24-methylene-cholesterol (15) could be a sterol precursor of withanolides based on studies 
using radiolabelled 24-methylene-cholesterol (15) which was incorporated into 
withanolides such as withaferin A (5) and withanolide D (6) (Figure 7).
23  
 
 
Figure 7. Structure of 24-methylene-cholesterol (15), withaferin A (5) and  
withanolide D (6). 
 
Based on crossbreeding studies by Lavie’s group in 1977,24 Garg and co-workers identified 
the ergostene diol 16 as a potential intermediate in the biosynthetic sequence leading to the 
 7 
 
formation of the side chain lactone of withanolides.
2
 Their biosynthetic proposal suggested 
that the appropriate hydroxylation of C-22 and C-26 and subsequent cyclisation would 
form the key lactol side chain 19 which has been reported to be present in various 
withanolides.
 
The final oxidation step of C-26 hydroxyl group would furnish the desired 
unsaturated δ-lactone side chain characteristic of withanolides (Scheme 1). 
 
 
Scheme 1. Proposed intermediates in the biogenesis of the δ-lactone side chain of the 
withanolides. 
 
In 1981, Lavie and co-workers proposed that a new withanolide 21, an analogue of 
withanolide E (7) extracted from Withania somnifera Dunal (Figure 8), could be a key 
intermediate in the biogenesis of the withanolides.
25
 This compound 21 was then submitted 
to biomimetic reactions involving the formation of a C-1-oxo derivative followed by the 
elimination of the C-3β hydroxyl group in order to build the 2-en-1-one substitution pattern 
of the A-ring, characteristic of various withanolides. By analogy with the synthetic 
sequence using 1α,3β-hydroxycholesterol developed by Ikekawa and co-workers in 1975,26 
the biomimetic synthesis began with the selective acetylation of the C-3β hydroxyl 
function of 21 to form monoacetate 22. The 1α-hydroxyl group of compound 22 was 
subsequently oxidised using Jones’ reagent followed by elimination of the 3β-acetate 23 
under alkaline conditions to afford 2,5-dien-1-one 24 (Scheme 2). Unfortunately, no yields 
were reported for these steps. 
 8 
 
 
Figure 8. Withania somnifera Dunal species. 
 
 
Scheme 2. Biomimetic synthesis of 2,5-dien-1one 24. 
 
Reagents and conditions: i. Ac2O, AcOH, 80 °C, 4 h, ii. CrO3, acetone, rt, iii. 1.5% aq. 
NaOH, 1,4-dioxane, rt, 6 h. 
 
Furthermore, Lavie’s group concluded that the presence of the δ-lactone side chain in the 
isolated compound 21 implied that the formation of the unsaturated side chain of 
withanolides in vivo occurred prior to the oxidation reactions of the A-ring.
25
 This 
interesting observation might be useful for the development of future synthetic methods.  
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1.4. Previous Total Synthesis of Withanolides 
Synthetic achievements on the withanolides have been mainly focused on the three  
well-known withanolides extracted from the Withania somnifera Dunal plant by Lavie  
et al. (Figure 9): the first withanolide isolated in 1965 was withaferin A (5) (chemotype 
I),
7
 followed by withanolide D (6) (chemotype II) isolated in 1968
9 
and
 
withanolide E (7) 
(chemotype III) isolated in 1972.
 27 
 
 
Figure 9. Well-known withanolides. 
 
1.4.1. The synthesis of withaferin A (5) 
The first stereoselective synthesis of withaferin A (5) was carried out by Ikekawa’s group 
and was based on their own previous work on the withanolides.
28
 Epoxide 26 was obtained 
from 3β-hydroxybisnorchol-5-enoic acid (25) in 5 steps in 7% yield and was converted 
into diethyl phosphonate 29, key precursor for the δ-lactone formation, via a 
bromoacetylation step followed by an Arbuzov reaction (Scheme 3). The subsequent 
intramolecular Wittig-Horner condensation allowed the synthesis of the desired δ-lactone 
side chain 30. The introduction of the hydroxymethyl group at C-25 was achieved using 
standard reaction conditions.  Thus, the δ-lactone moiety 31 was synthesised in 14% yield 
over 10 steps from carboxylic acid 25. The key step of this total synthesis was the  
allyl sulfoxide-sulfenate rearrangement of 6β-phenylthio-2,4-dienone 33. Hence, the 
rearrangement of the conjugated 2,4-dienone 33 under rigorous conditions, i.e. no oxygen 
and light, enabled the formation of the desired 4β-hydroxy-2,5-dien-1-one 35, in 52% yield 
which after further epoxidation gave (+)-withaferin A (5) in an overall 0.09% yield. 
 
 10 
 
 
Scheme 3. Synthesis of withaferin A (5). 
 
Reagents and conditions: i. 2-Me-1,3-dithiane, 
nBuLi, THF, −78 °C; ii. HgO, BF3•Et2O, rt 
(76% over two steps); iii. BrCH2COBr, pyridine, Et2O, 0 °C; iv. P(OEt)3, 100 °C,  
50 min; v. NaH, THF, rt, 30 min (79% over three steps); vi. m-CPBA, CHCl3;  
vii. TBDMSCl, imidazole, DMF; viii. PDC, DMF (49% over three steps); ix. PhSH, Al2O3, 
Et2O (37%); x. p-TsOH; H2O, benzene, 60 °C (100%); xi. m-CPBA, CHCl3; xii. excess 
P(OMe)3, MeOH, THF, rt, absence of light (52% of 35). 
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1.4.2. The synthesis of withanolide D (6) 
The first stereocontrolled synthesis of withanolide D (6) was reported in 1984 by Ikekawa 
and co-workers.
29
 The key steps of the synthesis were similar to those discussed for 
Ikekawa’s synthesis of withaferin A (5) (Scheme 3) such as the functionalisation of the 
A/B-ring. The construction of the side chain of withanolide D (6) involved a 
stereocontrolled γ-coupling reaction of a lithium enolate with protected 20-hydroxy-22-
aldehyde 40 (Scheme 4).
30
 The latter 40 was prepared from commercially available 
pregnenolone (36) in 11 steps in 10% yield via an interesting Birch reduction using 
unusual conditions (lithium metal and ammonium chloride in THF) developed by Barton 
and co-workers in 1973.
31
 The key step of the synthesis was the installation of the  
δ-lactone 41 achieved in very good yield via an interesting aldol condensation method. 
Subsequent modifications of the A/B-ring system allowed the formation of epoxyketone 42 
in 45% yield over four steps. The concluding part of the synthesis, which followed the 
sequence of reactions described in step vii to xii in Scheme 3 enabled the formation of  
(+)-withanolide D (6) in an overall 0.96% yield from pregnenolone (36). 
 
 12 
 
 
Scheme 4. Synthesis of withanolide D (6). 
 
Reagents and conditions: i. NaBH4, MeOH, THF, 0 °C, 40 min; ii. DDQ, 1,4-dioxane, 
reflux, 8 h; iii. DHP, p-TsOH, CH2Cl2, rt, 3 h; iv. H2O2 (30% w/w), 10% NaOH in MeOH, 
MeOH, 15 °C, overnight (51% over four steps); v. Li/NH3, NH4Cl, THF, −40 °C, 4 h 
(76%); vi. 1) MOMCl, diethylcyclohexylamine, 1,4-dioxane, reflux, 6 h, 2) 2 M aq. HCl, 
MeOH, rt, 2 h (60%); vii. PCC, NaOAc, CH2Cl2, rt, 3 h (80%); viii. 1,3-dithiane, 
n
BuLi, 
THF, −5 °C, 8 h (78%); ix. HgO, BF3•Et2O, aq. THF, reflux, 30 min; x. MOMCl,  
diethylcyclohexylamine, 1,4-dioxane, reflux, 8 h (69% over two steps); xi. ethyl  
2,3-dimethylbut-2-enoate, LDA, THF/DMPU, − 78 °C, 6 h (86%) ; xii. 6 M aq. HCl, THF, 
rt, 3 h ; xiii. TBSCl, imidazole, DMF, rt, 1 h; xiv. m-CPBA, CH3Cl, −5 °C, 40 min;  
xv. PDC, DMF, −5 °C, 8 h (45% over four steps). 
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1.4.3. The synthesis of withanolide E (7) 
(+)-Withanolide E (7) was first synthesised in 1991 by Grieco and Medrano using a  
hetero-Diels-Alder reaction between benzyl nitrosoformate and dienol acetate 44 as the 
key step.
32
 This strategy enabled the introduction of the correct stereochemistry at the C-14 
position, i.e. an α-hydroxyl group. Diacetate 43 was first converted into a silyl enol ether 
following Miller’s procedure,33 and was then transformed into dienol acetate 44 via a 
Saegusa reaction and by exposure to isopropenyl acetate (Scheme 5).
34 
Compound 44 was 
then treated with benzyl nitrosoformate to undergo a 1,4-cycloaddition and allowed the 
formation of the isomeric cycloadducts 45α and 45β in a 2:1 ratio. The minor adduct 45β 
was converted into the desired adduct 45α via brief refluxing in toluene. Thus, cycloadduct 
45α was synthesised in an overall 85% yield. Once the stereochemistry of the C-14 
hydroxyl group was established, the synthesis focused on establishing the β-configuration 
of the C-17 hydroxyl group which proved to be less simple than expected. To address the 
difficulties of this strategy, the (17Z)-ethylidene steroid 48, obtained from ketone 47 in 
85% yield over two steps, was treated with osmium tetroxide to afford a 1.4:1 mixture of 
glycols 49α and 49β which were readily separated by column chromatography on silica.  
A straightforward route was proposed to complete the functionalisation of the A/B-ring 
and the construction of the side chain lactone 52 through a similar aldol type reaction as 
used in the total synthesis of withanolide D (6) (Scheme 4) allowing the synthesis of  
(+)-withanolide E (7) in a 2.4% overall yield over 25 steps. 
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Scheme 5. Synthesis of withanolide E (7). 
 
Reagents and conditions: i. TMSI, (TMS)2NH, Et3N, ClCH2CH2Cl, −23 °C, 45 min;  
ii. Pd(OAc)2, K2CO3, CH3CN, 12 h; iii. 
i
PrOAc, TsOH, reflux (86% over three steps); 
 iv. benzyl nitrosoformate; v. toluene, reflux (85% over two steps); vi. H2, 5% Pd-Ba2SO4, 
EtOH, 3 h; vii. 1) CuCl2•2H2O, H2O, THF, 4 h (79% over two steps), 2) 5% KOH, MeOH, 
reflux, 2 h (100%); viii. TsCl, pyridine, 12 h; ix. TBSOTf, Et3N, CH2Cl2, 0 °C. 30 min;  
x. KOAc, MeOH, reflux, 12 h; xi. TBAF, THF, 4 d (50% over four steps);  
xii. Ph3PCHCH3, THF; xiii. MOMCl, 
i
Pr2NEt, dioxane, 80 °C, sealed tube (85% over two 
steps); xiv. OsO4, pyridine (80%); xv. TFAA, DMSO, Et3N, CH2Cl2, −78 °C, 1.5 h (89%); 
xvi. CH2CHLi, THF, −78 °C, 1 h (97%); xvii. MOMCl, 
i
PrNEt2, dioxane, 90 °C, 24 h, 
sealed tube; xviii. 1) O3, MeOH, −100 °C, 2) Me2S, 30 min (70%);  
xix. ethyl 2,3-dimethylbut-2-enoate, LDA, THF/HMPA, −78 °C to rt, 1.5 h (86%). 
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1.4.4. The synthesis of withanolide A (8) 
It was only recently (2011) that the first total synthesis of withanolide A (8) was reported 
by Gademann and co-workers (Scheme 6).
35
 They observed that the -unsaturated 
ketone in the A-ring was a chemically sensitive fragment towards lactonisation reaction 
conditions whereas the -lactone side chain and the hydroxyepoxide in the B-ring were 
considerably more stable functionalities of the molecule. The main features of the synthetic 
strategy were a singlet-oxygen ene reaction and a Wharton carbonyl transposition. The 
synthesis started with pregnenolone (36), also used as precursor in the synthesis of 
withanolide D (6), as a cheap and commercially available reagent. The first five steps of 
the reaction sequence served to stereoselectively construct the -lactone side chain in 49% 
yield using the same vinylogous aldol condensation method as developed by Ikekawa for 
the synthesis of withanolide D (6).
30
 The next key step was the regioselective introduction 
of the hydroxyepoxide moiety in the B-ring. This was achieved by a singlet-oxygen-
mediated photooxygenative olefin migration that led to the formation of an allylic tertiary 
alcohol 57 which was in turn submitted to stereoselective epoxidation conditions forming 
the epoxyalcohol 58 in 61% yield.
36
 The required enone functionality in the A-ring was 
established via treatment of triol 58 with IBX under optimised conditions developed by 
Nicolaou and co-workers.
37
 Further epoxidation of enone 59 enabled the synthesis of the 
diepoxide 60 in good yield (60%). The next key step of the synthesis was the Wharton 
carbonyl transposition which allowed the conversion of epoxy ketone 60 into the rather 
sensitive -unsaturated ketone functionality of the molecule.38 Thus, (+)-withanolide A 
(8) was synthesised in 14 steps in a 4.5% overall yield. 
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Scheme 6. Synthesis of withanolide A (8). 
 
Reagents and conditions: i. TBSCl, imidazole, THF, rt, (98%); ii. 1,3-dithiane, 
n
BuLi, 
THF, −78 °C to rt (84%); iii. NCS, CH2Cl2, rt (73%); iv. MOMCl, NaI, DIPEA, DME, 
reflux (94%); v. ethyl 2,3-dimethylbut-2-enoate, LiHMDS, THF/DMPU, −78 °C to rt 
(87%); vi. HCl, THF/H2O, rt (87%); vii. O2, TPP, hγ 589 nm, pyridine, PPh3, rt (61%); 
viii. m-CPBA, CH2Cl2, 0 °C to rt (96%); ix. HCl, THF/H2O, rt (80%); x. TPAP, NMO, 
CH2Cl2, rt (95%); xi. IBX, MPO, DMSO, 40 °C (81%); xii. H2O2, triton B, THF, 0 °C 
(60%); xiii. N2H4•HCl, Et3N, 0 °C to rt (62% over two steps); xiv. PDC, CH2Cl2, rt (80%). 
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1.5. Structure Activity Relationship (SAR) Studies 
In recent years, investigation of the bioactivity of the withanolides in diverse biological 
fields led to speculations about the structure-activity relationship of these complex 
molecules. In 2003, Nair and co-workers showed that the presence of an  
α,β-unsaturated δ-lactone side chain was critical for the selective inhibition of the  
COX-2 enzyme.
39
 Another interesting observation was that the 2-en-1-one and the  
5β,6β-epoxy functionalities had a positive influence on some biological properties such as 
the cytotoxicity and the cell differentiation induction (Figure 10).
39
 
 
 
Figure 10. Pharmacophoric features for different bioactivities of withanolides. 
 
In 2009, studies on the inhibition of T- and B-cell proliferation by withanolides and 
withacoagulins extracted from Withania coagulans resulted in important conclusions 
regarding the SAR (Figure 11).
4
  
 
 
Figure 11. Withania coagulans Dunal species. 
 
Thus, comparisons of the bioactivities of these compounds outlined the following 
interesting suggestions (Figure 12): 
 Withanolides with a 2,5-dien-1-one functionality in the A/B-ring showed stronger 
activities than their 3,5-dien-1-one isomers. 
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 The presence of the 17β-hydroxyl group increases the inhibition of T-cell 
proliferation. 
 The presence of a methyl group at the C-27 position enhances the bioactivity 
compared to withanolides with a CH2OH functionality at the same carbon. 
 The 15α-hydroxyl group lowers the bioactivity. Whereas the 14α-hydroxyl 
functionality did not show any significant effect in the activity of withanolides. 
 
 
Figure 12. SAR of withanolides. 
 
1.6. Project Aims 
Although withanolide F (1) may be considered a direct precursor of withanolide E (7), to 
date there have been no reported syntheses of withanolide F (1) in the literature.  
The investigation of analogues of this compound would not only enable a better evaluation 
of its biological activity but also facilitate the development of the total synthesis of 
withanolide F (1). 
In the course of our synthetic studies towards the framework of the steroid withanolide F 
(1) and taking into consideration the prior SAR evaluation of withanolides (Figure 13i), 
we became interested in the influence of the C-14 and the C-17 hydroxyl groups and the 
stereochemistry of the C-17 side chain on the biological activity. In order to develop 
synthetic access to these structures, we set molecule 24 lacking these hydroxyl groups and 
with a β-orientated side chain at C-17 as our first target (Figure 13ii).  
 
 19 
 
                                                                                                             
                                i                                                                                              ii 
Figure 13 i. SAR evaluation of withanolide F (1), ii. Structure of 14,17-dideoxy-17-epi-
withanolide F (24). 
 
The target molecule named 14,17-dideoxy-17-epi-withanolide F (24) is known and was 
isolated from Withania coagulans Dunal plant by Choudhary et al. in 2003.
40
 The structure 
was determined through 
1
H-NMR and 
13
C-NMR spectroscopy together with mass 
spectrometry. Key features included three downfield signals at δ 5.85 (dd, J2,3 = 9.8 Hz,  
J2,4 = 3.0 Hz), 6.74 (m) and 5.58 (br d, J6,7 = 6.0 Hz) which represented three protons H-2, 
H-3 and H-6, respectively, and a downfield signal at δ 4.20 (dd, J22,23α = 13.2 Hz,  
J22,23β = 3.4 Hz) which was assigned to H-22 methine proton of the δ-lactone side chain.
   
As previously mentioned, 14,17-dideoxy-17-epi-withanolide F (24) has been synthesised 
by Lavie et al. in 1981 in three steps from triol 21 via a biomimetic synthesis which 
included a acetylation-oxidation-elimination sequence (Scheme 2).
25
 Unfortunately, no 
yields and details on the scale and the reproducibility of this synthesis were reported in the 
literature.
 
Moreover, during the course of our research, the formation of the δ-lactone side chain of 
the target system revealed to be more challenging than expected given the extensive 
successful work previously published towards its synthesis. Therefore, this synthetic 
challenge required to develop a new method to build the δ-lactone side chain, a key 
structural feature characteristic of withanolides. 
Thus, the core project aims were as follow: 
(i) to synthesise 14,17-dideoxy-17-epi-withanolide F (24). 
(ii) to devise a new method towards the construction of δ-lactone side chain and apply it to 
the total synthesis of analogues of withanolide F (1). 
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Chapter 2. Synthesis of the Key Aldehyde for 
Withanolide Synthesis. 
 
2.1. Retrosynthesis of 14,17-Dideoxy-17-Epi-Withanolide F (24) 
As previously discussed, the synthesis of target compound 24, an analogue of withanolide 
F (1) lacking the C-14 and C-17 hydroxyl functionalities and with an inverted 
configuration at C-17, was targeted to develop a general synthetic access to the core 
structure of withanolide F (1). The retrosynthesis of the 14,17-dideoxy-17-epi-withanolide 
F (24) was based on established chemistry on structurally related withanolides and in 
particular the syntheses of withanolide D (6)
29
 and withanolide E (7).
32 
From a 
retrosynthetic point of view, enone 24 can be obtained by selective acetylation of the  
C-3 hydroxyl group and oxidation of the C-1 hydroxyl functionality of diol 21, followed 
by the selective elimination of the C-3 acetyl group.  
 
 
Scheme 7. Proposed retrosynthesis of 14,17-dideoxy-17-epi-withanolide F (24) via key 
aldehyde 40. 
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The retrosynthetic strategy relies on the formation of the -lactone side chain of compound 
21 via a nucleophilic attack of a lithium enolate on the key aldehyde 40. In turn, aldehyde 
40 was envisioned to arise from ketone 61 via a Corey-Seebach reaction. Finally, diol 61 
could be accessed from commercially available pregnenolone (36) via a key Birch 
reduction step (Scheme 7). 
 
2.2. Oxidation of the A/B-Ring System: Literature Routes 
The withanolides differ from other natural polyhydroxysteroids having the δ-lactone side 
chain and complex functional groups on the A/B-ring system. Therefore, the synthesis of 
such complex structures necessitated the development of new synthetic methods for 
establishing those particular functionalities of the A/B-ring of the withanolides. 
 
2.2.1. 5β,6β-Epoxy-1-oxo-2-en-4β-ol: literature examples 
Initial studies towards the modification of the A/B-ring focused on the synthesis of the 
5β,6β-epoxy-1-oxo-2-en-4β-ol fragment common to various withanolides, including 
withaferin A (5) and withanolide D (6). As part of studies towards the development of new 
synthetic methods, model compounds based on cholesterol (74) were used by Ikekawa’s 
group. They synthesised a cholestane derivative possessing the same epoxide and  
quinoid-like moiety in the A/B-ring.
41 Appropriate modifications of 6β-acetoxy-1α,2α-
epoxycholestan-3-one (62) via the sequence of reactions shown in Scheme 8 afforded 
5β,6β-epoxy-1-oxo-cholest-2-en-4β-ol (66) in 26% yield over 9 steps.  
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Scheme 8. Synthesis of 5β,6β-epoxy-1-oxo-cholest-2-en-4β-ol (66). 
 
Reagents and conditions: i. N2H4; ii. CrO3; iii. KOH; iv. POCl3, pyridine (45% over four 
steps); v. m-CPBA (69% of 64β and 25% of 64α); vi. NaOH (97%); vii. MsCl, NaHCO3-
pyridine; viii. OsO4, NaOH (85%). 
 
An alternative synthesis of related cholestane derivatives was developed by Weissenberg 
and co-workers which started from 1α,2α-epoxycholestan-4-en-3-one (67) and allowed the 
formation of the 5β,6β-epoxy-1-oxo-cholest-2-en-4β-ol (66) in 10 steps in a 53% overall 
yield (Scheme 9).
42 
 
 
Scheme 9. Alternative synthesis of 5β,6β-epoxy-1-oxo-cholest-2-en-4β-ol (66). 
 
Reagents and conditions: i. H2, 5% Pd-CaCO3 (100%); ii. LiAlH4; iii. PhCO3H; iv. Ac2O, 
pyridine; v. CrO3; vi. Al2O3 (70% over five steps); vii. H2SO4, AcOH; viii. Ac2O, pyridine, 
(75% over two steps); ix. SOCl2; x. Ba(OMe)2; xi. PhCO3H (100% over three steps). 
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2.2.2. 1α,3β-Dihydroxy-5-pregnene system: literature examples 
1α,3β-Dihydroxy-5-pregnene systems were key intermediates in numerous total syntheses 
of various natural products. The synthetic strategy was first established by Barton et al. 
during their studies towards the synthesis of 3β-hydroxy-vitamin D3 (77).
31
 It involved the 
oxidation of the A/B-ring to the corresponding 1,4,6-trien-3-one followed by epoxidation 
under alkaline conditions which led to the formation of 1α,2α-epoxycholesta-4,6-dien- 
3-one (67) in poor yield (45% over two steps). The synthesis relied on the key Birch 
reduction step using a large excess of lithium metal in liquid ammonia to afford the desired 
1α,3β-dihydroxy-5-pregnene structure (75) in an acceptable 60% yield (Scheme 10).  
 
 
Scheme 10. Synthesis of 3β-hydroxyl-vitamin D3 (77). 
 
Reagents and conditions: i. DDQ, 1,4-dioxane, reflux; ii. H2O2 (30% wt), 10% NaOH in 
MeOH, MeOH, 15 °C, overnight (45% over two steps); iii. Li/NH3, NH4Cl, THF, −40 °C, 
(60%); iv. Ac2O, DMAP, pyridine, rt; v. DBDMH, hexane; vi. (MeO)3P, xylene, reflux, 
(34% over three steps). 
 
In 1984, Ikekawa’s group applied this previously described method in the synthesis of 
withanolide D (6), a natural product structurally related to our target 24.
29
 Thus,  
1,4,6-trien-3-one 78 was obtained from commercially available pregnenolone (36) by 
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oxidation of the A/B-ring system using DDQ in 61% yield. The next steps included 
protecting the C-20 hydroxyl with a THP group and epoxidation of the 1,2-double bond of 
the A-ring using hydrogen peroxide. In turn, 1α,2α-epoxy-4,6-dien-3-one 37 was reduced 
using Birch reduction conditions previously developed by Barton and co-workers and 
allowed the synthesis of the key 1α,3β-dihydroxy-5-pregnene 38 in very good yield (76%) 
(Scheme 11).  
 
 
Scheme 11. Synthesis of withanolide D (6). 
 
Reagents and conditions: i. NaBH4, MeOH, THF, 0 °C, 40 min; ii. DDQ, 1,4-dioxane, 
reflux, 8 h (61% over two steps); iii. DHP, p-TsOH, CH2Cl2, rt, 3 h; iv. H2O2 (30% wt), 
10% NaOH in MeOH, MeOH, 15 °C, overnight (83% over two steps); v. Li/NH3, NH4Cl, 
THF, −40 °C, 4 h (76%); vi. 1) MOMCl, diethylcyclohexylamine, 1,4-dioxane, reflux, 6 h, 
2) 2 M aq. HCl, MeOH, rt, 2 h (60%); vii. PCC, NaOAc, CH2Cl2, rt, 3 h (80%). 
 
During their work on the total synthesis of (25R)-ruscogenin (83), Liu et al. reported that 
the key Birch reduction required carefully controlled reaction conditions in order to avoid 
side products such as Δ6-1α,3β-diol (Scheme 12).43 Later, inspired by Liu’s work, Saito 
and co-workers showed during their studies towards the synthesis of an analogue of 
vitamin D that performing the Birch reduction with sodium in liquid ammonia, instead of 
lithium, led to a mixture of the desired 1α,3β-diol 81 and its C-3 α-epimer in a  
9:1 ratio in favour of the 1α,3β-diol 81.44 
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Scheme 12. Synthesis of (25R)-ruscogenin (83). 
 
Reagents and conditions: i. DDQ, 1,4-dioxane, reflux, 8 h; ii. H2O2 (30% wt), NaOMe, 
MeOH, rt, overnight (47% over two steps); iii. Li/NH3, NH4Cl, THF, −40 °C, 3 h;  
iv. TBSCl, imidazole, DMF, rt, overnight (53% over two steps); v. PDC, CH2Cl2, rt, 1 h;  
vi. NaBH4, THF, 6 h (64% over two steps); vii. 5 M HCl, acetone, rt, 1 h (96%). 
 
This method to install the 1α,3β-dihydroxy-5-pregnene functionality in the A/B-ring 
system was  also applied by El Sheik et al. in the synthesis of cyclocitrinols, another class 
of natural products characterised by a steroid core structure and a unique 
bicyclo[4.4.1]undecane A/B-ring system  (Scheme 13).
45 
They observed that during the 
Birch reduction step, the reaction temperature should not be re-cooled to −78 °C after 
addition of the epoxide 85 as suggested in previously reported procedures, in order to 
avoid the formation of 1α-hydroxyl-4,5-en-3-one as the major product of the reaction. 
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Scheme 13. Synthesis of cyclocitrinol 16 (87). 
 
Reagents and conditions: i. (CH2OH)2, TsOH, benzene, reflux; ii. DDQ, 1,4-dioxane, 
reflux, 8 h (56% over two steps); iii. H2O2 (30% wt), 10% NaOH in MeOH, MeOH, 10 °C, 
overnight (68%); iv. Li/NH3, NH4Cl, THF, −40 °C, 4 h; v. Ac2O, DMAP, pyridine, rt;  
vi. TsOH, H2O, THF, rt (56% over three steps). 
 
2.3. Oxidation of the A/B-Ring System: Results and Discussion 
2.3.1. 1α,3β-Dihydroxy-5-pregnene system: initial synthetic route 
We devised a first retrosynthetic route for the synthesis of the key 1α,3β-dihydroxy- 
5-pregnene (61) intermediate based on precedent published by Ikekawa et al. in their total 
synthesis of withanolide D (6) (Scheme 14).
29 
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Scheme 14. Proposed retrosynthesis of 1α,3β-dihydroxy-5-pregnene (61) via THP 
protection. 
 
As shown in Scheme 15, commercially available pregnenolone (36) was first reduced 
using sodium borohydride to form diol 90 in quantitative yield as an inseparable mixture of 
two diastereoisomers at C-20, which was subsequently oxidised with DDQ to afford 
trienone 89 in poor yield (38%) compared to the published yield (61%).
29
 This modest 
yield may in part be due to the purification which included two column chromatography 
steps in order to properly purify the trienone 89. The published procedure also suggested to 
purify the crude mixture by column chromatography twice, first on alumina and then on 
silica gel, but in our hands this led to substantial loss of material.
45
 Next, the C-20 alcohol 
89 was protected as its THP ether giving an inseparable mixture of four diastereoisomers at 
C-20 and C-22 (78). The crude mixture was exposed to alkaline hydrogen peroxide to 
provide stereoselectively the α-epoxide 37 as another mixture of four diastereoisomers at 
C-20 and C-22 in poor yield (30%) compared to the 86% yield reported by Ikekawa’s 
group in the literature.
29
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Scheme 15. Initial synthetic route to epoxide 37.  
 
Reagents and conditions: i. NaBH4, MeOH, THF, 0 °C, 40 min; ii. DDQ, 1,4-dioxane, 
reflux, 8 h (38% over two steps); iii. DHP, p-TsOH, CH2Cl2, rt, 3 h (86%); iv. H2O2  
(30% w/w), 10% NaOH in MeOH, MeOH, 15 °C, 12 h (30%). 
 
The presence of a doublet at δ 3.70 (J1,2 = 4.3 Hz) and a doublet doublet at δ 3.38  
(J2,1 = 4.3 Hz and J2,4 = 2.0 Hz) in the 
1
H-NMR spectrum attributed to H-1 and H-2, 
respectively, supported the assigned structure of the epoxide in the A-ring. Furthermore, 
the “W-coupling” between H-2 and H-4 protons (4J = 2.0 Hz) confirmed the  
α-configuration of the epoxide 37 (Figure 14). These 1H-NMR data are consistent with 
those previously reported in the literature.
29 
 
 
Figure 14. “W-coupling” between H-2 and H-4 of epoxide 37. 
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2.3.2. 1α,3β-Dihydroxy-5-pregnene system: revised synthetic route 
A thorough examination of the synthetic strategy led to the conclusion that changing the 
protected C-20 hydroxyl functionality to a ketal would allow access to the key intermediate 
1α,3β-diol 61 in two steps fewer than the previously published synthesis by Ikekawa  
et al. (Scheme 14).
29
 Furthermore, this route avoids the problematic formation of mixtures 
of inseparable diastereoisomers. With this in mind, a new synthetic route was designed 
(Scheme 16). 
 
 
Scheme 16. Revised retrosynthesis of 1α,3β-dihydroxy-5-pregnene (61) via ketal 
protection. 
 
Based on work by El Sheik et al. described in Scheme 13,
45
 the C-20 ketal 93 was 
synthesised by protection of commercially available pregnenolone (36) with ethylene 
glycol under standard conditions.
 
Subsequently, oxidation using DDQ furnished the 
corresponding 1,4,6-trien-3-one 92 in a moderate 38% yield over two steps compared to 
56% reported in the literature using same procedures on a similar substrate.
45
 In turn, 
trienone 92 was converted into epoxide 91 using hydrogen peroxide under alkaline 
conditions in a slightly improved 72% yield compared to the 68% yield published in the 
literature (Scheme 17).
45 
Unfortunately, the scale-up of steps ii and iii from 0.150 mmol  
to 1.00 mmol resulted in poorer yields (22% and 25%, respectively). 
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Scheme 17. Revised synthetic route to epoxide 91. 
 
Reagents and conditions: i. ethylene glycol, p-TsOH, toluene, 130 °C, 12 h (90%);  
ii. DDQ, 1,4-dioxane, reflux, 8 h (22%); iii. H2O2 (30% w/w), 10% NaOH in MeOH, 
MeOH, 15 °C, 12 h (25%). 
 
2.3.3. Optimisation studies of the oxidation step 
Unfortunately, this new synthetic route presented a recurring problem concerning low 
yields during the scale-up of the oxidation step which had been already encountered in the 
first synthetic route. In this new scheme, the low yield may be attributed to the 
deprotection of the C-20 ketal group of the starting material 93 and of the final product 92 
by DDQ, as it is a mildly acidic reagent. This is supported by the fact that varying amounts 
of starting pregnenolone (36) and C-20 ketone 94 could be isolated from this reaction 
(Scheme 18). In order to address this problem, several conditions were tried, including 
working under rigorously anhydrous and under basic conditions. Nevertheless, none of 
these attempts were successful in improving the outcome of the reaction as summarised in 
Table 1. 
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Scheme 18. Synthesis of trienone 92. 
 
Reagents and conditions: DDQ (5.0 eq.), conditions see Table 1. 
 
Table 1. Optimisation study of the DDQ oxidation of compound 93. 
 
Entry Conditions
*
 Outcome 
1 pyridine (excess),  1,4-dioxane, 110 °C, 24 h rsm 93 
2 KOH (excess), 1,4-dioxane, 110 °C, 24 h decomposed mixture 
3 benzene, 90 °C, 72 h 
92: 13%  
36: 15%  
4 4 Å molecular sieves, 1,4-dioxane, 110 °C, 48 h 
92: 19%  
94: 6% 
5 K2CO3 (excess), 1,4-dioxane, 100 °C, 48 h 
93: 24% 
94: 23% 
6 1,4-dioxane, 110 °C, 24 h 
92: 28%  
94: 16%  
 
*
 Anhydrous conditions and under an argon atmosphere. 
 
Considering that none of the aforementioned conditions gave satisfactory results, we 
decided to turn to alternative and more recently developed literature oxidation conditions. 
Shvo and co-workers reported a new method to transform cyclic ketones and alcohols into 
their α,β-unsaturated derivatives under mild reaction condition in good yields using 
Pd(OAc)2 and diethyl allyl phosphate (ADP) as the hydrogen source (Scheme 19).
46
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Scheme 19. Catalytic oxidation of cholesterol (74) to trienone 95. 
 
Reagents and conditions: i. Pd(OAc)2, ADP, Na2CO3, THF, 80 °C, 40 h (75%). 
 
Furthermore, in 2000, Nicolaou et al. developed an IBX-mediated dehydrogenation 
process which was applicable to steroid systems and allowed oxidation in high yields and 
under mildly acidic conditions (Scheme 20).
47 
 
 
 Scheme 20. Catalytic oxidation of C-3-oxo-androsterone (96) to dienone 97. 
 
Reagents and conditions: i. IBX, ADP, Na2CO3, toluene/DMSO (2:1), 85 °C, 48 h (72%). 
 
Based on these previously published results, a screen of various oxidative conditions was 
undertaken as shown in Table 2. An interesting outcome of the reaction was the isolation 
of the dienone intermediate 98 as a side product which suggests that the last step of the 
catalytic cycle may be the formation of the 1,2-double bond (Scheme 21). 
 
 
Scheme 21. Oxidation of ketal 93. 
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Table 2. Alternative oxidation conditions to form trienone 92. 
Entry Reagents Conditions
* 
Outcome 
 
1 IBX (4.0 eq.), Na2CO3 (4.0 eq.)
47 toluene/DMSO (2:1), 85 °C, 
48 h 
98: 14%  
93: 27% 
complex mixture 
  
2 IBX (4.0 eq.), K2CO3 (4.0 eq.) 
toluene/DMSO (2:1), 85 °C, 
48 h 
98: 18%  
93: 13% 
complex mixture 
 
3 
 
 
Pd2(dba)3•CHCl3 (0.04 eq.), ADP (3.5 eq.), 
Na2CO3 (4.2 eq.) 
THF, 86 °C, 72 h 
98: 22%  
93: 72% 
4 
Pd2(dba)3•CHCl3 (0.04 eq.), ADP (3.5 eq.), 
K2CO3 (4.2 eq.) 
DMF, 86 °C, 72 h 
98: 31%  
93: 61% 
 
5 
Pd(OAc)2 (0.04 eq.), ADP (3.5 eq.), 
Na2CO3 (4.2 eq.)
46 
 
THF, 85 °C, 72 h 
98: 47%  
93: 16% 
 
6 
Pd(OAc)2 (0.1 eq.), ADP (8.8 eq.), 
Na2CO3 (10.5 eq.) 
 
THF, 86 °C, 72 h 
98: 53%  
93: 17% 
 
7 
Pd(OAc)2 (0.04 eq.), ADP (3.5 eq.), 
 K2CO3 (4.2 eq.) 
DMF, 86 °C, 72 h 
98: 71% 
93: 26% 
8 
Pd(OAc)2 (0.04 eq.), ADP (3.5 eq.), 
Na2CO3 (4.2 eq.) 
(g scale) DMF, 180 °C, 72 h 
92: 20%  
decomposed 
mixture 
9 
Pd(OAc)2
 
(0.04 eq.), ADP (3.5 eq.), 
Na2CO3 (4.2 eq.)
48
 
DMF, 160 °C, 72 h 
92: 27%  
98: 46% 
 
10 
Pd(OAc)2(0.04 eq.), ADP (3.5 eq.), 
 Na2CO3 (4.2 eq.) 
DMF, 180 °C, 72 h 
92: 50%  
98: 25%  
11 
Pd(OAc)2 (0.04 eq.), ADP (3.5 eq.), 
Na2CO3 (4.2 eq.) 
DMSO, 190 °C, 72 h rsm 93 
12 
Pd(OAc)2
 
(0.1 eq.), ADP (8.8 eq.), 
Na2CO3 (10.5 eq.) 
(g scale) DMF, 160 °C, 72 h 
92: 62%  
98: 7%  
94: 3% 
 
 
*
 Anhydrous conditions and under an argon atmosphere. 
 
The use of IBX as an oxidising agent returned complex mixtures of products and therefore, 
the investigation of these reaction conditions was not pursued (Table 2, entries 1 and 2). 
The optimisation study of the oxidation step relied on repeating the work of Shvo et al. 
work on cholesterol (74),
46
 by varying the conditions in order to obtain an optimal yield 
and purity of the desired trienone 92. The next four experiments were run at low 
temperature (85-86 °C) and only led to the formation of intermediate 98 in low yields 
(Table 2, entries 5 to 7) except for entry 6 in which a 53% yield of dienone 98 was isolated 
which implied that increasing the amount of the catalyst complex could potentially push 
the reaction towards completion. Moreover, changing parameters such as the catalyst, the 
solvent or the base did not show any positive effect (Table 2, entries 3 and 4).  
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The conditions assayed in entry 9 (DMF at reflux) have been disclosed by a Chinese 
patent
48
 using C-17 ketal protected pregnenolone as the substrate which, in their case, gave 
trienone 84 in excellent yield (85%). Disappointingly, in our hands these conditions 
allowed the formation of trienone 92 in poor yield (27%). Nevertheless, under the same 
conditions only at higher temperature, trienone 92 was isolated in an improved 50% yield 
(Table 2, entry 10). Based on the previous result, it was thought that increasing the 
temperature could positively influence the outcome of the reaction. In order to validate this 
hypothesis, solvents with higher boiling points were used. Unfortunately, this experiment 
led to the recovery of the starting material 93 (Table 2, entry 11). At this point, the best 
result developed in entry 9 was scaled up but mostly led to poor yields. Indeed, as shown 
in entry 8, scaling up the reaction at an oil bath temperature of 180 °C in DMF led to low 
yield (20%). Decomposition of DMF at vigorous reflux was assumed to be the problem.  
In order to avoid this situation, this reaction was run at a more gentle reflux (oil bath 
temperature at 160 °C) which led to a more acceptable yield on gram scale (entry 12, 62% 
yield). Considering that entry 12 gave the best outcome in terms of yield (62% yield) and 
purity (>99%), these conditions were adopted as the preferred procedure for the second 
step of the synthesis. 
In order to improve the overall yield of the oxidation step, dienone 98 was submitted to 
different oxidation conditions (Scheme 22, Table 3). 
 
 
Scheme 22. Oxidation of dienone 98 in trienone 92. 
 
Table 3. Oxidation of 1,2-double bond of dienone 98. 
Entry Reagents Conditions
*
 Outcome 
1 IBX (4.0 eq.), K2CO3 (4.0 eq.) 
toluene/ DMSO (2:1),  
85 °C, 48 h 
rsm 98 
2 
Pd(OAc)2 (0.04 eq.), ADP (3.5 eq.), 
Na2CO3 (4.2 eq.) 
DMF, 160 °C, 72 h 
92: 46%  
98: 33%  
3 DDQ (3.5 eq.) 1,4-dioxane, 110 °C, 48 h 
92: 58%  
94: 23%  
*
 Anhydrous conditions and under an argon atmosphere. 
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The conversion of dienone 98 into trienone 92 proceeded in an acceptable yield when the 
reaction was run under the DDQ-mediated oxidation conditions (Table 3, entry 3) and 
hence, these conditions were used when repeating this reaction.  
 
2.3.4. Optimisation studies of the epoxidation reaction 
There are a number of reports in the literature for the nucleophilic epoxidation of the  
1,2-double bond of the A-ring of steroids using peroxide-containing reagents in acceptable 
to good yields (up to 85%) and on various scales.
49,50,51
 Unfortunately, in our hands this 
step proceeded in low yield upon scale-up. This was partly because of recovery of 
unreacted trienone 92, and prompted a screening of different epoxidation conditions 
(Scheme 23, Table 4).  
 
 
Scheme 23. Synthesis of epoxide 91. 
 
Table 4. Screening of epoxidation conditions. 
Entry Reagents Conditions Outcome 
1 
t
BuOOH (70% w/w in H2O)  
(30.0 eq.), DBU (cat.) 
MeOH,  0 °C  rt, 24 h 
91: 27% + 
mixture
*
 
2 
t
BuOOH (70% w/w in H2O) 
 (30.0 eq.), triton B (cat.) 
THF,  0 °C  rt, o/n 
91: 45% + 
mixture
*
 
3 [H2O2.urea] (30.0 eq.), TBD (cat.) CH2Cl2, 0 °C  20 °C, 24 h rsm 92 
4 
H2O2 (30% w/w) (30.0 eq.) 
K2CO3 (3.0 eq.) 
MeOH,  15 °C  rt, o/n rsm 92 
5 
H2O2 (30% w/w) (30.0 eq.) 
NaOH (5% in MeOH) (cat.) 
MeOH,  15°C  rt, o/n rsm 92 
6 
H2O2 (30% w/w) (30.0 eq.) 
triton B (0.05 eq.) 
THF/H2O,  0 °C  rt, o/n 
91: 47% 
92: 10% 
7 
H2O2 (30% w/w) (27.0 eq.) 
NaOH (10% in MeOH) (cat.) 
MeOH , 15 °C  rt, 24 h 
91: 46% 
92: 20%  
 
8 
H2O2 (30% w/w) (30.0 eq.) 
NaOH (10% in MeOH) (cat.) 
MeOH,  15 °C  rt, 24 h 
91: 48% 
92: 24% 
 36 
 
Table 4 (continued). Screening of epoxidation conditions. 
Entry Reagents Conditions Outcome 
9 H2O2 (30% w/w) (40.0 eq.),  
NaOH (10% in MeOH) (cat.) 
(g scale) MeOH,  15 °C  rt, 
24 h 
91: 51% + 
mixture
*
 
10 H2O2 (30% w/w) (40.0 eq.), 
NaOH (10% in MeOH) (cat.) 
i
PrOH, 15 °C  rt, 24 h 
91: 72% 
 92: 16% 
 
 
*
 Another fraction of at least four by-products, that could not be separated and characterised, was 
collected. 
 
As shown in entries 1 to 3, using sterically hindered reagents such as
 t
BuOOH and 
[H2O2.urea] complex with DBU or triton B and TBD, respectively, as the base did lead to 
an improvement in the yield. The use of a milder base in order to avoid multiple 
epoxidation returned only the recovery of trienone 92 (Table 4, entries 4 and 5), whilst 
using triton B as the base produced the desired epoxide in a moderate yield (Table 4, entry 
6). Entries 7 to 9 showed that increasing the number of equivalents of hydrogen peroxide 
significantly improved the yield. Thus, increasing the equivalents of hydrogen peroxide to  
40 equivalents (entry 9) gave the best result in terms of yield (51%) and purity (> 99%).  
It was hypothesised that methanol could either react with the dienone functionality of the  
A/B-ring system via a conjugate addition or cleave the epoxide ring accounting for the 
lower yield. Therefore, the reaction was run in 
i
PrOH, a less nucleophilic solvent and this 
lead to the formation of epoxide 91 in an improved yield (72%) on small scale (53 mg, 
0.150 mmol) (entry 10). Furthermore, this result was fairly reproducible on a larger scale 
(up to 5.00 g, 14.1 mmol) albeit with a slight drop of the yield to 60%.  
 
2.3.5. Discussion of the stereoselectivity of the epoxidation step 
The prefered α-configuration of the epoxide was assumed based on the favoured 
nucleophilic attack of the 1,2-double bond in the A-ring, from the bottom face of the 
molecule as the top face was sterically hindered by the axial bridgehead C-19 methyl 
group. In addition, a small 
4
J (2.0 Hz) 
“
W-coupling” between H-2 and H-4 was observed, 
consistent with the α-configuration (Figure 15). The structure of epoxide 91 was 
confirmed through single crystal X-ray analysis. This crystal structure confirmed the  
α-configuration of the epoxide and the consequent “W-type” alignment of the H-2 and H-4 
protons (Figure 14). 
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Figure 15. X-ray crystal structure of 1α,2α-epoxyketal 91 depicted using Mercury 3.0. 
ORTEP representation shown with ellipsoid at 50% probability. (CCDC 983154, 
Appendix I). 
 
2.3.6. The Birch reduction 
The next key step of the total synthesis was the conversion of epoxide 91 into 1α,3β-diol 
99 via a Birch reduction using lithium in ammonia and ammonium chloride. Repeating the 
procedure used in the total synthesis of withanolide D (6)
29
 afforded 1α,3β-diol 99 in  
40% yield alongside with hydroxyenone 100 in 56% yield (Scheme 24). In a previous 
study of this reaction by El Sheikh for the synthesis of the core structure of the 
cyclocitrinol,
45
 it was hypothesised that quenching the reaction mixture at low temperature 
(−78 °C) led to the formation of undesired hydroxyenone as the major product. Taking this 
suggestion into consideration, the scale-up of the reaction was carried out at higher 
temperature, i.e. the reaction mixture was quenched between −10 °C and −20 °C. This 
experiment enabled the formation of 1α,3β-diol 99 in good yields on a one gram scale 
(76%) along with the diastereoisomer 1α,3α-diol 101 (10%) separable by column 
chromatography; and without the formation of hydroxyenone 100. 
 
 
Scheme 24. Birch reduction of epoxide 91. 
 
Reagents and conditions: i. Li/NH3, THF, 4 h then NH4Cl. 
1 
2 
4 
19 
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The diastereoisomers 1α,3β-diol 99 and 1α,3α-diol 101 were each subjected to Corey’s 
acidic conditions to cleave the C-20 ketal protecting group and gave the corresponding  
C-20 ketone 61 and  C-20 ketone 102, respectively, in quantitative yields (Scheme 25).
52
  
 
 
Scheme 25. Synthesis of C-20 ketones 61 and 102 under acidic conditions. 
 
Reagents and conditions: i. AcOH/H2O/THF (65:35:10), rt, 12 h (100% of 61 and 100% of 
102). 
 
2.3.7. Structural assignment of ketones 61 and 102 
At this point, the structure of 1α,3β-diol 61 was proved through single crystal X-ray 
analysis (Figure 16). This X-ray crystallography gave an insight into the stereochemistry 
of the molecule showing the axial and equatorial configurations of C-1 hydroxyl and  
C-3 hydroxyl groups, respectively. 
 
                     
Figure 16. X-ray crystal structure of 1α,3β-diol 61 depicted using Mercury 3.0. ORTEP 
representation shown with ellipsoid at 50% probability. (CCDC 983153, Appendix I). 
 
The stereochemistry of 1α,3α-diol 102 was further supported by strong nOe interactions 
between H-2α (δ 1.99-1.96, m) and H-3 and between  H-4α (δ 2.69-2.67, m) and  
H-3, suggesting that H-3 is in an equatorial position (Figure 17). 
 
3 
1 
20 
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Figure 17. Key nOe interactions of 1α,3α-diol 102 (Appendix II). 
 
2.4. C-1 Homologation of Ketone 61 to Aldehyde 40 
2.4.1. The Corey-Seebach umpolung methodology: literature examples 
In 1972, Lettré et al. investigated the synthesis of 20-hydroxyaldehydes via the addition of 
1,3-dithiane to derivatives of pregnenolone (36).
53
 Under standard reaction conditions 
using 1.0 eq. of 1,3-dithiane and 
n
BuLi, ketone 103 was converted into dithiane adduct 104 
in good yield as a mixture of diastereoisomers at C-20 (Scheme 26). Unfortunately,  
no ratio of the diastereoisomers was reported in the literature. Subsequent hydrolysis of the 
dithiane adduct 104 afforded the corresponding 20R-aldehyde 105 in a moderate  
63% yield. 
 
 
Scheme 26. Synthesis of dithiane adduct 104 by Lettré et al. 
 
Reagents and conditions: i. 1.0 eq. 1,3-dithiane, 1.0 eq. 
nBuLi, THF, −30 °C to 0 °C, 24 h 
(77%); ii. HgCl2/HgO, CH3CN, reflux, 5 h (63%). 
 
Since then, this synthetic route has been used successfully to synthesise and/or extend the 
side chain of steroid-related compounds in moderate to good yields.
30,54,55,56 
For example, 
during the synthesis of (Z)-20(22)-didehydrocholesterol (108), Koreeda et al. applied 
similar reactions conditions as Lettré’s group to form dithiane adduct 106 in 70% yield  
(Scheme 27).
54
 
 
 40 
 
 
Scheme 27. Synthesis of dithiane adduct 106 by Koreeda et al. 
 
Reagents and conditions: i. 1.0 eq. 2-isopropyl-1,3-dithiane, 1.0 eq. 
nBuLi, THF, −25 °C,  
7 h (70%); ii. HgCl2-CaCO3, CH3CN/THF/H2O, reflux, 50 h (51%). 
 
More recently (2007), Shingate et al. successfully used the Corey-Seebach umpolung 
methodology during their stereoselective syntheses of 20-epi-cholanic acid derivatives,  
e.g. 110.
56
 Thus, ketone 109 was treated with 1.5 eq. of 1,3-dithiane and 1.8 eq. of 
n
BuLi at 
low temperature to afford the corresponding 20R-hydroxydithiane adduct 53 in 82% yield 
(Scheme 28). 
 
 
Scheme 28. Synthesis of dithiane adduct 53 by Shingate et al. 
 
Reagents and conditions: i. 1.5 eq. 1,3-dithiane, 1.8 eq. 
nBuLi, THF, −25 °C, 7 h (82%). 
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2.4.2. Synthesis of dithiane adduct 112 
We decided to explore this dithiane chemistry using similar reaction conditions on the 
unprotected 1α,3β-dihydroxyketone 61, but unfortunately, the synthesis of dithiane adduct 
111 was low yielding and led mostly to the recovery of unreacted ketone 61. Indeed, the 
dithioacetal 111 was obtained as a mixture of C-20R- and C-20S-diastereoisomers in a  
6:1 ratio in 44% yield (91% brsm). Subsequently, the hydroxyl groups in triol 111 were 
protected as tris-MOM derivatives in good yield (83%) (Scheme 29).
29
 Therefore, the 
dithiane adduct 112 was synthesised from the C-20 ketone 61 in 37% yield over two steps. 
Both dithiane adducts 111 and 112 were novel compounds and therefore, fully 
characterised. 
 
 
Scheme 29. Synthesis of dithiane adduct 112. 
 
Reagents and conditions: i. 5.0 eq. 1,3-dithiane, 5.0 eq. 
nBuLi, THF, −5 °C, 8 h (44%,  
91% brsm); ii. MOMCl, 
i
Pr2EtN, 1,4-dioxane, reflux, 12 h (83%). 
 
2.4.3. Alternative route to dithiane 112 
It was proposed that by protecting diol 61 as a bis-MOM the yield of the Corey-Seebach 
reaction may be improved. MOM-protected ketal 113 was therefore prepared and 
submitted to Corey’s deprotection conditions to afford ketone 38 in 92% yield over two 
steps.
52
 The next key step was the Corey-Seebach dithiane reaction which was carried out 
using standard conditions and provided a 6:1 mixture of C-20 hydroxydithioacetal 
diastereoisomers 39 and 114 which were readily separated by column chromatography and 
gave the dithiane adduct 39 in 71% yield. This reaction has also been disclosed by Ikekawa 
et al. in a comparable yield (78%).
29
 Subsequently, the C-20 hydroxyl 39 was protected as 
a methoxymethylene ether in very good yield (85%) (Scheme 30). Thus, the dithiane 
adduct 112 was synthesised in a slightly improved 42% yield over four steps. 
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Scheme 30. Revised synthetic route to dithiane adduct 112. 
 
Reagents and conditions: i. 7.4 eq. MOMCl, 1,4-dioxane, reflux, 6 h (92%);  
ii. AcOH/H2O/THF (65:35:10), rt, 12 h (100%); iii. 5.0 eq. 1,3-dithiane, 5.0 eq.  
n
BuLi, 
THF, −5 °C, 8 h (71% of 39 and 4% of 114); iv. MOMCl, iPr2EtN, 1,4-dioxane, reflux,  
12 h (85%). 
 
2.4.4. Discussion of the stereoselectivity of the Corey-Seebach reaction 
The stereochemical aspects of different approaches to construct and/or extend the side 
chain of steroid-related molecules have been reviewed previously by Piatak and Wicha.
57
 
Here, they reported that the stereochemistry at C-20 was assumed to be R according to the 
preferential nucleophilic attack of the bulky 2-lithio-1,3-dithiane on the less sterically 
hindered face of ketone 38, i.e. from the C-16 side and therefore, the opposite face of the 
steroid core structure as illustrated by the Felkin-Ahn model described in Figure 18.  
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Figure 18. Felkin-Ahn model for diastereoselective attack of 2-lithio-1,3-dithiane on 
ketone 38. 
 
Furthermore, it was expected that the diagnostic 
1
H-NMR signals at C-21 and C-22 offered 
the best option for the confirmation of the stereochemistry at C-20. Indeed, it was 
anticipated that the H-21 of the C-20β isomer would show a signal more downfield than its  
C-20α diastereoisomer.57 In our case, the 1H-NMR spectrum of the desired  
20R-hydroxydithiane 39 presented a downfield signal at δ 1.42 (s) representative of  
H-21 whereas the 
1
H-NMR spectrum of the undesired 20S-hydroxydithiane 114 showed a 
signal at δ 1.32 (s). Likewise, H-22 of the undesired C-20S-diastereoisomer was expected 
to show a signal more downfield due to interactions between H-22 and the C-20α hydroxyl 
group.  Thus, the H-22 of the undesired 20S-hydroxydithiane 114 was observed in the  
1
H-NMR spectrum at δ 4.33 (s) whereas the 1H-NMR spectrum of the desired  
20R-hydroxydithiane 39 showed a signal at δ 4.13 (s). From these observations and 
precedent, it was concluded that 20R-hydroxydithiane 39 was the major product in the 
Corey-Seebach reaction (Scheme 30).  
 
Similar arguments were used to assign the R- and S-diastereoisomers of adduct 111.  
Thus, in the 
1
H-NMR spectrum of adduct 111, H-22 and H-21 of the desired  
20R-hydroxydithiane showed signals at δ 4.19 (s) and δ 1.40 (s), respectively; H-22 and  
H-21 of the 20S-hydroxydithiane were observed at δ 4.35 (s) and δ 1.38 (s), respectively. 
 
2.4.5. Dithiane adduct cleavage: synthesis of the model system 117  
The next key step in the total synthesis was the hydrolysis of dithiane adduct 112 to form 
the corresponding aldehyde 40. This reaction was carried out on a similar substrate  
20R-hydroxydithiane 39 in good yield (85%) under standard mercuric oxide conditions as 
reported by Ikekawa’s group during the synthesis of withanolide D (6).29 Unfortunately, 
using the same procedure with MOM-protected C-20 hydroxydithiane 112 gave the desired 
aldehyde 40 in poor yield (27%) and mostly led to decomposition (Scheme 31). 
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Scheme 31. Hydrolysis of dithiane adduct 112 under mercuric oxide conditions.  
. 
Reagents and conditions: i. HgO, BF3•Et2O, THF/H2O (1:1), reflux, 4 h (27%). 
 
This step required an extensive optimisation study and in order not to use all the dithiane 
adduct material 112, we proposed to screen a range of conditions for the cleavage step on a 
model steroid system 117 which was a novel compound and easily accessible from 
pregnenolone (36). Towards this aim, the C-3 hydroxyl group of commercially available 
pregnenolone (36) was protected as the methoxymethylene ether 115 in very good yield on 
gram scale. In turn, ketone 115 was treated under Corey-Seebach reaction conditions to 
afford the dithiane adduct 116 in 78% yield as a mixture of diastereoisomers at C-20 in a 
6:1 ratio. Finally, the tertiary alcohol was protected using standard conditions which 
afforded compound 117 in excellent yield (Scheme 32). Both of these dithiane adducts 116 
and 117 were novel and therefore, fully characterised. 
 
 
Scheme 32. Synthesis of the model steroid system 117. 
Reagents and conditions: i. MOMCl, 
i
Pr2EtN, 1,4-dioxane, reflux, 12 h (88%);  
ii. 1,3-dithiane, 
nBuLi, THF, −5 °C, 8 h (78%, 6:1 ratio at C-20); iii. MOMCl, iPr2EtN, 
1,4-dioxane, reflux, 12 h (92%). 
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2.4.6. Structural assignment of dithiane adducts 116 and 117  
Similar arguments previously discussed to confirm the structural assignment of dithiane 
adducts 111 and 39 were used to assign the R- and S-diastereoisomers of adduct 116. 
Hence, H-21 and H-22 showed a downfield signal at δ 1.44 (s) and a highfield signal at  
δ 4.13 (s), respectively, which is characteristic of the desired C-20R-diastereoisomer 116. 
Likewise, the H-21 and H-22 of the undesired C-20S-diastereoisomer of adduct 116 were 
observed at δ 1.33 (s) and δ 4.36 (s), respectively. 
 
Furthermore, an X-ray crystal structure was obtained of the dithiane adduct 117 in order to 
confirm its structure and stereochemistry (Figure 19). Pleasingly, the assigned  
C-20R-configuration was confirmed with the C-21 methyl group pointing “down”. 
Likewise, the C-3β configuration of the protected alcohol was verified as the H-3 is clearly 
in an axial position. We are therefore confident of earlier assignments. 
 
               
Figure 19. X-ray crystal structure of R-enantiomer of dithiane adduct 117 depicted using 
Mercury 3.0. ORTEP representation shown with ellipsoid at 50% probability.  
(CCDC 983152, Appendix I). 
 
 
 
 
 
 
 
 
 
19 
18 
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2.4.7. Completion of the synthesis of aldehyde 40 
Several successful methods for the hydrolysis of the dithiane moiety have been 
investigated in the past few years.
58,59,60 
Therefore, model dithiane 117 was subjected to a 
series of these different reaction conditions in order to form the corresponding aldehyde 
118 as listed in Table 5 (Scheme 33). 
 
  
Scheme 33. Hydrolysis of dithiane 117.  
 
Table 5. Screening of conditions for the cleavage of dithiane 117. 
Entry Reagents Conditions Outcome 
1 DMP (2.0 eq.), NaHCO3 (1.0 eq.) 
CH3CN/H2O/CH2Cl2 
(8:1:1), rt, 48 h 
rsm 117 
2 DMP (2.0 eq.), Na2CO3 (1.0 eq.) 
CH3CN/H2O/CH2Cl2 
(8:1:1), rt, 48 h 
rsm 117 
3 DMP (2.0 eq.), K2CO3 (1.0 eq.) 
CH3CN/H2O/CH2Cl2 
(8:1:1), rt, 48 h 
rsm 117 
4 
NaI (0.01 eq.), p-benzoquinone  
(1.2 eq.)
67 
CH3CN/H2O (10:1),  
100 °C, 48 h 
rsm 117 
5 
NCS (4.0 eq.), AgNO3 (4.5 eq.), 
2,6-lutidine (10 eq.)
64
 
 
MeOH/THF (1:1), rt, o/n 
118: 5% 
121: 68% 
6 PIDA (2.0 eq.)
61 
CH3CN/H2O (9:1), rt, o/n 
  118: 9% 
decomposed mixture 
7 
NCS (4.0 eq.), AgNO3 (4.5 eq.), 
2,6-lutidine (10 eq.) 
 
THF, rt, o/n 
118: 20% 
decomposed mixture 
 
8 HgO (2.2 eq.), BF3•Et2O (2.2 eq.)
29
 
 THF/H2O (1:1), 70 °C, 
30 min 
118: 35% 
119: 27% 
120: 49% 
9 
NCS (4.0 eq.), AgNO3 (4.5 eq.), 
2,6-lutidine (10 eq.)
 H2O/THF (1:1), rt, o/n 
118: 40% 
decomposed mixture 
 
10 NCS (2.1 eq.)
35
 
CH2Cl2/H2O (10:1), rt,  
2 h 
118: 54% 
11 DMP (2.0 eq.)
62
 
 CH3CN/H2O/CH2Cl2 
(8:1:1), rt, o/n 
118: 70% 
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Table 5 (continued). Screening of conditions for the cleavage of dithiane 117. 
Entry Reagents Conditions Outcome 
12 NCS (3.9 eq.), AgNO3 (4.4 eq.)
65 CH3CN/H2O (4:1), 0 °C, 
30 min 
118: 77% 
13 NBS (6.0 eq.), 2,6-lutidine (12 eq.)
 63
 
 CH3CN/H2O (4:1),  
0 °C  rt,  o/n 
decomposed mixture 
14 
NCS (4.0 eq.), AgNO3 (4.5 eq.), 
2,6-lutidine (10 eq.)  
 
CH3CN/THF (1:1), rt,o/n decomposed mixture 
15 
NCS (4.0 eq.), AgNO3 (4.5 eq.), 
2,6-lutidine (10 eq.) 
CH2Cl2/THF (1:1), rt, o/n decomposed mixture 
16 NaClO2 (10.0 eq.), NaH2PO4.H2O  
(5.0 eq.), 2-Me-2-butene (10.0 eq.)
66 
 
MeOH/H2O (3:1), rt, 1 h decomposed mixture 
 
Traditionally, the deprotection of dithiane moieties has required drastic hydrolysis 
conditions or the use of toxic mercury salts.
68
 Nevertheless, as seen in entry 8, using 
mercuric oxide resulted in the formation of compound 118 in poor yield (35%). Moreover, 
it was found that the reaction conditions were too acidic and resulted in the deprotection of 
either the C-3 or the C-20 methoxymethylene ether group. Therefore, a screening of more 
recently developed conditions was undertaken. The conditions assayed in entry 6 (DMP) 
gave a good yield (70%).
62 
Unfortunately, the use of NaHCO3, NaCO3 and K2CO3 as bases 
typically resulted in no reaction at all which might suggests that the acidity of the reagent 
positively influenced the outcome of the reaction (entries 1 to 3). Likewise, conditions 
assayed in entry 5 using NCS gave promising results.
64
 It was thought that changing the 
solvent system could help avoid the formation of the undesired acetal 121 and favor the 
reaction towards the formation of the corresponding aldehyde 118. Unfortunately, this was 
not observed, at best it gave aldehyde 118 in 40% yield (entries 7, 9 14 and 15). Pleasingly, 
the Smith reaction conditions (NCS and AgNO3, entry 12) gave a very good yield (77%).
65
 
The conditions of entry 10 have been disclosed by Gademann et al. in the total synthesis of 
withanolide A (5) and delivered the aldehyde 54 in 73% yield.
35
 Disappointingly, in our 
case, the yield was not improved when compared to entry 12 (54%). Similarly, none of the 
reaction conditions recently developed on related substrates tested on the dithiane adduct 
117 were successful (entries 4 and 16).
66, 67 
Entry 12 constitutes the best option for the hydrolysis of the dithiane adduct 117 in terms 
of yield and safety, although, these conditions led to a lower yield on a gram scale  
(57% yield). Fortunately, when applied to target dithiane adduct 112, these reaction 
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conditions worked successfully and pleasingly delivered the corresponding aldehyde 40 in 
a very good yield (85%) which was reliably reproducible on a gram scale without MOM 
hydrolysis (Scheme 34). Compound 40 exhibited the typical aldehyde peaks in  
1
H- and 
13
C-NMR spectra, i.e. a downfield signal at δ 9.68 (s) and a downfield signal at  
δ 205.4 which represented H-22 and C-22, respectively, and was fully characterised. 
 
 
Scheme 34. Synthesis of aldehyde 40. 
 
Reagents and conditions: i. NCS, AgNO3, CH3CN/H2O (4:1), 0 °C, 30 min (85%). 
 
2.5. Summary and Future Work 
2.5.1. Summary 
Initial efforts towards the total synthesis of 14,17-dihydro-17-epi-withanolide F (24) 
concerned the synthesis of aldehyde 40, a key intermediate in the proposed retrosynthesis 
(Scheme 7). Pleasingly, aldehyde 40 was synthesised in nine steps and an overall  
14% yield from pregnenolone (36) (Scheme 35). 
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Scheme 35. Optimised synthetic route to aldehyde 40. 
Reagents and conditions: i. ethylene glycol, p-TsOH, toluene, 130 °C, 12 h 
(90%); ii. Pd(OAc)2, ADP, Na2CO3, DMF, 160 °C, 72 h (62%); iii. H2O2 (30% w/w),  
10% NaOH in MeOH, 
i
PrOH, 15 °C, 12 h (72%); iv. Li/NH3, NH4Cl, THF, −78 °C  
to −40 °C to −20 °C, 4 h (76%); v. MOMCl, 1,4-dioxane, reflux, 6 h (92%);  
vi. AcOH/H2O/THF (65:35:10), rt, 12 h (100%); vii. 1,3-dithiane, 
n
BuLi, THF,  
−5 °C, 8 h (71%); viii. MOMCl, iPr2EtN, 1,4-dioxane, reflux, 12 h (85%); ix. NCS, AgNO3, 
CH3CN/H2O (4:1), 0 °C, 30 min (85%). 
 
The key steps of the synthesis included a Pd(OAc)2-mediated catalytic oxidation process, a 
Birch reduction, a C-1 homologation via a Corey-Seebach reaction and an efficient 
dithiane hydrolysis 
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2.5.2. Future work 
With aldehyde 40 in hand, further studies towards the construction of the δ-lactone side 
chain were planned.  It was envisioned that the key α,β-unsaturated lactone in the side 
chain could be installed via a stereoselective vinylogous aldol reaction using a procedure 
developed by Ikekawa et al.
69  
The strategy outlined previously would involve the 
condensation of the steroidal aldehyde 40 with the lithium enolate derived from ester 122 
(Scheme 36). This investigation is discussed in Chapter 3 
 
 
 Scheme 36. Construction of δ-lactone 41. 
 
Suggested reagents and conditions: i. LDA, THF/DMPU, −78 °C, 6 h. 
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Chapter 3. Construction of the δ-Lactone Side Chain  
As discussed in Chapter 2, the key step in the total synthesis of  
14,17-dideoxy-17-epi-withanolide F (24) was the δ-lactone side chain formation.  
The installation of this structural feature, which is unique to the withanolides in steroid 
synthesis, has been thoroughly investigated over the past few years and has led to the 
development of a number of different methods for its construction. 
 
3.1. δ-Lactone Construction: Literature Examples 
In 1973, Hermann et al. developed a deconjugative alkylation method to form a quaternary 
carbon center bearing a vinyl substituent, a key structural feature found in a number of 
natural compounds such as vernolepin (125), as sesquiterpene lactone.
70
  
A non-nucleophilic form of LDA as a complex with HMPA was used in order to avoid any 
Michael addition of the base to the ethyl crotonate 123 and gave the desired alkylated 
crotonate 124 in high yields (88% - 98%) using a broad range of alkyl halides  
(Scheme 37). 
 
 
Scheme 37. Deconjugative alkylation to form quaternary carbon center. 
 
Reagents and conditions: i. LDA/HMPA (1:1), RX, THF, −78 °C; ii. LDA/HMPA (1:1), 
R’X, THF, −78 °C (88% up to 98%). 
 
The first studies on the construction of the α,β-unsaturated δ-lactone side chain of 
withanolides were conducted by Ikekawa’s group in 1975.69 Using the method of 
Herrmann’s group outlined above,70 esters 122 and 130 were reacted with LDA/HMPA 
and the resulting dienolates 126 and 131, respectively, were treated with steroidal aldehyde 
127 (Scheme 38). Their studies led to the discovery of exclusive γ-coupling in the aldol 
reaction of tetrasubstituted esters to give the corresponding α,β-unsaturated lactones 128 
and 132, respectively. The steroidal lactones thus formed were structurally identical to the 
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side chains of withanolides but with the C-22S stereochemistry instead of the  
C-22R-configuration.  
 
 
Scheme 38. δ-Lactone formation via γ-coupling of lithium enolates. 
 
Reagents and conditions: i. LDA, THF, −78 °C, 20 min; ii. THF, −78 °C, 1 h (56% of 128 
and 22% of 129): iii. THF, −78 °C, 1 h (11% of 132 and 55% of 133).  
 
Later, Gonzalez et al. investigated an aldol condensation of aldehyde 134 with acetone 
under alkaline conditions which allowed the formation of α,β-unsaturated ketone 135 and 
hydroxyketone 136 (no yields were reported in the paper).
71
 The alcohol 136 was 
acetylated and treated under Reformatsky conditions using ethyl α-bromopropionate to 
form the corresponding ester 137. After alkaline hydrolysis of the ester 137, the 
corresponding carboxylic acid cyclised under acidic conditions. The concomitant 
dehydration of the tertiary C-24 hydroxy group gave the δ-lactone 138 (Scheme 39). It was 
suggested that the product formed was a mixture of epimers at C-22 with  
S-configuration as the major one according to the Cotton effect of the lactone  
(Δϵ258 −3.72).
69
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Scheme 39. δ-Lactone formation via aldol condensation. 
 
Reagents and conditions: i. acetone, 10% aq. NaOH; ii. 1) Ac2O, 2) ethyl  
α-bromopropionate, zinc; iii. 1 M NaOH, MeOH, rt ; iv. 2 M HCl, MeOH, 60 °C, 24 h. 
 
Ikekawa et al. subsequently investigated the construction of the lactone side chain by the 
condensation of the C-20 hydroxyaldehyde 139 with the lithium enolate of  
α,β-unsaturated ester 122 and obtained ketone 36 in 80% yield, which was suggested to 
arise from elimination of the C-20 formyl group under basic conditions (Scheme 40).
30
 
 
 
Scheme 40. Deformylation under lactone-forming conditions. 
 
Reagents and conditions: i. ethyl 2,3-dimethylbutenoate (122), LDA/HMPA, THF, −78 °C,  
3 h, rt, 19 h (80%). 
 
On the other hand, the condensation of the corresponding C-20 methoxymethylene ether 
protected aldehyde 140 with a lithium enolate of α,β-unsaturated ester 122 allowed the 
formation of the desired C-22R-lactone 142 in 16% yield and the hydroxyester 141 in  
44% yield (Scheme 41). These results have demonstrated the importance of protecting the 
C-20 hydroxyl functionality in order to avoid subsequent deformylation during the 
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condensation step and to promote the formation of lactone 142 with the desired  
C-22R-configuration.  
 
 
Scheme 41. δ-Lactone formation with the desired C-22R-configuration. 
 
Reagents and conditions: i. ethyl 2,3-dimethylbutenoate (122), LDA/HMPA, THF, −78 °C 
to −35 °C, 8 h (44% of 141 and 16% of 142). 
 
Cleavage of the MOM protecting group also promoted the lactonisation of hydroxy ester 
141 to form the final compound 143 in good yield (83%) (Scheme 42). In the literature,
30 
 it was proposed that this result suggested that the C-22 alcohol was hindered by the MOM 
functionality which, consequently, did not favour the lactonisation step. 
 
 
Scheme 42. MOM deprotection using iodine. 
 
Reagents and conditions: i. I2, THF, 50 - 60 °C, 16 h (83%). 
 
Ikekawa and co-workers developed an alternative procedure to obtain the  
C-22R-configuration for the δ-lactone following the synthetic strategy developed by 
McMorris for the synthesis of the 23-deoxyantheridiol (152).
72,73
 As shown in Scheme 43, 
after alkylation of the epoxide 144 using 2-methyl-1,3-dithiane followed by deprotection of 
the hydroxythioketal with mercury(II) oxide, hydroxyketone 145 was treated with 
bromoacetyl bromide which following the McMorris procedure, gave the lactone 148 with 
the correct C-22R-configuration. The C-25 hydroxymethyl was introduced via formation of 
phenylthio-lactone 149 as a mixture of diastereoisomers at C-25 in a 2:1 in favour of the  
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α-configuration separable by column chromatography. Subsequent exposure of the latter 
149 to an excess of formaldehyde, m-CPBA oxidation of the sulfide 149 to the 
corresponding sulfoxide and desulfenylation at high temperature allowed the formation of 
the unsaturated lactone 150 in 14% yield over 10 steps. The latter 150 possesses the same 
δ-lactone side chain as found in the well-known withanolide, withaferin A (5).  
The dimethyl-lactone 151 was also prepared by this route (Scheme 43). 
 
 
Scheme 43. Stereoselective synthesis of the -lactone side chain. 
 
Reagents and conditions: i. 2-methyl-1,3-dithiane, 
nBuLi, THF, −78 °C; ii. HgO, 
BF3•Et2O, rt (76% over two steps); iii. BrCH2COBr, pyridine, Et2O, 0 °C; iv. P(OEt)3,  
100 °C, 50 min; v. NaH, THF, rt, 30 min (79% over three steps); vi. H2, Pd-C, NaHCO3,  
1,4-dioxane, rt (100%); vii. 1) LiCHA, THF, −78 °C, 30 min, 2) (PhS)2, HMPA, THF,  
−78 °C, 20 min (28% of 149α and 15% of 149β); viii. 1) LiCHA, THF, −78 °C, 1 h,  
2) CH2O, THF, −78 °C, 30 min (76%); ix. m-CPBA, CHCl3, 0 °C, 10 min; x.100 °C  
(70% over two steps); xi. 1) LiCHA, THF, −78 °C, 1 h, 2) MeI, −78 °C, 1 h. 
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Casinovi et al. proposed a synthesis of the δ-lactone moiety of the withanolides via the 
condensation of the steroidal aldehyde 153 with ethyl 4,6-dimethyl-2-oxo-2H-pyran- 
5-carboxylate (154) under alkaline conditions.
74
 The diacid 155 thus formed in good yield 
(75%) was then decarboxylated by heating and simultaneously lactonisation took place to 
give the desired δ-lactone 156 in 33% yield (Scheme 44). 
 
 
Scheme 44. δ-Lactone formation via decarboxylation of diacid 155. 
 
Reagents and conditions: i. ethyl 4,6-dimethyl-2-oxo-2H-pyran-5-carboxylate (154), 
NaOH, MeOH, reflux, 1 h (75%); ii. 2,4-dimethylpyridine, toluene, 100 °C, 1 h (33%). 
 
Another strategy was proposed by Honda and co-workers for the construction of the side 
chain characteristic of the withanolides.
75
 Their method was based on the ring-enlargement 
of a furylcarbinol type of compound. The stereoselective synthesis of C-22S-furylcarbinol 
159 was achieved in good yield via the addition of 2-lithio-3,4-dimethylfuran to the 
aldehyde 157. The next key step was the ring-enlargement via an Achmatowicz reaction 
using NBS to give the lactol 160 in 84% yield. The following reactions using standard 
chemistry gave access to the desired lactone 164 in 13% yield over four steps  
(Scheme 45). This synthetic approach was successfully applied in the total synthesis of  
minabeolide-3 (165) achieved in 30% yield over 12 steps.    
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Scheme 45. δ-Lactone formation via ring-enlargement of the C-22S-furylcarbinol 159. 
 
Reagents and conditions: i. 3,4-dimethylfuran, 
n
BuLi, methylaluminium bis(2,4,6-tri-tert-
butylphenoxide), CH2Cl2, rt, 2 h (80%); ii. NBS, anhydrous NaOAc, aq. THF, 0 °C, 30 min 
(84%); iii. PCC, celite, anhydrous NaOAc, CH2Cl2, rt, 2 h; iv. NaBH4, MeOH, 0 °C,  
30 min (73%  over two steps); v. 1) Ac2O, DMAP, pyridine, CH2Cl2, 0 °C, 1 h (95%),  
2) zinc-amalgam, HCl, Et2O, −15 °C, 15 min (21%, 77% brsm); vi. DBU, THF, rt, 2 h 
(91%). 
 
3.2. Synthesis of Ethyl 2,3-Dimethylbutenoate (122)  
Based on the previous literature precedents, the most straightforward method and valid in 
terms of obtaining the desired C-22R-configuration was the one step synthesis conducted 
by Ikekawa’s group.30 It consisted of a nucleophilic attack of the lithium dienolate of ester 
122 onto the steroidal aldehyde 40 as shown in Scheme 36.  
Unfortunately, the ethyl 2,3-dimethylbutenoate (122) is not commercially available; 
therefore, its synthesis was investigated.  
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3.2.1. Synthesis of ethyl 2,3-dimethylbutenoate (122): literature routes 
The synthesis of ethyl 2,3-dimethylbutenoate (122) has been exhaustively examined by 
many groups over the years and we herein describe the most successful results.   
 
Initially, Gallagher et al. achieved the synthesis of ethyl 2,3-dimethylbutenoate (122)  via a 
Wittig reaction with triphenylphosphorane 167 using standard conditions (Scheme 46).
76 
Unfortunately, the yield of the reaction was not reported in the publication. Furthermore, 
later on Isaacs and El-Din reported that the same reaction conditions delivered the desired 
unsaturated ester 122 in only 1% yield. In their case, the Wittig reaction required very high 
pressure conditions (P = 9 kbar) to be able to access ethyl 2,3-dimethylbutenoate (122) in 
good yield (80%).
77
 
 
 
 
Scheme 46. Synthesis of ethyl 2,3-dimethylbutenoate (122) via a Wittig reaction. 
 
Reagents and conditions: i. CH2Cl2, reflux, 12 h. 
 
Another interesting approach was the direct silylation of lithium enolate derived from ester 
168 followed by a Peterson-type of reaction to afford the corresponding ethyl  
2,3-dimethylbutenoate (122) in 54% yield (Scheme 47).
78 
 
 
Scheme 47. Synthesis of ethyl 2,3-dimethylbutenoate (122) via a Peterson reaction. 
 
Reagents and conditions: i. LDA, THF, −78 °C, 30 min, ii. Ph2CH3SiCl, −78 °C, 1.5 h, rt, 
2 h (93% over two steps); iii. acetone, LDA, THF, −78 °C, 1.5 h, reflux, 1.5 h (54%). 
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Skibbie et al. were able to prepare the desired ester 122 via a Horner-Wadsworth-Emmons 
reaction using triethyl phosphonopropionate (170) with sodium hydride in DME in 69% 
yield (Scheme 48).
79
  
 
 
Scheme 48. Synthesis of ethyl 2,3-dimethylbutenoate (122) via a Horner-Wadsworth-
Emmons reaction. 
 
Reagents and conditions: i. NaH, DME, 0 °C then reflux, 12 h (69%). 
 
3.2.2. Synthesis of ethyl 2,3-dimethylbutenoate (122): results and discussion 
Unfortunately, in our hands any attempts to repeat the procedure developed by Skibbie  
et al. only led to the recovery of triethyl phosphonopropionate (170) (Scheme 48).
79
 Other 
bases (
n
BuLi, LiHMDS) and solvent (THF) were screened but none of these conditions 
resulted in the formation of the desired product 122. Likewise, the synthesis of ethyl  
2,3-dimethylbutenoate (122) via a Wittig reaction with triphenylphosphorane 167 using 
standard conditions only led to recovery of the starting material 166 after purification 
(Scheme 46).  
The synthesis of ethyl 2,3-dimethylbutenoate (122) was considered via a Br/Li exchange. 
Lithiation of commercially available bromobutene 171 and trapping with CO2 delivered 
the desired carboxylic acid 172 in 36% yield (Scheme 49). This reaction has been 
disclosed in the literature in a comparable 34% yield.
80
 Further esterification was 
attempted using different reaction conditions (EtOH with SOCl2 or H2SO4). Thus, the 
reaction mixture needed to be stirred for a long period of time (3 days) and at 50 °C in 
order to push the reaction to completion. Pleasingly, the desired ethyl  
2,3-dimethylbutenoate (122) was observed in the crude 
1
H-NMR spectrum, in conjunction 
with ethanol. Unfortunately, ester 122 is very volatile and concentration as well as 
distillation of the solvent did not offer a good separation; therefore, no conclusive yield can 
be reported. 
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Scheme 49. Synthesis of ethyl 2,3-dimethylbutenoate (122) via esterification. 
 
Reagents and conditions: i. Li, CO2, THF, −30 °C to −78 °C to rt (36%); ii. SOCl2 or 
H2SO4, EtOH, 50 °C, 3 d. 
 
Considering that none of the aforementioned conditions were useful, another method for 
the synthesis of ethyl α,β-dimethylbutenoate (122) was considered via a Br/Li exchange. It 
was proposed that lithiation of commercially available bromobutene 171 and trapping with 
ethyl chloroformate (173) would give the desired crotonate 122 directly (Scheme 50).
81
 
Unfortunately, upon purification by column chromatography, decomposition of the crude 
residue was observed. Likewise, the use of 
s
BuLi led only to a decomposed mixture. 
 
 
Scheme 50. Synthesis of ethyl 2,3-dimethylbutenoate (122) via lithiation of bromobutene 
171. 
 
Reagents and conditions: i. 
n
BuLi or 
s
BuLi, Et2O, −78 °C to rt, 3 h. 
 
Another method for the synthesis of α,β-unsaturated ester 122 was based on the treatment 
of enol triflate 175 accessible from the commercially available β-ketoester 174 with a 
cuprate reagent.
 
Thus, β-ketoester 174 was treated with triflic anhydride under  
Schotten-Baumann type conditions to furnish the corresponding (Z)-enol triflate 175 in an 
increased yield when compared to the literature (100% vs. 67%).
82
 The  
(Z)-configuration of the product 175 was established by the presence of the high field 
signal of the C-5 methyl group at δ 2.15 in the 1H-NMR spectrum which was consistent 
with 
1
H-NMR data previously published in the literature.
82 
Indeed, the C-5 methyl group in 
the (E)-enol triflate was expected to show at δ 2.42 according to the literature.83 
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Lipshutz and Elworthy described in the literature that for the coupling between vinyl 
triflates and allylic cuprates, cyanocuprates presented the highest reactivity.
84
 Therefore, 
(Z)-enol triflate 175 was treated with methyl cyanocuprate in order to synthesise the 
desired α,β-unsaturated ester 122. Disappointingly, the outcome of the reaction was a 
decomposed mixture (Scheme 51).  
 
 
Scheme 51. Synthesis of ethyl 2,3-dimethylbutenoate (122) via a cuprate coupling. 
 
Reagents and conditions: i. Tf2O, aq. LiOH, toluene, 5 - 10 °C, 30 min (100%); ii. CuCN, 
MeLi , Et2O, −78 °C, 1 h. 
 
A screening of different cuprate reagents was therefore undertaken as summarised in  
Table 6 (Scheme 52).  
 
 
Scheme 52. Coupling between (Z)-enol triflate 175 and an organocuprate. 
 
Reagents and conditions: i. 1.0 eq. CuX, 2.0 eq. MeLi, Et2O, −78 °C, 1 h. 
 
Table 6. Screening of cuprate reagents. 
Entry CuX Outcome 
1 CuOAc decomposed mixture 
2 CuCl rsm 175 
3 CuOTf decomposed mixture 
4 CuI  122: 87%  
 
Most of the reaction conditions assayed led to decomposition or recovery of the starting 
material 175 (Scheme 52, Table 6, entries 1 to 3). Fortunately, the use of copper iodide 
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delivered ethyl 2,3-dimethylbutenoate (122) in very good yield (87%) (Table 6, entry 4). 
This result was pleasingly reproducible on large scale (up to 4 g, 9.56 mmol).  
 
The absence of signal at δ 118 (q, JCF = 318 Hz) in 
13
C-NMR spectrum characteristic of the 
CF3 group of the triflate functionality of the starting material 175 along with the presence 
of a third methyl group at δ 1.82-1.80 (m) in the 1H-NMR spectrum confirmed the 
structural assignment of ethyl 2,3-dimethylbutenoate (122). 
 
3.3. Studies Towards the Construction of δ-Lactone 41 
3.3.1. Studies using ethyl 3,3-dimethylbutenoate (178) 
Our first approach was to test the vinylogous aldol type reaction using conditions 
developed by Ikekawa et al. on a simple and easily accessible model system such as  
2,2-dimethylphenylacetaldehyde (177) using commercially available ethyl  
3,3-dimethylacrylate (178). Hence, 2,2-dimethylphenylacetaldehyde (177) was obtained 
from 2-phenylpropionaldehyde (176) repeating a published procedure in very good yield 
(87% vs 77% in the literature).
85
 Unfortunately, submitting  
2,2-dimethylphenylacetaldehyde (177) to the previously described aldol condensation 
conditions resulted exclusively in the recovery of the starting material 177 (Scheme 53). 
 
 
Scheme 53. Attempted δ-lactone formation using a model aldehyde 177. 
 
Reagents and conditions: i. NaH, MeI, THF, 0 °C, 1 h (87%); ii. LDA, DMPU, THF,  
−78 °C to rt, 6 h. 
 
The δ-lactone synthesis was attempted on benzaldehyde (180) repeating the same literature 
procedure developed by Ikekawa et al. using commercially available ethyl  
3,3-dimethylbutenoate (178).
30
 Pleasingly, this reaction delivered the desired lactone 
product 181 in excellent yield (78%) along with the hydroxyester 182 in 8% yield  
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(Scheme 54). 
1
H-NMR data of these two compounds 181 and 182 were consistent with 
those previously published in the literature.
86,87
  
 
 
Scheme 54. δ-Lactone 181 formation using benzaldehyde (180). 
 
Reagents and conditions: i. LDA, DMPU, THF, −78 °C to rt, 5.5 h (78% of 181 and  
8% of 182). 
 
Unfortunately, these reaction conditions were unsuccessful when applied to the steroidal 
model system 118 and only led to decomposition (Scheme 55). 
 
 
Scheme 55. Attempted δ-lactone 183 formation upon deprotonation with LDA. 
 
Reagents and conditions: i. LDA, DMPU, THF, −78 °C to rt, 12 h. 
 
Another option was the optimised reaction conditions for the δ-lactone formation 
developed by Gademann et al. during their synthesis of withanolide A (8).
35
 To this end, 
aldehyde 118 was treated with ethyl 3,3-dimethylbutenoate (178) and LiHMDS in 
THF/DMPU at low temperature (Scheme 56). The δ-lactone 183 was isolated as a mixture 
of diastereoisomers at C-22 in a 1:1 ratio in poor yield (9%). The structural assignment of 
lactone 183 will be discussed later in this Chapter. The major product isolated was the 
α,β,γ,δ-dienoic acid 184 (25% yield). Mechanistically, it was thought that the open chain 
lactone was first synthesised as a hydroxyester which underwent subsequently dehydration 
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to give the isolated dienoic acid 184. The latter 184 was a novel compound and as such 
was fully characterised. Its structure was confirmed by key signals in the 
1
H-NMR 
spectrum including three downfield signals at δ 7.55 (d, J22,23 = 16.4 Hz), δ 6.26  
(d, J22,23 = 16.4 Hz) and at δ 5.68 (s) representative of the vinylic protons H-23, H-22 and  
H-25, respectively, along with downfield signals in the 
13
C-NMR spectrum at δ 153.1  
(C-24), δ 144.1 (C-22), δ 125.9 (C-23), δ 116.6 (C-25) characteristic of the  
α,β,γ,δ-unsaturated diene. The carboxylic acid moiety was confirmed by IR spectroscopy, 
namely by the presence of typical peaks at 2934 cm
-1
 and at 1714 cm
-1
 representative of the 
O-H stretch and the C=O stretch, respectively. 
 
 
Scheme 56. δ-Lactone 183 formation upon deprotonation with LiHMDS. 
 
Reagents and conditions: i. LiHMDS, THF, DMPU, −78 °C to rt, 18 h (9% of 183 and  
25% of 184). 
 
Given the side reaction encountered when using ethyl 3,3-dimethylbutenoate (178), it was 
proposed that the latter 178 did not constitute a good model system to use for this type of 
sensitive reaction. Therefore, the studies towards the δ-lactone formation were henceforth 
carried out exclusively using ethyl α,β-dimethylbutenoate (122).  
 
3.3.2. Studies using ethyl 2,3-dimethylbutenoate (122) 
Initially, the studies towards the unsaturated lactone side chain construction were focused 
on the steroidal model aldehyde 118 (Scheme 57). A screening of reaction conditions were 
run in order to optimise the synthesis of the desired lactone 185 as summarised in Table 7. 
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Scheme 57. Synthesis of δ-lactone using the model aldehyde 118. 
 
Table 7. Screening of conditions for the -lactonisation on model system 118. 
 
Entry Deprotonation step conditions Addition step conditions Outcome 
1 
122 (2.7 eq.), LDA (3.0 eq.), 
THF/DMPU* (8:2), −78 °C, 1.5 h 
118 (1.0 eq.), −78 °C  rt, o/n 
decomposed 
mixture 
2 
122 (2.7 eq.), NaHMDS (3.0 eq.), 
THF, −78 °C, 1.5 h 
118 (1.0 eq.), −78 °C, 5 h 
decomposed 
mixture 
3 
122 (2.7 eq.), KHMDS (3.0 eq.), 
THF/DMPU* (8:2), −78 °C, 1.5 h 
118 (1.0 eq.), −78 °C, 5 h 
decomposed 
mixture 
4 
122 (2.7 eq.), LiHMDS (3.0 eq.), 
THF, −78 °C, 1.5 h 
118 (1.0 eq.), −78 °C, 5 h 115: 48% 
5 
122 (1.5 eq.), LiHMDS (1.4 eq.) 
THF/DMPU* (8:2), −78 °C, 1.5 h 
118 (1.0 eq.), −78 °C, 5 h 
118: 12% 
115: 35% 
6 
122 (2.7 eq.), LiHMDS (3.0 eq.), 
THF/DMPU* (8:2), −78 °C, 1.5 h 
 
118 (1.0 eq.), −100 - −90 °C, 5 h 
185: 11% 
115: 52% 
 
7 
122 (2.7 eq.), LiHMDS (3.0 eq.), 
THF/DMPU* (8:2), −78 °C, 1.5 h 
118 (1.0 eq.), −78 °C, 6 h 
185: 33% 
115: 8% 
8 
122 (2.7 eq.), LiHMDS (3.0 eq.), 
THF/DMPU* (8:2), −78 °C, 1.5 h 
118 (1.0 eq.), −78  −40 °C, 6 h 
185: 38% 
115: 12% 
9 
122 (2.7 eq.), LiHMDS (3.0 eq.) 
THF/DMPU* (8:2), −78 °C, 1.5 h 
118 (1.0 eq.), −78  −40 °C, 1 h 
185: 61% 
115: 10% 
10
i
 
122 (2.7 eq.), LiHMDS (3.0 eq.) 
THF/DMPU* (8:2), −78 °C, 1.5 h 
 
118 (1.0 eq.), −78 °C, 6 h 
185: 73% 
115: 15% 
 
*: DMPU freshly distilled over CaH2. 
i
: inverted addition, i.e. a solution of the lithium dienolate derived from 122 was added to the 
aldehyde 118 at –78 °C. 
 
When applied to steroidal aldehyde 118, the conditions developed by Ikekawa et al. led to 
decomposition as predicted by the test reaction run on the model system 118 using ethyl 
3,3-dimethylbutenoate (178) (Scheme 55) (Table 7, entry 1).
30
 Subsequently, the δ-lactone 
185 synthesis was attempted using the optimised reaction conditions developed by 
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Gademann et al. as previously described.
35
 To this end, ethyl 2,3-dimethylbutenoate (122) 
was deprotonated using LiHMDS in THF/DMPU (8:2) at low temperature, subsequently,  
aldehyde 118 was added slowly over 15 min. Fortunately, these conditions led to formation 
of the desired δ-lactone 185 in 33% yield along with ketone 115 in 8% yield (Table 7, 
entry 7).
 
In order to optimise the yield, the reaction was run at higher temperature (−40 °C) 
so that the nucleophilic attack would be favoured (Table 7, entry 8). After noticing by 
TLC that the desired product 185 was formed predominantly within the first hour of the 
reaction and then decomposed into other products after 5 h, the reaction was repeated at 
−40 °C for one hour. Pleasingly, a significant improvement of the yield was observed 
(Table 7, entry 9). Moreover, in order to try a broad range of temperatures, the reaction 
was attempted at very low temperature (between –100 °C and –90 °C) which surprisingly 
delivered a small amount of the desired product 185 in poor yield (11%) and 
predominantly afforded the C-20 ketone 115 (52% yield, Table 7, entry 6). One hypothesis 
to explain the recurring low yield of this reaction was that the initial deprotonation step 
was not complete, leaving an excess of base in the reaction mixture upon addition of the 
aldehyde 118. The base may be involved in the cleavage of the methoxymethylene ether 
protecting group of the C-20 alcohol 118 which followed by a deformylation step would 
lead to the formation of the C-20 ketone 115 as the major product. With this in mind, it 
was thought that reducing the number of equivalents of the base and of the ethyl  
2,3-dimethylbutenoate (122) could positively influence the reaction and help avoid the 
synthesis of the C-20 ketone 115. Unfortunately, this was not observed (Table 7, entry 5). 
Other bases such as NaHMDS and KHMDS did not improve the outcome of the reaction 
either (Table 7, entries 2 and 3). Additionally, the presence of DMPU seemed to be 
determining for the formation of the δ-lactone side chain as shown in entry 9. Fortunately, 
the desired δ-lactone 185 was obtained in very good yield (73%) when using the standard 
conditions but transferring the dienolate into a solution of aldehyde 118 via canula at  
–78 °C (Table 7, entry 10i). The desired δ-lactone 185 was a novel compound, and 
therefore, fully characterised. Its structural assignment will be discussed later in this 
Chapter. 
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3.3.3. Synthesis of δ-lactone 41 
Considering the aforementioned optimisation study, the most promising reaction 
conditions to form the unsaturated lactone side chain were tested using the target aldehyde 
40 as described in Table 8 (Scheme 58). 
 
 
Scheme 58. Synthesis of δ-lactone using the target aldehyde system 40. 
 
Table 8. Screening of conditions for the -lactonisation of steroidal aldehyde 40. 
Entry Deprotonation step conditions Addition step conditions Outcome 
1 
122 (2.7 eq.), LiHMDS (3.0 eq.) 
THF/DMPU* (8:2), −78 °C, 1.5 h 
40 (1.0 eq.), −78  −40 °C, 1 h 
40: 68% 
38: 11% 
2 
122 (2.7 eq.), LiHMDS (3.0 eq.) 
THF/DMPU* (8:2), −78 °C, 1.5 h 
40 (1.0 eq.), −78 °C, 6 h 
41: 33% 
38: 41% 
3
i
 
122 (2.7 eq.), LiHMDS (3.0 eq.) 
THF/DMPU* (8:2), −78 °C, 1.5 h 
40 (1.0 eq.), −78 °C, 6 h 
41: 67% 
38: 4% 
186: 3% 
*: DMPU freshly distilled over CaH2. 
i
: inverted addition, i.e. a solution of the lithium dienolate derived from 122 was added to the 
aldehyde 40 at –78 °C. 
 
When applying the conditions developed by Gademann et al. to the target system 40,
35
 the 
desired lactone 41 was formed in 33% yield along with 41% of the deformylated side 
product 38 (Table 8, entry 2). Therefore, the same strategy as with the model system 118 
was used and the reaction was repeated at –40 °C for 1 h using the target aldehyde steroid 
40. Unfortunately, in this case, most of the starting material 40 was recovered along with 
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some C-20 ketone 38 (Table 8, entry 1). Fortunately, inverting the order of addition of the 
reagents helped once again to deliver the desired lactone 41 in an improved 67% yield 
along with 4% yield of the C-20 ketone 38 and 3% yield of the hydroxyl ester 186 both of 
which were readily separable by column chromatography (Table 8, entry 3i). Hence, these 
conditions were used when repeating this reaction. 
 
3.3.4. Discussion of the stereoselectivity of the δ-lactonisation step 
The structural assignment of δ-lactone 41 was confirmed by the presence of a downfield 
signal at δ 4.23 as a doublet doublet (3J22, 23ax = 13.3 Hz and 
3
J22, 23eq = 3.2 Hz) in the  
1
H-NMR spectrum characteristic of a methine proton of the δ-lactone side chain. The  
C-22 configuration of the δ-lactone side chain was anticipated to be R. Indeed, according 
to Cram’s rules, the condensation of the lithium dienolate with the aldehyde 40 was 
assumed to occur through a Cram chelate cyclic model. Therefore, the nucleophilic attack 
would arise along the less hindered face, i.e. on opposite face of the steroid core structure 
to deliver the C-22R-configuration as shown in Figure 20. 
 
 
Figure 20. Cram chelate cyclic model for diastereoselective vinylogous aldol condensation 
of lithium dienolate 126 with aldehyde 40. 
 
Similar arguments were used to confirm the structural assignment of δ-lactones 185 and 
183 which both presented key downfield methine proton signals in their 
1
H-NMR spectra. 
Hydroxyester 186 exhibited typical ethyl peaks in 
1
H-NMR spectrum, i.e. a downfield 
signal at δ 4.16 (br q, J27,28 = 7.1 Hz) assigned to the CH2 group of the ethyl functionality 
and a high field signal at δ 1.25 (t, J27,28 = 7.1 Hz), the methyl group of the ethyl moiety of 
ester 186.  
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3.4. Synthesis of Triol 21 
3.4.1. Study on model system 185 
The next step in the total synthesis of 14,17-dideoxy-17-epi-withanolide F (24) was the 
cleavage of the methoxymethylene ether protecting groups at C-1, C-3 and C-20 using 
strongly acidic conditions.
29
 The 6 M aq. HCl in THF conditions were first tested on the 
model steroid system 185 and proceeded to give the desired diol 56 in quantitative yield 
(Scheme 59). The structure of diol 56 was confirmed by 
1
H- and 
13
C-NMR spectra missing 
the signals characteristic of MOM group, namely two downfield signals at ~ δ 5.0 
representative of the CH2 groups and two singlets at ~ δ 3.35 characteristic of the methyl 
groups of the MOM functionality. These data were consistent with those previously 
published in the literature.
35 
 
 
Scheme 59. MOM deprotection under acidic conditions. 
 
Reagents and conditions: i. 6 M aq. HCl, THF, rt, 3 h (100%). 
 
3.4.2. Application to target system 41 
In the same manner, lactone 41 was submitted to 6 M aq. HCl conditions to deliver 
quantitatively the corresponding triol 21 (Scheme 60). This reaction has been previously 
disclosed in the literature in a lower yield (82%) using the exact same reaction conditions 
and substrate 41 as reported by Ikekawa et al. during the synthesis of withanolide D (6).
29 
Moreover, the absence of 
1
H-NMR signals characteristic of MOM group of the starting 
material 41 confirmed the structure of triol 21 which was fully characterised.
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Scheme 60. MOM deprotection of lactone 41. 
Reagents and conditions: i. 6 M aq. HCl, THF, rt, 7 h (100%). 
 
3.5. Summary and Future Work 
3.5.1. Summary 
The δ-lactone side chain of 14,17-dideoxy-17-epi-withanolide F (24) was successfully 
introduced using methodology developed during the synthesis of the model compound 185. 
Extensive optimisation studies were required to obtain the desired lactone 41 upon aldol 
condensation of aldehyde 40 with lithium dienolate derived from ester 122, readily 
prepared from a coupling with vinyl triflate 175 as previously outlined in Scheme 52. 
Subsequent cleavage of the methoxymethylene ether groups of lactone 41 under strongly 
acidic conditions allowed the synthesis of triol 21, a key intermediate in the suggested 
retrosynthetic strategy (Scheme 7), in 67% yield over two steps (Scheme 61). 
 
 
Scheme 61. Synthesis of triol 21. 
Reagents and conditions: i. 122, LiHMDS, THF/DMPU (8:2), −78 °C, 6 h; ii. 6 M aq. 
HCl, THF, rt, 7 h (67% over two steps). 
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3.5.2. Future work 
Future work was focused on completing the total synthesis of 14,17-dideoxy-17-epi-
withanolide F (24) via A/B-ring functionalisation to construct the desired 2,5-dien-1-one 
fragment. Namely, it was proposed to selectively acetylate triol 21 at C-3 and the  
C-1 hydroxyl functionality would then be oxidised under standard conditions. Finally, the 
desired target compound 24 could be accessed via the elimination of the C-3 acetate group 
of compound 23 (Scheme 62). The culmination of the total synthesis is further detailed in 
Chapter 4. 
 
 
 
Scheme 62. Construction of A/B-ring 2,5-dien-1-one fragment. 
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Chapter 4. A/B-Ring Functionalisation: The 
Synthesis of 14,17-Dideoxy-17-Epi-Withanolide F 
(24) 
 
4.1. A/B-Ring Functionalisation: Synthesis of 2,5-Dien-1-One Fragment 
 
4.1.1. 2,5-Dien-1-ones: literature examples 
As previously mentioned in Chapter 1, the 2,5-dien-1-one fragment is common for the 
A/B-rings of different withanolides (Figure 3). Several syntheses of this key structure have 
been disclosed in the literature.
88-90
 Most of them followed the same synthetic strategy; 
namely the conversion of the 1,3-diol functionality in the A-ring into the corresponding  
α,β-unsaturated ketone, via a selective protection of the C-3 alcohol, oxidation of the  
C-1 hydroxyl group and elimination of the C-3 leaving group. 
 
In 1975, Ikekawa et al. developed a synthetic sequence to convert 1α-hydroxycholesterol 
(187) into the corresponding cholesta-2,5-dien-1-one (189) in 54% yield over three steps. 
A selective acetylation at C-3 under standard conditions and the oxidation of C-1 alcohol 
187 using Jones’ reagent were followed by elimination with aq. NaOH in dioxane (Scheme 
63).
26
  
 
 
Scheme 63. Synthesis of cholesta-2,5-dien-1-one (189). 
 
Reagents and conditions: i. Ac2O, AcOH, 80 °C, 4 h (60%), ii. CrO3, acetone, rt,  
iii. 1.5% aq. NaOH, 1,4-dioxane, rt, 6 h (90%  over two steps). 
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Okamura et al. used the same strategy when studying the synthesis of vitamin D3 (191) and 
analogues with modified A-rings.
88
 Thus, selective benzoylation at C-3 under standard 
conditions was achieved in good yield. Subsequent oxidation with Jones’ reagent and 
elimination of the C-3 benzoyl group using DBN as the base delivered the desired  
2,5-dien-1-one 189 in 36% yield over two steps (Scheme 64). 
 
 
Scheme 64. Synthesis of 2-en-1-one fragment via selective benzoylation of diol 187. 
 
Reagents and conditions: i. BzCl, pyridine, 0 °C, 15 - 20 min (72%); ii. CrO3, acetone,  
10 min (98%); iii. DBN, Et2O, rt, 1.5 h (37%). 
 
In 1982, Ikekawa et al. applied the same synthetic approach during the synthesis of 
jaborosalactone A (195).
89
 Hence, diol 192 was selectively protected at C-3 with a 
TBDMS group followed by oxidation of the C-1 alcohol in moderate yield under standard 
conditions. The final sequence of reactions of the synthesis involved cleavage of the silyl 
ether protecting group under acidic conditions, acetylation of the corresponding  
C-3 alcohol and subsequent elimination which was achieved under mildly basic conditions 
using alumina to deliver 2,5-dien-1-one 194 in 13% yield over eight steps (Scheme 65). 
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Scheme 65. Synthesis of jaborosalactone A (195). 
 
Reagents and conditions: i. TBDMSCl, imidazole, DMF (63%); ii. 1) m-CPBA, CHCl3, 
−78 °C, 2) 100 °C (63%); iii. MEMCl, iPr2NEt, CH2Cl2; iv. PDC, DMF (41% over two 
steps); v. AcOH, H2O, THF; vi. Ac2O, pyridine; vii. Al2O3, benzene; viii. H2SO4, THF 
(81% over four steps); ix. m-CPBA, CH2Cl2 (71%). 
 
Another similar example was reported by Grieco and co-workers during the total synthesis 
of (+)-withanolide E (7).
32
 Thereby, the selective acetylation of 1α,3β-diol 196 at C-3 and 
subsequent Swern oxidation of C-1 hydroxyl group furnished ketone 198 in 56% yield 
over two steps. The elimination of C-3 acetyl group was successfully achieved using DBN 
and the final epoxidation step using peracid delivered (+)-withanolide E (7) in 71% yield 
over two steps (Scheme 66). 
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Scheme 66. Synthesis 2,5-dien-1-one fragment via selective acetylation. 
 
Reagents and conditions: i. Ac2O, DMAP, pyridine, rt, 15 h (72%); ii. (COCl)2, DMSO, 
Et3N, CH2Cl2, −78 °C to rt, 1.5 h (78%); iii. DBN, CH2Cl2, rt, 40 min; iv. m-CPBA, 
NaHCO3, CH2Cl2, 18 h (71% over two steps). 
 
More recently (2001), Sodano’s group was able to similarly synthesise 2,5-dien-1-one 201 
in 55% yield from diol 199 over three steps during the total synthesis of 11-acetyl-24-
desmethyl-stoloniferone C (202), a bioactive secondary metabolite from a marine 
invertebrate (Scheme 67).
90 
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Scheme 67. Synthesis of 11-acetyl-24-desmethyl-stoloniferone C (202). 
 
Reagents and conditions: i. Ac2O, pyridine, rt, 12 h (91%); ii. PDC, 3 Ǻ molecular sieves, 
CH2Cl2, rt, 6 h (75%); iii. Al2O3, benzene, reflux (80%); iv. m-CPBA, NaHCO3, CH2Cl2, 0 
°C, 5 h (28%). 
 
4.1.2. Studies of the A-ring functionalisation using a model system  
 
In order to investigate the A-ring functionalisation, an optimisation study was undertaken 
using ketone 61 as a model system. The first step was the selective acetylation of diol 61 at 
C-3, to this aim several conditions were attempted and are summarised in Table 9 
(Scheme 68). 
 
 
 
Scheme 68. Attempted selective acetylation of diol 61. 
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Table 9. Screening of conditions for the selective acetylation of diol 61. 
 
Entry Reagents Conditions Outcome 
1 Ac2O (2.2 eq.), pyridine (5.0 eq.), DMAP (0.1 eq.),  CH2Cl2, rt, 1.5 h 
203: 8% 
  204: 62% 
2 Ac2O (3.6 eq.), NEt3 (2.6 eq.), DMAP (0.1 eq.),  CH2Cl2, rt, o/n 
203: 24% 
204: 67% 
3 Ac2O (1.8 eq.), NEt3 (1.3 eq.), DMAP (0.1 eq.),  CH2Cl2, rt, o/n 
203: 43% 
204: 24% 
4 Ac2O (3.6 eq.), NEt3 (2.6 eq.), DMAP (0.1 eq.)  CH2Cl2, 0 °C, o/n 
203: 44% 
204: 19% 
 
5 Ac2O (1.8 eq.), NEt3 (1.3 eq.), DMAP (0.1 eq.),  CH2Cl2, rt, 1.5 h 
203: 49%,  
85% brsm  
204: 10% 
6 Ac2O (2.2 eq.), pyridine (5.0 eq.), 
 
CH2Cl2, rt, o/n 203:  50% 
7 Ac2O (3.6 eq.), NEt3 (2.6 eq.), DMAP (0.05 eq.) CH2Cl2, rt, o/n 
203: 65% 
204: 20% 
 
 
As outlined in Scheme 67 for the synthesis of 11-acetyl-24-desmethyl-stoloniferone C 
(202), the selective acetylation of C-3 hydroxyl group has been reported in the literature in 
good yield.
90
 Unfortunately, in our hands these reaction conditions only led to moderate 
yield (Table 9, entry 6). Similarly, the conditions used by Gademann’s group for the total 
synthesis of withanolide A (8)  (Scheme 6) were attempted and unfortunately, the major 
compound isolated was the diacetylated product 204 in 67% yield, probably because of the 
excess of acetic anhydride used (Table 9, entry 2).
35
 Therefore, a screening study was 
undertaken based on the variation of the previous reaction conditions such as changing the 
base, decreasing the number of equivalent of the reagents, varying the time and the 
temperature of the reaction (Table 9, entries 1, 3, 4 and 5). Disappointingly, none of these 
reaction conditions significantly improved the yield of the reaction. Fortunately, decreasing 
the number of equivalent of the DMAP catalyst helped deliver the desired compound 203 
in an acceptable 65% yield (Table 9, entry 7). Hence, these conditions were used when 
applying this reaction to the target steroidal system 21. The desired acetate 203 was a novel 
compound and therefore, fully characterised. 
1
H- and 
13
C-NMR data of diacetate 204 were 
consistent with those previously published in the literature.
91 
 
It was considered that the protection of diol 61 could be achieved with better selectivity 
using bulkier protecting groups. Therefore, diol 61 was selectively protected at C-3 with 
the benzoyl functionality using benzoyl chloride under standard reaction conditions 
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allowing the formation of the desired product 205 in 68% yield alongside with the 
dibenzoylated product 206 in 19% yield (Scheme 69).
92 
 
 
 
Scheme 69. Selective benzoylation of diol 61. 
 
Reagents and conditions: i. BzCl, pyridine, CH2Cl2, rt, 12 h (68% of 205 and 19%  
of 206). 
 
Another option was to protect diol 61 with a pivaloyl group. This reaction was run under 
standard conditions and unfortunately, led mostly to the recovery of the starting material 
61 alongside formation of the desired compound 207 selectively but in poor yield (14%) 
(Scheme 70).
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Scheme 70. Selective pivaloylation of diol 61. 
 
Reagents and conditions: i. PvCl, pyridine, CH2Cl2, rt, 12 h (14%). 
 
These three last compounds 205, 206 and 207 were novel and therefore, fully 
characterised. 
 
The next key step was the oxidation of C-1 alcohol 205 to the corresponding ketone using 
Dess-Martin reaction conditions. Unfortunately, decomposition reactions competed and the 
desired ketone 208 was only formed in poor yield (32%). Furthermore, the following 
elimination step using KOH was unsuccessful in this instance and only led to recovery of 
the starting material 208 (Scheme 71).   
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Scheme 71. Synthesis of 2,5-dien-1-one 209 via elimination of C-3 benzoyl group. 
 
Reagents and conditions: i. DMP, CH2Cl2, rt, 12 h (32%); ii. 0.1 M KOH, dioxane, rt, 15 
min. 
 
Given the previous results, it was suggested that using this benzoyl protecting group was 
not the best option. Fortunately, the Dess-Martin oxidation of the acetoxy protected  
C-1 alcohol 203 was successful and pleasingly delivered the desired ketone 210 
quantitatively (Scheme 72). Ketone 210 was a novel compound and therefore, fully 
characterised.
 
 
 
Scheme 72. Dess-Martin oxidation of alcohol 203. 
 
Reagents and conditions: i. DMP, CH2Cl2, rt, 12 h (100%). 
 
The elimination step of acetate 210 to obtain the corresponding 2-en-1-one 209 was 
investigated next (Scheme 73, Table 10). 
 
 
Scheme 73. Synthesis of 2,5-dien-1-one 209. 
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Table 10. Screening of conditions for the elimination of C-3 acetate group 210. 
 
Entry Conditions Outcome 
1 0.1 M KOH (0.5 mL), dioxane, rt, 3 h 209: 76%, 100% brsm 
2 DBN (2.0 eq.), rt, 40 min
 
211: 89% yield 
3 DBN (0.5 eq.), rt, 10 min
 
211/209: (1:0.12) 
4 Al2O3 (25 eq.), benzene, rt  55 °C, 5 h 209: 95% 
 
 
Considering that a related elimination was reported in the literature using DBN as the base, 
these reaction conditions were the first to be tested with our model system 210.
32,88
 
Surprisingly, upon elimination of the acetate group, 3,5-dien-1-one 211 was isolated as the 
major compound in a very good yield (Table 10, entry 2). It was initially proposed that the 
prolonged time of the reaction might have facilitated isomerisation of the double bond 
from the 2,3- to the 3,4-position. Therefore, the previous reaction was run under the same 
conditions but for 10 min which led to an inseparable mixture of 3,5-dien-1-one 211 and 
2,5-dien-1-one 209 in a 1:0.12 ratio (Table 10, entry 3). Fortunately, other basic conditions 
using less hindered bases delivered the desired 2-en-1-one 209 in very good to excellent 
yields (Table 10, entries 1 and 4).  
Both dienone products 209 and 211 were novel compounds and therefore, fully 
characterised. 
 
4.1.3. Discussion of the elimination step 
It is likely that the elimination step in Scheme 73 proceeded by an E1CB type of 
elimination leading to give the 2-en-1-one substitution in the A-ring.  The assignment of 
enone 209 was supported by typical peaks in its 
1
H- and 
13
C-NMR spectrum indicating the 
presence of an α,β-unsaturated ketone, namely a signal at δ 6.77 (ddd, J3,2 = 10.0 Hz,  
J3,4β = 4.9 Hz, J3,4α = 2.5 Hz) and at δ 5.87 (dd, J3,2 = 10.0 Hz, J2,4β = 2.1 Hz) assigned to the 
vinylic protons H-3 and H-2, respectively; and peaks at δ 204.4, δ 145.2, δ 127.9 attributed 
to C-1, C-3, and C-2, respectively.  
 
Given the aforementioned results of the screening of different bases for the elimination 
reaction leading to two different substitution patterns in the A-ring, we initially thought 
that alkene isomerisation of 209 led to the formation of 211, but an alternative hypothesis 
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is that the steric hindrance between DBN and the C-19 axial methyl group may lead to  
E2-type elimination of H-4 rather than an E1CB elimination. The structural assignment of 
the 3,5-dien-1-one 211 was verified by the presence of distinctive peaks in the 
1
H- and  
13
C-NMR spectra, i.e. two downfield signals at δ 6.03 (br d, J3,4 = 9.3 Hz), δ 5.61-5.59 (m) 
assigned to the vinylic protons H-4 and H-3, respectively, and two high field peaks at  
δ 129.4 and at δ 121.6 attributed to C-4 and C-3, respectively.  
 
4.1.4. “The End Game”: the synthesis of 14,17-dideoxy-17-epi-withanolide F (24) 
 
Given the aforementioned optimisation studies on the model system 61 towards the 
synthesis of the 2-en-1-one fragment in the A-ring, the best results were applied to the 
desired steroidal target; thus, diol 21 was selectively acetylated at C-3 in good yield  
(only 17% of the bisacetylated compound 212 was isolated). Subsequent Dess-Martin 
oxidation of C-1 hydroxyl group 22 delivered ketone 23 in 84% and the final elimination 
step using basic alumina allowed the formation of the desired target 2,5-dien-1-one 24 in 
excellent yield (Scheme 74). The data of acetate 22, the undesired diacetate 212 and 
ketone 23 were consistent with those previously published in the literature.
25 
 
 
Scheme 74. Construction of A-ring 2-en-1-one fragment of target compound 24. 
 
Reagents and conditions: i. Ac2O, Et3N (50% in CH2Cl2), DMAP, CH2Cl2, rt, 6 h (72%); 
ii. DMP, CH2Cl2, rt, 2 h (84%); iii. Al2O3, benzene, 50 °C, 3.5 h (90%). 
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4.1.5. Characterisation of 14,17-dideoxy-17-epi-withanolide F (24) 
Once the total synthesis of 14,17-dideoxy-17-epi-withanolide F (24) was completed,  
1
H- and 
13
C-NMR spectral data of the synthetic sample  (see Appendix III for copies of 
NMR spectra) were compared to the data previously reported in the literature  
by Choudhary et al.
40
 Although most of the signals match, some errors were noticed in the 
published literature. The incorrect peaks reported in the literature are highlighted in Tables 
11 and 12. 
 
 
 
 
 
Table 11. Comparison of 
1
H-NMR spectral data. 400 MHz, CDCl3. 
Atom (ppm) Reported* (ppm) Synthetic 
2 5.89 (dd, 9.8, 3.0) 5.87 (dd, 9.9, 3.0) 
3 6.74 (m) 6.75 (ddd, 9.9, 4.6, 3.0) 
4 2.79 (dd, 21.6, 4.8) 3.27 (dd, 21.4, 2.4), 2.85 (dd, 21.4, 4.6) 
 
 
2.85 (dd, 21.4, 4.6) 
6 5.58 (br d, 6.0)
 
5.55 (br d, 6.10) 
7 1.98 (m), 1.90 (m)
 
1.97-1.94 (m), 1.52-1.45 (m) 
8 1.52 (m)
 
1.42-1.37 (m) 
9 1.60 (m)
 
1.64-1.59 (m) 
11 1.50 (m)
 
2.18 (br dd, 13.1, 3.4) 
1.55-1.47 (m) 
12 1.69 (m)
 
2.04 (br d, 12.8) 
1.42-1.34 (m) 
14 3.65 (m)
 
1.11-1.07 (m) 
15 1.25-1.09 (m)
 
1.62-1.59(m) 
1.18-1.14(m) 
16 2.01 (m)
 
1.98-1.95(m) 
1.55-1.50 (m) 
17 1.58 (m)
 
1.47-1.43 (m) 
18 1.21 1.21 
19 0.89 0.89 
21 1.28 1.29 
22 4.20 (dd, 13.2, 3.4) 4.20 (dd, 13.4, 3.3) 
23 2.38 (m), 2.10 (m)
 
2.39 (br dd, 15.6, 15.0) 
2.11 (br dd, 17.4, 2.8) 
27 1.86 1.87 
28 1.93 1.97 
*1
H-NMR spectral data recorded at 500 MHz in CDCl3. 
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Table 12. Comparison of 
13
C-NMR spectral data. 125 MHz, CDCl3. 
Atom (ppm) Reported* (ppm) Synthetic 
1 204.5 204.4 
2 127.9 127.9 
3 145.2 145.1 
4 33.4 33.5 
5 135.9 135.9 
6 124.7 124.7 
7 31.6 30.7 
8 39.7 32.6 
9 40.1 42.8 
10 50.1 50.5 
11 21.9 23.4 
12 23.4 40.2 
13 49.6 42.9 
14 54.7 56.7 
15 29.6 23.9 
16 42.9 21.8 
17 56.6 54.7 
18 18.9 19.0 
19 13.6 13.6 
20 75.2 75.2 
21 20.5 21.0 
22 81.0 81.0 
23 30.6 31.6 
24 149.0 148.8 
25 122.0 122.0 
26 166.2 166.0 
27 12.7 12.4 
28 21.7 20.5 
*13
C-NMR spectral data recorded at 125 MHz in CDCl3. 
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As can be seen in the above tables (Tables 11 and 12), our spectroscopic data for  
14,17-dideoxy-17-epi-withanolide F (24) fail to match that reported by Choudhary et al. in 
the original isolation paper. In order to gather a clearer conclusion as to the discrepancies 
observed in the 
1
H- and 
13
C-NMR spectra, a sample of 14,17-dideoxy-17-epi-withanolide 
F (24) or the original NMR spectroscopic data will be requested directly from the authors 
of the isolation paper. Only upon receipt and processing of the raw data will we be able to 
confirm that the hypothesis that original structural assignement was incorrect. 
 
4.2. Synthesis of Other Analogues of Withanolide F (1) 
As mentioned in Chapter 1, biological properties of analogues of withanolide F (1) have 
not been studied in detail yet. Therefore, in order to broaden the SAR studies of compound 
(1), the syntheses of other withanolide F (1) analogues were investigated. 
 
4.2.1. The first synthesis of 3,4-dihydro-Δ3,4-14,17-dideoxy-17-epi-withanolide F (213) 
An interesting outcome of the optimisation study on the model system 61 was the 
formation of the 3-en-1-one compound 211 when using DBN as the base. These basic 
conditions were attempted on acetate 23 and led to a mixture of 3-en-1-one 213 and  
2-en-1-one 24 in a 1:0.18 ratio and in excellent yield (91%) (Scheme 75). Unfortunately, 
these two compounds 213 and 24 were not separable by column chromatography. 
 
 
Scheme 75. Synthesis of 3,5-dien-1-one 213 via elimination of acetate group 23. 
 
Reagents and conditions: i. DBN, CH2Cl2, rt, 45 min (91% of 213/24 in 1:0.18 ratio). 
 
In the literature, the migration of the A-ring double bond from a 2,3-position to the  
3,4-position has been disclosed by Lavie et al. strictly under acidic conditions (both in 
nature and under synthetic conditions).
25 
Fortunately, in our hands,  isomerisation of the 
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2,3-double bond in the A-ring was successful under basic conditions and delivered the 
desired 3,4-dihydro-Δ3,4-14,17-dideoxy-17-epi-withanolide F (213) as a single product in 
excellent yield (Scheme 76).  
 
 
Scheme 76. Synthesis of 3,5-dien-1-one 213 via isomerisation of 2,3-double bond. 
 
Reagents and conditions: i. DBN, CH2Cl2, rt, 3 h (98%). 
 
This constitutes the first total synthesis of 3,4-dihydro-Δ3,4-14,17-dideoxy-17-epi-
withanolide F (213), an interesting analogue of withanolide F (1), that is novel and was 
never been isolated. It has been reported in the literature by Lavie et al. that this 3-en-1-one 
substitution pattern is rarely observed in nature and the only isolated withanolides that 
possess it are withanolide I (214)
11
 and withanolide K (215)
94
 (Figure 21).
 
 
 
Figure 21. Structures of withanolide I (214) and withanolide K (215).
 
 
4.2.2. Characterisation of 3,4-dihydro-Δ3,4-14,17-dideoxy-17-epi-withanolide F (213) 
Based on comparison of the 
1
H- and 
13
C-NMR signals of withanolide I (214) and K (215) 
that possess the same 3,5-dien-1-one system, the structure of 3,4-dihydro-Δ3,4-14,17-
dideoxy-17-epi-withanolide F (213) was confirmed (see Appendix IV for copies of NMR 
spectra).
11
 Thus, the coupling pattern of the olefinic protons H-3 (δ 5.60-5.58, m),  
H-4 (δ 6.03, d, J4,3 = 9.2 Hz), H-6 (δ 5.63, br d, J = 3.1 Hz) and of the CH2 group H-2  
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(δ 3.28, br d, J = 19.5 Hz and δ 2.73, dd, J = 19.5 Hz, J2,3 = 4.3 Hz) together with the high 
value of C-19 methyl signal at δ 1.35 were consistent with a 3,5-dien-1-one substitution 
pattern. 
 
4.2.3. Attempted synthesis of glycoside 216 
Promising results of cardiac glycosides that produced strong inhibitors of Hh/Gli signalling 
pathway expressed in human pancreatic cancer cells during their in vitro screening were 
previously outlined in Chapter 1.
12
 Moreover, a sugar derivative of withanolide F (1) was 
isolated from Withania adpressa by AnalytiCon Discovery GmbH and showed some 
interesting bioactivity during the in vivo testing (these results cannot be reported here for 
confidentiality reasons). Given these previous observations, it became clear that it would 
be interesting to synthesise a similar C-3 aglycone analogue 216 (Figure 22). 
 
.  
Figure 22. Structure of C-3 aglycone analogue 216. 
 
To this aim, a synthetic route was designed using a key intermediate from the total 
synthesis previously described. Triol 21 was selectively protected at C-3 using a THP ether 
protecting group. Under standard reaction conditions and at room temperature the reaction 
was not selective; the bis-THP protected compound 218 was obtained as an inseparable 
mixture of four diastereoisomers at C-29 and C-34.
29
 However, pleasingly the desired  
C-3 THP protected compound 217 was obtained in 57% yield as a mixture of inseparable 
two diastereoisomers at C-29 when carrying out the reaction at low temperature with fewer 
equivalents of DHP (Scheme 77).  The following oxidation step allowed the formation of 
ketone 219 in 61% yield under Dess-Martin reaction conditions. The subsequent cleavage 
of THP protecting group using standard acidic conditions led to the desired C-3 alcohol 
220 quantitatively.
29
 These three key intermediates 217, 219 and 220 in the synthesis of  
C-3 aglycone analogue 216 were novel, and therefore, fully characterised. 
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Scheme 77. Synthesis of hydroxyketone 220. 
 
Reagents and conditions: i. DHP, p-TsOH, CH2Cl2, rt, 3 h (57% of 217 and 19% of 218); 
ii. DMP, CH2Cl2, rt, 3 h (61%); iii. 2 M HCl, MeOH, rt, 2 h (100%). 
 
Unfortunately, an attempted glycosylation of alcohol 220 with commercially available 
acetobromo-α-D-glucose (221) and CF3SO3Ag promotion was unsuccessful.
95
 This 
reaction only led to the synthesis of acetate 23 and 2,5-dien-1one 24, which probably 
resulted from the elimination of C-3 acetate 23 under basic conditions (Scheme 78).  
This reaction was run on a very small scale (~ 15 mg, 0.0329 mmol), therefore, no 
conclusive yields were obtained. 
 
Scheme 78. Attempt to glycosylate alcohol 220. 
Reagents and conditions: i. CF3SO3Ag, 4 Ǻ molecular sieves, CH2Cl2, 0 °C to rt, 6 h. 
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The competing hydrolysis of glucose derivative 221 via ortho-ester formation was 
previously reported in the literature by Polt et al. during their synthesis of O-linked 
glycopeptides analogues of encephalin (Scheme 79).
95  
 
 
Scheme 79. Ortho-ester formation. 
 
Reagents and conditions: i. CF3SO3Ag, 4 Ǻ molecular sieves, 0 °C to rt, 6 h. 
 
They suggested that using a sugar protected with benzyl groups could help avoid this side 
reaction. Unfortunately, in our case, there is a good chance that the subsequent 
deprotection of the benzyl groups under hydrogenation conditions would also hydrogenate 
the 5,6-double bond of the desired target molecule 216.  
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4.3. Summary and Future Work 
4.3.1. Summary 
In summary, the acetylation-oxidation-elimination sequence enabled the total synthesis of 
14,17-dideoxy-17-epi-withanolide F (24) to be achieved in 14 steps and in an overall  
5.3% yield (Scheme 80). The key features of the total synthesis included a Birch reduction, 
a C-1 homologation process through a Corey-Seebach reaction, an efficient dithiane 
cleavage and a vinylogous aldol reaction to build the key δ–lactone side chain. Pleasingly, 
a novel analogue of withanolide F (1), 3,4-dihydro-Δ3,4-14,17-dideoxy-17-epi-withanolide 
F (213), was synthesised in 15 steps and in 5.2% overall yield (Scheme 80). The key step 
of the total synthesis was the migration of the 2,3-double bond of  
14,17-dideoxy-17-epi-withanolide F (24) under basic conditions. 
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Scheme 80. Total syntheses of 14,17-dideoxy-17-epi-withanolide F (24) and 3,4-dihydro-
Δ3,4-14,17-dideoxy-17-epi-withanolide F (213). 
 
Reagents and conditions: i. ethylene glycol, p-TsOH, toluene, 130 °C, 12 h (90%); ii. 
Pd(OAc)2, ADP, Na2CO3, DMF, 160 °C, 72 h (62%); iii. H2O2 (30% w/w),  
10% NaOH in MeOH, 
i
PrOH, 15 °C, 12 h (72%); iv. Li/NH3, NH4Cl, THF, −78 °C  
to −40 °C to −20 °C, 4 h (76%); v. MOMCl, 1,4-dioxane, reflux, 6 h (92%);  
vi. AcOH/H2O/THF (65:35:10), rt, 12 h (100%); vii. 1,3-dithiane, 
n
BuLi, THF,  
−5 °C, 8 h (71%); viii. MOMCl, iPr2EtN, 1,4-dioxane, reflux, 12 h (85%); ix. NCS, AgNO3, 
CH3CN/H2O (4:1), 0 °C, 30 min (85%); x. LiHMDS, THF/DMPU (8:2), −78 °C,  
6 h; xi. 6 M aq. HCl, THF, rt, 7 h (67% over two steps); xii. Ac2O, Et3N (50% in CH2Cl2), 
DMAP, CH2Cl2, rt, 6 h (72%); xiii. DMP, CH2Cl2, rt, 2 h (84%); xiv. Al2O3, benzene,  
50 °C, 3.5 h (90%); xv. DBN, CH2Cl2, rt, 3 h (98%). 
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4.3.2. Future work 
Future work will focus on building a library of other analogues of withanolide F (1) using 
14,17-dideoxy-17-epi-withanolide F (24) and 3,4-dihydro-Δ3,4-14,17-dideoxy-17-epi-
withanolide F (213) via A/B-ring functionalisation and variation of the side chain. Many 
variants should be available using standard chemistry such as, for example, epoxidation to 
form a 5β,6β-epoxide;29 this is a key feature that has showed some positive influence on 
the bioactivity of some withanolides (see SAR studies in Chapter 1).
39
 Completing the 
synthesis of the C-3 aglycone analogue 216 by using other sugars that possess different 
protecting groups should also be investigated.
96
 Other methods could be studied in order to 
synthesise different sugar derivatives, for example, via the Ferrier reaction using 
commercially available tri-O-acetyl-D-glucal (224) to form glycoside 225, another novel 
analogue of withanolide F (1) (Scheme 81).
97,98 
 
 
Scheme 81. Synthesis of glycoside analogue 225 via Ferrier reaction. 
 
Suggested reagents and conditions: i. BF3•Et2O, CH2Cl2, −20 °C to rt, 1 h; ii. K2CO3, 
MeOH/H2O (4:1), rt, 1 h. 
 
As mentioned in Chapter 1, the main purpose of building a library of analogues of 
withanolide F (1) is to allow a better understanding of their possible biological activity and 
to develop SAR studies. Therefore, the next step of this project should be the biological 
testing of the compounds 24 and 213 so far synthesised along with intermediates of the 
total syntheses previously described. These tests should mainly be focused on the influence 
of these molecules and their structural features on the Hh-Gli and Wnt-TCF biological 
pathways.
99,100
 The experiments would involve Luciferase reporter assays which would be 
performed on three different cancer cell types and the level of target gene expression for 
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both signalling pathways would be examined. These experiments should indicate whether 
the tested compounds are Gli and/or TCF agonists or antagonists.  
 
 
Figure 23. Structures of withanolideF (1) and analogues 24 and 213. 
 
Moreover, given the low yields encountered during the synthesis of the  
δ-lactone side chain of the target molecule 24, a new synthetic approach to the synthesis of 
the side chain and later a methodology towards the construction of other type of 
heterocycles as side chains is needed. To this end, a new general methodology for the 
construction of the δ-lactone side chain is discussed in Chapter 5 
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Chapter 5. Methodology Towards the Construction 
of δ-Lactones  
 
5.1. Overview of Published Routes to δ-Lactones 
An overview of published routes to δ-lactone has been described in Chapter 3. From all 
the methods to construct the δ-lactone side chain developed so far, the one step vinylogous 
condensation of an enolate with an aldehyde developed by Ikekawa et al. was the most 
efficient in terms of stereospecificity and yield. As shown in Scheme 4, this reaction has 
been disclosed in the literature to deliver the desired C-22R δ-lactone 41 in a very good 
yield (86%) during the total synthesis of withanolide D.
29
 More recently (2011), this 
procedure has been repeated by Gademann et al. using slightly optimised reaction 
conditions to deliver C-22R δ-lactone 55 in 87% yield (Scheme 6).35 
 
Unfortunately, as discussed earlier in Chapter 3, problems were encountered when trying 
to repeat these literature procedures to form the δ-lactone side chain, 29,35 Another future 
project would be to develop improved procedures. A very short study was carried out to 
evaluate a new variant of the Dreiding-Schmidt reaction for this purpose.
101 
 
5.2. The Dreiding-Schmidt Reaction 
5.2.1. The Dreiding-Schmidt reaction: literature examples 
In 1970 using Dreiding’s previous work on the treatment of cyclohexanone with γ-bromo 
and β’-bromo-tiglic esters under Reformatsky’s conditions,102 Schmidt’s group developed 
a zinc-mediated reaction between a ketone 226 and a bromomethyl acrylic ester 227 to 
give α-methylene-γ-lactones 228 in good yields (42% to 100%) (Scheme 82).101 
 
 
Scheme 82. Synthesis of α-methylene-γ-lactone 228 via the Dreiding-Schmidt reaction. 
Reagents and conditions: i. Zn, THF, 50 °C, 1 h (42% to 100%). 
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Csuk et al. investigated the stereoselectivity of the Dreiding-Schmidt reaction with 
carbohydrates.
103
 They achieved the formation of spiroanellated butyrolactones 231 with 
an additional stereocentre in the β-position of the anellated lactone ring. The yield and the 
stereoselectivity were significantly improved by using the highly reactive  
zinc-silver/graphite surface reagent when compared to using standard carbohydrate 
reaction conditions (24% yield reported in the literature).
104
 It was suggested that the 
favoured transition state of the reaction proceeds through a Re-Re attack which avoids  
1,3-diaxial interactions between the substituents (Scheme 83). 
 
 
Scheme 83. Synthesis of spiroanellated butyrolactone 231 via the Dreiding-Schmidt 
reaction. 
 
Reagents and conditions: i. Zn-Ag/graphite, THF, −30 °C (74%). 
 
Csuk’s group was also able to perform an asymmetric synthesis of  
α-methylene-γ-butyrolactones 236 via an diastereotioselective Dreiding-Schmidt 
reaction.
105
 Thus, non-racemic bromomethyl acrylate reagents were tested for their 
potential use as chiral reagents. Carboxylic acid 232 was transformed into amide 234 by 
using the amino moiety of (+)-Oppolzer’s sultam (233) in good yield (74%). The syn-
orientation of the chiral bromomethylacrylate 234 was favoured by the zinc chelation of 
the carbonyl functionalities present in the methacrylamide 234. The methacrylamide 234 
thus formed was submitted to the Dreiding-Schmidt reaction conditions which allowed the 
formation of the corresponding disubstituted butyrolactone 236. The scope of the reaction 
was extended to a broad range of aldehydes 235 and allowed the formation of the desired 
products 236 in very good yield (up to 95%) and e.e. (up to 82%) (Scheme 84). The chiral 
auxiliary 234 was recovered in good yields. It was suggested that the favoured six-
membered chair-like transition state would go through a Sizn-reagent-Realdehyde attack. Indeed, 
the attack of the Si-face of the zinc reagent 234 was preferred due to the steric hindrance of 
the camphor skeleton and the attack of the aldehyde 235 through its Re-face would bring 
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the R
1
 functional group into a favourable equatorial position and avoid any 1,3-diaxial 
interactions with the other substituents.  
 
 
Scheme 84. The Dreiding-Schmidt reaction via methacrylamide 234. 
 
Reagents and conditions: i. NaH, toluene, 25 °C, 2 h (74%); ii. Zn/Ag-graphite, THF, 
0 °C (68% up to 95% yield, 69% up to 82% ee). 
 
5.2.2. Possible new route to δ-lactones via the Dreiding-Schmidt reaction  
An mentioned earlier, given the problems we initially encountered with the published 
routes to build dimethylated δ-lactones (Scheme 58),29,35 we decided to devise a novel 
route. The plan was to use the Dreiding-Schmidt reaction of bromoester 237 and aldehyde 
40 to generate an intermediate lactone 238 in a one-step reaction. The cyclic sulfone 
moiety would ensure that there would be no E/Z issues; subsequent reductive removal of 
the sulfone group would reveal the α,β-dimethyl substitution of the desired δ-lactone 41 
(Scheme 85).  
 
 
Scheme 85. Synthesis of δ-lactone 41 synthesis via the Dreiding-Schmidt reaction. 
Suggested reagents and conditions: i. Zn-Ag/graphite, THF, 0 °C; ii. Raney nickel. 
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Unfortunately, bromoester 237 is not commercially available. Therefore, its synthesis was 
investigated. 
 
5.2.3. Literature routes to bromoester 237 
Unfortunately, to date, the synthesis of bromoester 237 has not been reported in the 
literature. On the other hand, Takayama et al. disclosed a synthetic approach to form 
dibromide 241 from commercially available 2,3-dimethylbuta-1,3-diene (239) in 75% 
yield over two steps (Scheme 86).
106
  
 
 
Scheme 86. Synthesis of dibromide 241. 
 
Reagents and conditions: i. SO2, hydroquinone, MeOH, rt (99%); ii. NBS, CH2Cl2, reflux 
(76%). 
 
Later, Ito et al. synthesised mono-bromide 242 from cyclic sulfone 240 in moderate yield 
by refluxing NBS and catalytic amounts of benzoyl peroxide in benzene (Scheme 87).
107
  
 
 
Scheme 87. Synthesis of mono-bromide 242. 
 
Reagents and conditions: i. NBS, (PhCO2)2, benzene, reflux, 3 h (50%). 
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More recently (2011), Jain et al. described the synthesis of sulfone 245 in 88% yield over 
two steps from commercially available 3-chloro-2-methylpropene (243).
108 
The final  
ring-closing metathesis step to synthesise cyclic sulfone 240 has been disclosed by Yao in 
excellent yield (Scheme 88).
109 
 
 
Scheme 88. Synthesis of cyclic sulfone 240. 
 
Reagents and conditions: i. Na2S, H2O, MeOH, rt to reflux, 8 h (88%); ii. m-CPBA, 
CH2Cl2, 0 °C, 45 min (100%); iii. 0.05 eq. of Grubbs II generation cat., CH2Cl2, reflux,  
24 h (99%). 
 
5.2.4. Proposed retrosynthesis of bromoester 237 
Based on the reactions outlined above, a retrosynthetic route for bromoester 237 was 
designed. Thus, from a retrosynthetic point of view bromoester 237 could be obtained from 
the key mono-bromide 242 via oxidation of the bromide functionality to give the 
corresponding aldehyde and subsequently, the carboxylic acid which, in turn, could be 
treated under standard conditions to form the ester moiety of the final compound 237. 
Finally, the latter could be submitted to standard bromination reaction conditions to form 
bromoester 237. This synthetic approach relies on a ring-closing metathesis of sulfone 245 
using Grubbs’ second generation catalyst, followed by treatment with NBS to give  
mono-bromide 242. In turn, it was envisaged that sulfone 245 could be prepared from 
commercially available 3-choro-2-methylpropene (243) (Scheme 89). 
 
 
Scheme 89. Proposed retrosynthesis of bromoester 237. 
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5.2.5. Synthesis of the key mono-bromide 242 
The initial efforts of the synthesis were focused on accessing mono-bromide 242, a key 
intermediate in the proposed retrosynthesis of bromoester 237 (Scheme 89). Thus, 
methallyl sulfide (244) was synthesised from commercially available 3-choro-2-
methylpropene (243) in an improved yield compared to the literature (100% vs. 88%).
108
 
Standard hydrogen peroxide conditions led only to the formation of the sulfoxide 246
110 
which in turn was oxidized to the corresponding sulfone 245 in quantitative yield using  
m-CPBA. Fortunately, methallyl sulfide (244) could be oxidized using three equivalents of 
m-CPBA to deliver directly sulfone 245 in good yield as previously reported in the 
literature (Scheme 90).
108 
 
 
 Scheme 90. Synthesis of sulfone 245. 
 
Reagents and conditions: i. Na2S, MeOH/H2O (1:1), reflux, 12 h (100%);  
ii. H2O2 (30% w/w), AcOH, rt, 12 h, (46%); iii. m-CPBA, CH2Cl2, 0 °C, 45 min (100%); iv. 
m-CPBA, CH2Cl2, 0 °C, 45 min (81%). 
 
The next key step of the synthesis was the ring-closing metathesis reaction using  
Grubbs’ second generation catalyst. As outlined in Scheme 88, this reaction was reported 
to work in excellent yield (99%) when using 5 mol% of the catalyst.
109
 Unfortunately, in 
our hands these reaction conditions delivered cyclic sulfone 240 in only 45% yield  
(79% brsm). During optimisation studies, it was observed that using 8 mol% of the catalyst 
added portion-wise over 4 h ensured the reaction went to completion. Pleasingly, the cyclic 
sulfone 240 was obtained in quantitative yield (Scheme 91). 
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Scheme 91. Synthesis of cyclic sulfone 240 via ring-closing metathesis. 
 
Reagents and conditions: i. Grubbs II generation cat., CH2Cl2, reflux, 24 h (100%). 
 
With the cyclic sulfone 240 in hand, the mono-bromination was attempted using similar 
reaction conditions as described by Takayama et al. to form dibromide 241.
106
 
Unfortunately, in our hands the reaction led only to recovery of the starting material 240 
(Table 13, entry 1). Therefore, the reaction was thoroughly investigated in order to find the 
optimum conditions (Scheme 92, Table 13). 
 
 
Scheme 92. Bromination of cyclic sulfone 240. 
Table 13. Optimisation study of the bromination step. 
Entry Reagents Conditions Outcome 
1 NBS (1.0 eq.) 
 
CH2Cl2, 45 °C, o/n rsm 240 
2 
NBS (1.6 eq.), 
(PhCO2)2 (0.05 eq.)
 CHCl3, 60 °C, o/n  
242: 22%, 73% brsm 
decomposed mixture 
3 
NBS (3.2 eq.), 
(PhCO2)2 (0.1 eq.) 
CHCl3
 
CHCl3, 60 °C, o/n  
242: 26%, 48% brsm 
decomposed mixture 
4 
NBS (1.2 eq.), 
(PhCO2)2 (0.08 eq.) 
CHCl3
 
benzene, 80 °C, o/n decomposed mixture 
5 
NBS (1.6 eq.), 
(PhCO2)2 (0.05 eq.) 
 chlorobenzene, 100 °C, o/n  
242: 29%, 241: 14% 
decomposed mixture 
6 
NBS (1.0 eq.), 
(PhCO2)2 (0.05 eq.) 
 CCl4, 80 °C, o/n 240/242: (1:1) 
7 
NBS (1.5 eq.), 
(PhCO2)2 (0.05 eq.) 
 CCl4, 80 °C, o/n  240/242: (1:6) 
8 
NBS (2.0 eq.), 
(PhCO2)2 (0.05 eq.) 
 CCl4, 80 °C, o/n 240/242/241: (0.29:1:0.14)  
 
 100 
 
It was first suggested that using catalytic amounts of benzoyl peroxide could help initiate 
the reaction. The reaction was run in chloroform which allowed the formation of the 
desired mono-bromide 242 in low yield (22%) (Table 13, entry 2). Increasing the quantity 
of the reagents did not improve the yield (Table 13, entry 3). Unfortunately, repeating the 
procedure previously published by Ito et al. to from mono-bromide 242 only led to 
decomposition in our case (Table 13, entry 4).
107
 Changing to a higher boiling solvent such 
as chlorobenzene resulted in a slight increase of the yield to 29% along with the isolation 
of dibromide 241 (Table 13, entry 5). Given the mixed decomposition fractions isolated 
previously, it was suggested that the brominated compounds 241 and 242 were not stable 
upon purification by column chromatography. The bromination step was attempted under 
Wohl-Ziegler reaction conditions,
111
 i.e. using CCl4 as the solvent, and varying the number 
of equivalents of NBS in order to allow the reaction to go to completion and to use the 
resulting mono-bromide 242 as crude mixture in the next step. As shown in entries 6 to 8 
(Table 13), when up to 1.5 eq. of NBS was used, no dibromide 241 was formed. 
Therefore, the best conditions were obtained by refluxing a mixture of cyclic sulfone 240 
and 1.5 eq. of NBS (Table 13, entry 6). The structure assignment of mono-bromide 242 
was supported by the presence of typical peaks in the 
1
H- and
 13
C-NMR spectrum 
indicating the presence of three CH2 groups at δ 4.06 (br s), δ 3.95-3.93 (m), δ 3.84-3.82 
(m) attributed to H-6, H-4 and H-1, respectively. Furthermore, the assignment of  
mono-bromide 242 was reinforced by the presence of one bromine atom in mass 
spectrometry (ESI) analysis. These data were consistent with those previously described in 
the literature.
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5.2.6. Studies towards the synthesis of bromoester 237 
The next key step towards the synthesis of bromoester 237 was the synthesis of aldehyde 
253 which was attempted via the Kornblum oxidation of mono-bromide 242. This reaction 
has been disclosed in the literature using allylic halides in moderate to good yields.
112,113  
A good example was reported recently (2006) by Kulinkovich et al. during the synthesis of 
(2S,3R,7R)-3,7-dimethyltridec-2-yl acetate (249), an insect pheromone, where they 
synthesised aldehyde 248 in 71% yield under standard reaction conditions (Scheme 93).
112 
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Scheme 93. Kornblum oxidation of allyl-bromide 247. 
 
Reagents and conditions: i. DMSO, NaHCO3, rt, 48 h (71%). 
 
The oxidation of allyl-bromide 250 has also been reported in the literature by Trauner et al. 
using IBX and DMSO in very good yield during the synthesis of shimalactone A (252),  
a neuritogenic natural product (Scheme 94).
113
  
 
 
Scheme 94. Oxidation of allyl-bromide 250 using IBX. 
 
Reagents and conditions: i. IBX, DMSO, 50 °C, 12 h (84%). 
 
Unfortunately, in our hands, these reaction conditions applied to our mono-bromide 
substrate 242 only led to decomposition (Scheme 95).
112,113 
 
 
Scheme 95. Kornblum oxidation of allyl-bromide 242. 
 
Reagents and conditions: i. DMSO, NaHCO3, rt, 12 h or IBX, DMSO, 50 °C, 12 h. 
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Considering that oxidation of allyl-bromide 242 to the aldehyde 253 was unsuccessful, an 
alternative synthetic route was designed and mono-bromide 242 was first hydrolysed to the 
corresponding alcohol 256 prior to the oxidation to form aldehyde 253. A similar reaction 
has been disclosed in the literature by Takayama et al. in the course of their studies 
towards the construction of furan-annelated 3-sulpholene (255).
114
 Thus, the hydrolysis of 
dibromide 241 by treatment with CF3CO2Ag delivered diol 254 in excellent yield  
(Scheme 96). 
 
 
Scheme 96. Synthesis of diol 254. 
 
Reagents and conditions: i. CF3CO2Ag, H2O, rt, 3 d (93%). 
 
Based on the reaction conditions described above, hydrolysis of mono-bromide 242 was 
attempted but only delivered the desired allylic alcohol 256 in poor yield (Scheme 97). 
Therefore, a screening of conditions was conducted as summarised in Table 14.  
 
 
Scheme 97. Synthesis of allyl-alcohol 256. 
 
Reagents and conditions: i. 2.0 eq. CF3CO2Ag, H2O, rt, 12 h (15%). 
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Table 14. Screening of conditions for the hydrolysis of mono-bromide 242. 
Entry Reagent Conditions Outcome 
1 AgNO3 (1.0 eq.) H2O, rt, o/n rsm 242 
2 AgO (2.0 eq.) H2O, rt, o/n 256: 83% 
3*
 
CF3CO2Ag (2.0 eq.) H2O, rt, o/n 256: 100%  
*: Inverted addition, mono-bromide 242 was added to a solution of 
CF3CO2Ag in H2O at rt. 
 
A screening of different silver salts was undertaken and the desired allyl-alcohol 256 was 
obtained in good yield when using silver oxide (Table 14, entry 2). It was suggested that 
the yield of the reaction could be improved by inverting the addition of the reagents and 
applying a vigorous stirring as the mono-bromide 242 was not soluble in water. Pleasingly, 
the reaction conditions described in entry 3* allowed the formation of novel alcohol 256 
quantitatively.  
 
The next step was the oxidation of alcohol 256 to aldehyde 253 which was carried out 
using standard reaction conditions as summarised in Table 15 (Scheme 98). 
 
 
Scheme 98. Synthesis of aldehyde 253 via oxidation of alcohol 256. 
 
Table 15. Screening of conditions for the oxidation of alcohol 256. 
Entry Conditions Outcome 
1
115 
MnO2 (5.0 eq.), CH2Cl2, rt, o/n 253:  40%, 96% brsm 
2
116 
DMP (2.0 eq.), CH2Cl2, rt, o/n 253: 49% 
 
Disappointingly, aldehyde 253 was synthesised in only moderate yields up to 49% under 
standard reaction conditions (Table 15, entries 1 and 2). Aldehyde 253 was a novel 
compound and therefore, fully characterised. 
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Unfortunately, attempt to access carboxylic acid 257 from aldehyde 253 was unsuccessful 
under Pinnick’s oxidation conditions and only led to decomposition (Scheme 99).117,118  
 
 
Scheme 99. Synthesis of carboxylic acid 257 via Pinnick oxidation. 
 
Reagents and conditions: i. NaClO2, NaH2PO4, 2-methyl-2-butene, CH3CN/H2O (3:1), rt, 
12 h. 
 
In order to address previous issues to synthesise the ester moiety of bromoester 237, 
another synthetic approach was investigated. One option was the one-pot tandem oxidation 
process developed by Taylor’s group to synthesise esters and amides from activated 
alcohols which was reported in moderate to excellent yield (Scheme 100).
119
 
 
 
Scheme 100. Synthesis of ester 259 via tandem oxidation process. 
 
Reagents and conditions: i. MnO2, NaCN, EtOH, THF, rt, 7 d (49%). 
 
Unfortunately, in our case, these reaction conditions only led to recovery of the starting 
material 256 (Scheme 101). 
 
 
Scheme 101. Synthesis of ester 260 via tandem oxidation process. 
 
Reagents and conditions: i. MnO2, NaCN, EtOH, THF, rt, 3 d. 
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5.3. Summary and Future Work 
5.3.1. Summary 
Although not yet completed, good progress has been made towards the first synthesis of 
bromoester 237, a key reagent for the Dreiding-Schmidt reaction. The synthesis of 
aldehyde 253 was achieved in 40% yield over six steps (Scheme 102). The key features of 
the synthesis included an efficient m-CPBA oxidation, a ring-closing metathesis and a 
silver salt promoted hydrolysis of bromide moiety. 
 
 
Scheme 102. Synthesis of aldehyde 253. 
Reagents and conditions: i. Na2S, MeOH/H2O (1:1), reflux, 12 h (100%);  
ii. m-CPBA, CH2Cl2, 0 °C, 45 min (81%); iii. Grubbs II generation cat., CH2Cl2, reflux,  
24 h (100%); iv. 1.5 eq. NBS, (PhCO2)2, chlorobenzene, 100 °C, 12 h; v. CF3CO2Ag, H2O, 
rt, 12 h; vi. DMP, CH2Cl2, rt, 12 h (49% over three steps). 
 
5.3.2. Future work 
The next key steps of the synthesis of bromoester 237 involve a screening of reaction 
conditions to oxidize aldehyde 253 to carboxylic acid 257 including using KMnO4, AgO, 
PDC.
120,121,122
 In turn, carboxylic acid 257 could be converted into the corresponding ester 
260 using standard esterification conditions.
123
 Finally, the desired bromoester 237 would 
be obtained using previously described Wohl-Ziegler reaction conditions (Scheme 103).
111
 
 
Scheme 103. Synthesis of the key bromoester 237. 
Suggested reagents and conditions: i. KMnO4 or AgO or PDC; ii. H2SO4, EtOH, reflux;  
iii. NBS, CCl4, reflux, 12 h. 
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On the other hand, Kulinkovich et al. has reported recently the synthesis of ester 262 from 
allyl-bromide 261 quantitatively in one step possibly via a Dreiding-Schmidt type reaction 
(Scheme 104).
124
  
 
 
Scheme 104. Synthesis of ester 262 from bromide 261. 
 
Reagents and conditions: i. Zn, CuCl, 1,2-dibromoethane, ClCO2Et, THF/Et2O, reflux,  
1.5 h (100%). 
 
This reaction outlined above would constitute an interesting option to access ester 260 
directly from mono-bromide 242 (Scheme 105).  
 
 
Scheme 105. Synthesis of ester 260 from allyl-bromide 242. 
 
Suggested reagents and conditions: i. Zn, CuCl, 1,2-dibromoethane, ClCO2Et, THF/Et2O, 
reflux, 1.5 h. 
 
With bromoester 237 in hand, a range of different aldehydes 263 including the model 
system aldehyde 118 synthesised in Chapter 2, could be submitted to the standard 
Dreiding-Schmidt reaction conditions to form the corresponding heterocyclic  
δ-lactones 264. In turn, the sulfone moitey of compound 264 could be reduced using 
standard Raney nickel conditions to allow the formation of the desired δ-lactone 265 
(Scheme 106). 
 
 107 
 
 
Scheme 106. Synthesis of δ-lactone 265 via the Dreiding-Schmidt reaction using  
bromoester 237. 
 
Suggested reagents and conditions: i. Zn-Ag/graphite, THF, 0 °C; ii. Raney nickel. 
 
From this screening of conditions on model steroid systems, optimum reaction conditions 
could be developed and implemented in the total synthesis of 14,17-dideoxy-17-epi-
withanolide F (24) in order to improve the yield of the δ-lactone side chain construction as 
described in Scheme 85. 
 
Another focus of the project in the future could involve variations of the side chain, in 
particular the substitution of the -lactone by other heterocycles. Lactams, carbamates, 
cyclic ethers and amines are options, as well as variation of the ring size to construct the 
corresponding -lactone or -lactone (Figure 23).  
 
 
Figure 24. Variation of the δ-lactone side chain. 
 
Variation of the side chains would give the opportunity to expand the library of analogues 
of withanolide F (1) and allow a better understanding of their possible biological activities.  
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Chapter 6. Experimental  
 
6.1. General Experimental Procedures 
NMR spectra were recorded on a Jeol ECX 400 instrument (
1
H: 400 MHz and  
13
C: 100 MHz) at the University of York and on a Bruker DPX 400 (
1
H: 400 MHz and 
13
C: 100 MHz) or a Bruker DRX 500 (
1
H: 500 MHz and 
13
C: 125 MHz) spectrometer at 
AnalytiCon Discovery GmbH, and measured at rt. Chemical shifts are quoted in ppm, 
they are calibrated to the residual non-deuterated solvent peak (
1
H, CHCl3:  
δ = 7.25 ppm, MeOH: δ = 3.31 ppm; 13C, CHCl3: δ = 77.0 ppm, MeOH: δ = 49.0 ppm) 
and are reported as follows: chemical shift δ/ppm (number of protons, multiplicity, 
coupling constant J/Hz, assignment) [br, broad; s, singlet; d, doublet; t, triplet; m, 
multiplet]. Coupling constants, J, are reported to the nearest 0.1 Hz. Structural 
assignments were verified by COSY, NOESY, HMBC and HSQC spectroscopy where 
necessary. The numbering of compounds is for characterisation purposes and, while it 
conforms to IUPAC where possible, it may vary from the numbering in the compound 
name. Infra-red spectra were recorded neat on a ThermoNicolet IR-100 spectrometer. 
Spectra were analysed as thin films on NaCl plates dispersed from CDCl3. Only 
structurally important absorptions are quoted. Absorption maxima (max) are quoted in 
wavenumbers (cm
-1
). Optical rotations were determined using a JASCO DIP-370 
Digital polarimeter using a sodium lamp at a wavelength of 589 nm and are quoted in 
units of 10
−1
 deg cm
2
 g
−1
. Concentrations are quoted in g/100 mL.
 
Mass-spectra (low 
and high resolution) were obtained by the University of York Mass Spectrometry 
Service, using electrospray ionization (ESI) on a Bruker Daltonics, Micro-tof 
spectrometer. Melting points were determined using a Gallenkamp melting point 
apparatus and are uncorrected. Thin layer chromatography (TLC) was performed on 
aluminium plates coated with Merck Silica gel 60 F254, and visualisation was achieved 
by UV light (λmax = 254 nm) and/or by staining with anisaldehyde or potassium 
permanganate. Flash column chromatography was carried out using Fluka flash silica 
gel 60 using head pressure by means of bellows and the specified eluent. Petroleum 
ether (PE) refers to the fraction boiling in the range 40-60 °C. When required, diethyl 
ether, THF, CH2Cl2, acetonitrile and toluene were obtained dry from an Innovative 
Technology Inc. PureSolv Purification System. Degassed solvent refers to solvent 
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which has been purged with argon for at least 2 h. All reactions were carried out in 
oven-dried glassware and under an inert atmosphere of argon unless stated otherwise. 
All commercially available reagents and solvents were used as supplied unless stated 
otherwise.  
The literature reference above the compound titles corresponds to known procedures 
either from the identical substrate or as a general procedure. The literature references 
corresponding to the data are included within the text. 
 
6.2. Experimental Procedures 
6.2.1 Chapter 2. Synthesis of the key aldehyde for withanolide synthesis 
20-Hydroxypregnolone (90)
29
  
 
 
 
 
 
 
NaBH4 (130 mg, 3.30 mmol, 1.0 eq.) was added over 5 min to a solution of pregnenolone 
(36) (1.00 g, 3.20 mmol, 1.0 eq.) in MeOH (10 mL) and THF (6 mL) at 0 °C. After  
50 min, the reaction mixture was carefully quenched with water (10 mL) and adjusted to 
pH 2 with 1 M aq. HCl. The mixture was then extracted with CH2Cl2 (20 mL). The organic 
fraction was dried over Na2SO4, filtered and concentrated to dryness in vacuo to give the 
title compound 90 (1.12 g, 3.51 mol, 100%) as a white foam and as an inseparable mixture 
of two diastereoisomers at C-20 in a 4:1 ratio: mp 188-191 °C decomposed (Lit.
125  
184-185 °C decomposed); Rf 0.39 (1:1 heptane/EtOAc); [α]D
23 −79.0 (c 1.0, CHCl3) 
(Lit.
126
 [α]D
20 −68.5, c 0.8, CHCl3); υmax/cm
-1
 (neat) 3374 (O-H stretch), 2895 (C-H 
stretch); δH (400 MHz, MeOD) 5.34 (1 H, br d, J 4.8, H-6), 3.67-3.59 (1 H, m, H-20), 
3.43-3.37 (1 H, m, H-3), 2.27-2.15 (3 H, m, H-4, H-12a), 2.00-1.77 (3 H, m, H-1a, H-2a, 
H-7a), 1.68-1.43 (7 H, m, H-2b, H-7b, H-8, H-11, H-16), 1.37-1.28 (1 H, m, H-17),  
1.24-1.14 (3 H, m, H-12b, H-15), 1.10 (3 H, s, H-21), 1.08-1.07 (1 H, m, H-1b), 1.04-1.03 
(1 H, m, H-14), 1.03 (3 H, s, H-19), 0.99-0.92 (1 H, m, H-9), 0.78 (3 H, s, H-18), 0.62  
(3 H, s, H-18*); δC (125 MHz, MeOD) 142.8 (C-5), 122.2 (C-6), 72.1 (C-3), 70.5 (C-20), 
59.1 (C-17), 58.7 (C-8), 57.5 (C-14), 51.7 (C-9), 43.4 (C-13), 42.7 (C-4), 40.4 (C-12), 38.4 
 110 
 
(C-1), 37.2 (C-10), 32.8 (C-7), 31.9 (C-2), 26.0 (C-16), 26.0 (C-15), 23.5 (C-21), 21.7  
(C-11), 19.6 (C-19), 12.2 (C-18); m/z (ESI) 341 [MNa]
+
. Calcd. for C21H34NaO2: 
341.2451. Found: [MNa]
+
, 341.2462 (−3.3 ppm error). *: signal of minor diastereoisomer. 
Data consistent with those previously reported in the literature.
127 
Lab. Book: LNB0084-001-01. 
 
20-Hydroxypregna-1,4,6-trien-3-one (89)
29
  
 
 
 
 
 
 
A solution of diol 90 (202 mg, 0.634 mmol, 1.0 eq.) and DDQ (475 mg, 2.09 mmol,  
3.3 eq.) in 1,4-dioxane (7 mL) was stirred at reflux temperature for 8 h. The reaction 
mixture was cooled to room temperature, filtered through Celite
®
 and washed with CH2Cl2 
(15 mL). The filtrate was concentrated to dryness in vacuo. The crude residue was purified 
by column chromatography on silica gel (6:4 to 3:7 heptane/EtOAc) to afford the title 
compound 89 (75.0 mg, 0.240 mmol, 38%) as a yellow solid and as an inseparable mixture 
of two diastereoisomers at C-20 in a 9:1 ratio: mp 129-132 °C decomposed (Lit.
29  
131-134 °C decomposed); Rf 0.27 (1:1 heptane/EtOAc); [α]D
23 −21.0 (c 0.1, CHCl3) 
(Lit.
128
 [α]D
20 −19.6, c 0.5, CHCl3); υmax/cm
-1
 (neat) 2932 (O-H stretch), 1646 (C=O 
stretch), 1598 (C=C stretch); δH (400 MHz, MeOD) 7.08 (1 H, d, J 10.2, H-1), 6.25 (1 H, 
br d, J 10.2, H-2), 6.23 (1 H, dd, J 10.0, 2.7, H-6), 6.03 (1 H, br d, J 10.0, H-7), 6.00 (1 H, 
br s, H-4), 3.78-3.73 (1 H, m, H-20), 2.30 (1 H, dd, J 10.3, 10.2, H-8), 2.21 (1 H, ddd,  
J 13.0, 3.4, 3.2, H-12a), 1.86-1.62 (4 H, m, H-11, H-16), 1.49-1.43 (1 H, m, H-9),  
1.40-1.23 (5 H, m, H-12b, H-14, H-15, H-17), 1.20 (3 H, s, H-19), 1.16 (3 H, d, J 6.1,  
H-21),  0.88 (3 H, s, H-18), 0.76 (3 H, s, H-18*); δC (125 MHz, MeOD) 187.2 (C-3), 
162.7 (C-5), 152.7 (C-1), 138.4 (C-7), 127.6 (C-2), 125.6 (C-6), 123.7 (C-4), 70.2 (C-20), 
57.9 (C-17), 53.2 (C-14), 48.3 (C-9), 42.5 (C-13), 41.2 (C-10), 39.4 (C-12), 37.8 (C-8), 
26.0 (C-16), 25.8 (C-15), 23.7 (C-21), 21.6 (C-11), 20.7 (C-19), 12.2 (C-18);  
m/z (ESI) 313 [MH]
+
. Calcd. for C21H29O2: 313.2162. Found: [MH]
+
, 313.2156 (2.1 ppm 
error). *: signal of minor diastereoisomer. Data consistent with those previously reported in 
the literature.
29
 Lab. Book: LNB0084-019-08. 
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20-Tetrahydropyranyloxypregna-1,4,6-trien-3-one (78)
29
  
 
 
 
 
 
 
 
 
A solution of hydroxy trienone 89 (156 mg, 0.499 mmol, 1.0 eq.), dihydropyran  
(0.123 mL, 1.45 mmol, 2.9 eq.) and p-TsOH (1.00 mg, 0.007 mmol, 0.013 eq.) in CH2Cl2 
(4 mL) was stirred at room temperature for 3 h. The reaction mixture was quenched with 
sat. aq. NaHCO3 (10 mL) and extracted with CH2Cl2 (10 mL). The aqueous layer was back 
extracted with CH2Cl2 (10 mL), the combined organic extracts were dried over Na2SO4, 
filtered and concentrated to dryness in vacuo to give the title compound 78 (170 mg,  
0.430 mmol, 86%) as a white solid and as an inseparable mixture of four diastereoisomers 
at C-20 and C-22: Rf 0.62 (1:1 heptane/EtOAc + 1.5% Et3N); δH (400 MHz, MeOD) 7.29 
(1 H, dd, J 5.2, 5.2, H-1), 6.30 (1 H, br d, J 9.6, H-6), 6.21 (1 H, dd, J 5.2, 5.2, H-2), 6.14 
(1 H, d, J 9.6, H-7), 5.98 (1 H, br s, H-4), 4.48 (1 H, dd, J 3.5, 3.4, H-22), 3.88-3.82 (1 H, 
m, H-26a), 3.73-3.64 (1 H, m, H-20), 3.55-3.49 (1 H, m, H-26b), 2.42-2.34 (1 H, m, H-8), 
2.26 (1 H, ddd, J 12.9, 3.4, 3.2, H-12a), 1.88-1.39 (13 H, m, H-9, H-11, H-15, H-16, H-23, 
H-24, H-25), 1.37-1.31 (1 H, m, H-17), 1.31-1.25 (2 H, m, H-12b, H-14), 1.23 (3 H, s,  
H-19), 1.11 (3 H, d, J 6.1, H-21), 0.91 (3 H, s, H-18), 0.84 (3 H, s, H-18*); δC (125 MHz, 
MeOD) 187.5 (C-3), 165.5 (C-5), 155.3 (C-1), 140.5 (C-7), 127.0 (C-2), 126.9 (C-6), 
122.5 (C-4), 100.2 (C-22), 69.5 (C-20), 61.8 (C-26), 58.0 (C-17), 53.9 (C-14), 49.0 (C-9), 
43.0 (C-13), 41.6 (C-10), 39.2 (C-12), 38.4 (C-8), 30.6 (C-16), 30.0 (C-23), 25.0 (C-25), 
25.0 (C-15), 25.0 (C-11), 22.9 (C-21), 19.9 (C-19), 19.5 (C-24), 11.2 (C-18);  
m/z (ESI) 397 [MH]
+
. Calcd. for C26H37O2: 397.2737. Found: [MH]
+
, 397.2733 (1.1 ppm 
error). *: signal of one of the minor diastereoisomers. Data consistent with those 
previously reported in the literature.
29 
Lab. Book: LNB0084-013-01. 
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1,2-Epoxy-20-tetrahydropyranyloxypregna-4,6-dien-3-one (37)29  
 
 
 
 
 
 
 
 
To a solution of trienone 78 (170 mg, 0.400 mmol, 1.0 eq.) in MeOH (4 mL) containing 
10% NaOH in MeOH (0.050 mL, cat.) was added hydrogen peroxide (30% w/w,  
0.320 mL, 0.010 mol, 25.0 eq.) at 0 °C. The reaction mixture was stirred 12 h at  
15 °C. The resulting solution was diluted with Et2O (10 mL) and concentrated to dryness in 
vacuo. The crude residue was purified by column chromatography on silica gel (9:1 
heptane/EtOAc) to afford the title compound 37 (50.0 mg, 0.121 mmol, 30%) as a white 
solid and as a mixture of four diastereoisomers at C-20 and C-22: Rf 0.68 (1:1 
heptane/EtOAc + 1.5% Et3N); δH (400 MHz, MeOD) 6.17-6.12 (2 H, m, H-6, H-7), 5.61 
(1 H, br s, H-4), 4.66-4.64 (1 H, m, H-22), 3.96-3.93 (1 H, m, H-26a), 3.86-3.84 (1 H, m, 
H-20), 3.70 (1 H, d, J 4.3, H-1), 3.51-3.48 (1 H, m, H-26b), 3.38 (1 H, dd, J 4.3, 2.0, H-2), 
2.32 (1 H, dd, J 10.8, 10.6, H-8), 2.19 (1 H, ddd, J 13.3, 3.1, 3.2, H-12a), 1.86-1.27 (16 H, 
m, H-9, H-11, H-12b, H-14, H-15, H-16, H-17, H-23, H-24, H-25), 1.21 (3 H, s, H-19), 
1.08 (3 H, d, J 5.9, H-21), 0.90 (3 H, s, H-18), 0.83 (3 H, s, H-18*); δC (125 MHz, MeOD) 
197.0 (C-3), 162.1 (C-5), 142.0 (C-7), 128.1 (C-6), 119.7 (C-4), 102.3 (C-22), 73.7 (C-20), 
64.2 (C-26), 60.3 (C-1), 57.8 (C-17), 55.3 (C-2), 54.2 (C-14), 47.6 (C-9), 43.9 (C-13), 40.4 
(C-12), 39.7 (C-10), 38.6 (C-8), 32.6 (C-16), 32.5 (C-23), 26.5 (C-25), 26.5 (C-15), 22.0 
(C-21), 21.8 (C-11), 21.0 (C-24), 18.7 (C-19), 12.7 (C-18*), 11.7 (C-18); m/z (ESI) 413 
[MH]
+
. Calcd. for C26H37O4: 413.2686. Found: [MH]
+
, 413.2687 (−0.1 ppm error).  
*: signal of one of the minor diastereoisomers. Data consistent with those previously 
reported in the literature.
29 
Lab. Book: LNB0084-014-02. 



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-Hydroxy-20,20-ethylenedioxypregn-5-ene (93) 
 
 
 
 
 
 
To a solution of pregnenolone (36) (10.0 g, 0.032 mol, 1.0 eq.) in toluene (130 mL) were 
added ethylene glycol (8.80 mL, 0.160 mol, 5.0 eq.) and p-TsOH (42.6 mg, 0.224 mmol, 
cat.) and the resulting mixture was stirred 12 h at 135 °C. The reaction mixture was 
quenched with sat. aq. NaHCO3 (100 mL) and extracted with EtOAc (100 mL). A white 
solid precipitated in the extraction funnel and was filtered afterwards on a Büchner funnel; 
it was a part of the title compound 93 which was stored in a separate flask. The organic 
layer was washed with H2O (60 mL) and brine (60 mL). The aqueous phase was back 
extracted with EtOAc (60 mL). The combined organic extracts were dried over Na2SO4, 
filtered and concentrated to dryness in vacuo to give the title compound 93 (10.3 g,  
0.029 mol, 90%) as a white powder which required no further purification: mp 164-165 °C 
decomposed (Lit.
129 
163-166 °C decomposed); Rf 0.45 (1:1 heptane/EtOAc + 1.5% NEt3); 
[α]D
23 −43.9 (c 1.0, CHCl3) (Lit.
129
 [α]D
26 −39.0, c 0.5, CHCl3); υmax/cm
-1
 (neat) 3241 (O-H 
stretch), 2887 (C-H stretch), 1633 (C=O stretch), 1037 (C-O-C stretch); H (400 MHz, 
MeOD) 5.34 (1 H, br d, J 5.0, H-6), 3.98-3.82 (4 H, m, H-22, H-23), 3.41-3.35 (1 H, m,  
H-3), 2.25-2.16 (2 H, m, H-4), 2.08 (1 H, ddd, J 12.8, 3.2, 3.1, H-12a), 1.98-1.95 (1 H, m, 
H-7a), 1.85-1.78 (1 H, m, H-1a), 1.78-1.69 (4 H, m, H-8, H-11, H-17), 1.64-1.61 (1 H, m, 
H-16a), 1.57-1.44 (5 H, m, H-7b, H-2, H-15), 1.26 (3 H, s, H-21), 1.22-1.19 (2 H, m,  
H-12b, H-16b), 1.09-1.06 (1 H, m, H-1b), 1.02-1.01 (1 H, m, H-14), 1.01 (3 H, s, H-19), 
0.96-0.91 (1 H, m, H-9), 0.79 (3 H, s, H-18); C (125 MHz, MeOD) 142.5 (C-5), 122.6  
(C-6), 112.8 (C-20), 72.3 (C-3), 65.9 (C-23), 63.9 (C-22), 59.4 (C-17), 58.0 (C-14), 51.6 
(C-9), 42.8 (C-4), 42.6 (C-13), 40.6 (C-12), 38.3 (C-1), 37.4 (C-10), 32.7 (C-7), 32.3 (C-2), 
31.9 (C-8), 24.6 (C-21), 24.5 (C-16), 23.8 (C-11), 21.5 (C-15), 19.7 (C-19), 13.3 (C-18); 
m/z (ESI) 361 [MH]
+
. Calcd. for C23H37O3: 361.2737. Found: [MH]
+
, 361.2740 (−0.8 ppm 
error). Data consistent with those previously reported in the literature.
128 
 
Lab. Book: LNB0107-008-11. 
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20,20-Ethylenedioxypregn-1,4,6-trien-3-one (92)  
 
 
 
 
 
 
DDQ procedure:
29
 A solution of ketal 93 (50.0 mg, 0.139 mmol, 1.0 eq.) and DDQ  
(110 mg, 0.485 mmol, 3.5 eq.) in 1,4-dioxane (3 mL) was stirred at 115 °C for 8 h. The 
reaction mixture was cooled to room temperature, filtered through Celite
®
 and washed with 
EtOAc (15mL). The filtrate was concentrated to dryness in vacuo. The crude mixture was 
purified by column chromatography on silica gel (7:3 heptane/EtOAc + 7.5% NEt3) to 
afford the title compound 92 (20.7 mg, 0.058 mmol, 42%) as a yellow solid.  
Lab. Book: LNB0084-029-02. 
Pd(OAc)2 procedure:
46
 To a solution of Pd(OAc)2 (405 mg, 1.80 mmol, 0.1 eq.) and ADP 
(28.3 mL, 0.159 mol, 8.8 eq.) stirred beforehand in DMF (12 mL) at room temperature for 
30 min was added Na2CO3 (20.1 g, 0.189 mol, 10.5 eq.) and ketal 93 (6.50 g, 0.018 mol, 
1.0 eq.) in DMF (13 mL) and the reaction mixture was stirred for 72 h at 160 °C under 
argon atmosphere. The resulting mixture was cooled to room temperature, diluted with 
EtOAc (50 mL) and concentrated in vacuo. The crude residue was dissolved in EtOAc 
(300 mL). A 100 mL portion of this solution was diluted with EtOAc (350 mL) and 
washed three times with ice-cold water (150 mL). This procedure was repeated three times 
(one time for each third of the crude). All the combined organic extracts were dried over 
Na2SO4, filtered and concentrated to dryness in vacuo. The crude residue was purified by 
column chromatography on silica gel (9:1 to 6:4 heptane/EtOAc + 7.5% NEt3) to afford the 
title compound 92 (3.95 g, 0.011 mol, 62%) as a yellow solid: mp 164-165 °C decomposed 
(Lit.
128 
162-163 °C decomposed); Rf 0.57 (1:1 heptane/EtOAc + 1.5% NEt3); [α]D
23 
11.9  
(c 1.0, CHCl3) (Lit.
128 [α]D
20 
13.6, c 0.5, CHCl3); υmax/cm
-1
 (neat) 2921 (C-H stretch), 1651 
(C=O stretch), 1599 (C=C stretch), 1049 (C-O-C stretch); δH (400 MHz, MeOD) 7.29  
(1 H, d, J 10.3, H-1), 6.31 (1 H, br d, J 9.8, H-6), 6.22 (1 H, br d, J 10.3, H-2), 6.16 (1 H, 
d, J 9.8, H-7), 5.98 (1 H, br s, H-4), 4.01-3.82 (4 H, m, H-22, H-23), 2.36 (1 H, dd, J 10.7, 
10.1, H-8), 2.16 (1 H, ddd, J 13.0, 3.2, 3.1, H-12a), 1.87-1.67 (6 H, m, H-11, H-15a, H-16, 
H-17), 1.45-1.33 (2 H, m, H-9, H-15b), 1.27 (3 H, s, H-19), 1.24-1.23 (2 H, m, H-12b,  
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H-14), 1.23 (3 H, s, H-21), 0.91 (3 H, s, H-18); δC (125 MHz, MeOD) 188.2 (C-3), 166.2 
(C-5), 156.1 (C-1), 140.9 (C-7), 127.9 (C-6), 127.7 (C-2), 123.3 (C-4), 112.5 (C-20), 65.6 
(C-23), 63.7 (C-22), 59.1 (C-17), 54.7 (C-14), 49.8 (C-9), 43.1 (C-13), 43.0 (C-10), 40.2 
(C-12), 38.8 (C-8), 24.4 (C-19), 23.8 (C-15), 23.2 (C-16), 21.5 (C-11), 20.6 (C-21), 13.0 
(C-18); m/z (ESI) 355 [MH]
+
. Calcd. for C23H31O3: 355.2268. Found: [MH]
+
, 355.2263 
(1.2 ppm error). Data consistent with those previously reported in the literature.
128
 
Lab. Book: LNB0107-033-08.
 
 
 
 
 
 
 
 
Also isolated was 20,20-ethylenedioxypregna-4,6-dien-3-one (98) (475 mg, 1.33 mmol, 
7%) as a yellow solid: mp 166-168 °C decomposed (Lit.
130 
164-166 °C decomposed);  
Rf 0.60 (1:1 heptane/EtOAc + 1.5% NEt3); [α]D
24 
57.9 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 
3381 (O-H stretch), 2899 (C-H stretch), 1636 (C=O stretch), 1593 (C=C stretch), 1033  
(C-O-C stretch); δH (400 MHz, MeOD) 6.24 (1 H, br d, J 9.8, H-6), 6.17 (1 H, dd, J 9.8, 
2.5, H-7), 5.64 (1 H, br s , H-4), 4.01-3.84 (4 H, m, H-22, H-23), 2.67-2.59 (1 H, m, H-2a), 
2.40-2.35 (1 H, m, H-1a), 2.27 (1 H, dd, J 10.8, 10.7, H-8), 2.13 (1 H, ddd, J 13.0, 3.2, 3.1, 
H-12a), 2.08-2.04 (1 H, m, H-1b), 1.89-1.77 (1 H, m, H-17), 1.76-1.70 (1 H, m, H-2b), 
1.59-1.30 (5 H, m, H-11, H-15, H-16a), 1.27 (3 H, s, H-21), 1.26-1.19 (4 H, m, H-9,  
H-12b, H-14, H-16b), 1.14 (3 H, s, H-19), 0.87 (3 H, s, H-18); δC (125 MHz, MeOD) 
202.6 (C-3), 167.6 (C-5), 143.2 (C-6), 128.3 (C-7), 123.5 (C-4), 112.8 (C-20), 65.6 (C-23), 
63.9 (C-22), 58.9 (C-17), 54.8 (C-14), 54.3 (C-10), 52.3 (C-9), 43.6 (C-13), 40.5 (C-12), 
38.3 (C-8), 34.6 (C-1), 34.4 (C-2), 24.6 (C-21), 24.2 (C-16), 24.1 (C-15), 21.4 (C-11), 16.1 
(C-19), 13.3 (C-18); m/z (ESI) 357 [MH]
+
. Calcd. for C23H33O3: 357.2424. Found: [MH]
+
, 
357.2422 (0.5 ppm error). Data consistent with those previously reported in the 
literature.
130
 
Lab. Book: LNB0107-033-06. 
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Further elution gave pregn-1,4,6-trien-3,20-dione (94) (155 mg, 0.499 mmol, 3%) as an 
orange solid: mp 136-140 °C decomposed (Lit.
131 
144-146 °C decomposed); Rf 0.44 (1:1 
heptane/EtOAc + 1.5% NEt3); [α]D
23 
45.2 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 2937 (C-H 
stretch), 1701 (C=O stretch), 1651 (C=O stretch), 1602 (C=C stretch); δH (400 MHz, 
MeOD) 7.29 (1 H, d, J 10.1, H-1), 6.32 (1 H, dd, J 9.8, 2.4, H-6), 6.23 (1 H, br d, J 10.1, 
H-2), 6.14 (1 H, d, J 9.8, H-7), 5.99 (1 H, br s, H-4), 2.66 (1 H, t, J 9.2, H-17), 2.38-2.33  
(1 H, dd, J 10.5, 10.1, H-8), 2.21-2.19 (1 H, m, H-12a), 2.16-2.14 (1 H, m, H-12b), 2.12  
(3 H, s, H-21), 1.95-1.85 (4 H, m, H-11, H-15a, H-16a), 1.57-1.43 (3 H, m, H-9, H-14,  
H-15b), 1.24-1.23 (1 H, m, H-16b), 1.23 (3 H, s, H-19), 0.74 (3 H, s, H-18); δC (125 MHz, 
MeOD) 211.8 (C-20), 188.6 (C-3), 166.3 (C-5), 156.3 (C-1), 140.4 (C-7), 128.6 (C-6), 
128.3 (C-2), 124.0 (C-4), 64.1 (C-17), 55.0 (C-14), 49.9 (C-9), 45.4 (C-13), 43.0 (C-10), 
39.6 (C-8), 39.5 (C-12), 31.6 (C-21), 23.8 (C-15), 23.0 (C-16), 21.2 (C-11), 20.9 (C-19), 
13.6 (C-18); m/z (ESI) 311 [MH]
+
. Calcd. for C21H27O2: 311.2006. Found: [MH]
+
, 
311.2009 (−1.0 ppm error). Data consistent with those previously reported in the 
literature.
132
 
Lab. Book: LNB0107-011-06. 
 
1-Epoxy-20,20-ethylenedioxypregna-4,6-dien-3-one (91)29 
  
 
 
 
 
 
To a solution of trienone 92 (53.0 mg, 0.150 mmol, 1.0 eq.) in 
i
PrOH (4 mL) containing 
10% NaOH in MeOH (0.03 mL, cat.) was added hydrogen peroxide (30% w/w, 0.180 mL, 
5.98 mmol, 40.0 eq.) at 0 °C. The resulting mixture was stirred overnight allowing to reach 
room temperature. The reaction mixture was diluted with Et2O (10 mL), quenched with 
brine (10 mL) and the organic layer was washed with H2O (2 × 10 mL). The combined 
 117 
 
organic extracts were dried over Na2SO4, filtered and concentrated to dryness in vacuo. 
The crude residue was purified by column chromatography on silica gel (9:1 
heptane/EtOAc + 7.5% NEt3) to afford the title compound 91 (40.0 mg, 0.108 mmol, 72%) 
as a white solid: mp 140-141 °C decomposed (Lit.
128 
137-138 °C decomposed); Rf 0.37 
(1:1 heptane/EtOAc + 1.5% NEt3); [α]D
23 
212.2 (c 1.0, CHCl3) (Lit.
128
 [α]D
20 
233.6, c 0.5, 
CHCl3); υmax/cm
-1
 (neat) 3346 (O-H stretch), 2888 (C-H stretch), 1633 (C=O stretch), 
1592 (C=C stretch), 1031 (C-O-C stretch); H (400 MHz, MeOD) 6.18-6.13 (2 H, m, H-7, 
H-6), 5.61 (1 H, br s, H-4), 4.01-3.83 (4 H, m, H-22, H-23), 3.69 (1 H, br d, J 4.1, H-1), 
3.37 (1 H, dd, J 4.1, 1.9, H-2), 2.34-2.30 (1 H, m, H-8), 2.19 (1 H, ddd, J 13.0, 3.1, 3.0,  
H-12), 1.89-1.70 (5 H, m, H-11, H-16, H-17), 1.62-1.57 (1 H, m, H-9), 1.40-1.31 (3 H, m, 
H-12, H-15), 1.29-1.28 (1 H, m, H-14), 1.28 (3 H, s, H-21), 1.20 (3 H, s, H-19), 0.90 (3 H, 
s, H-18); C (125 MHz, MeOD) 196.8 (C-3), 161.7 (C-5), 142.0 (C-7), 128.6 (C-6), 119.8 
(C-4), 111.5 (C-20), 65.8 (C-23), 64.1 (C-22), 60.4 (C-1), 59.1 (C-17), 55.6 (C-2), 54.6  
(C-14), 47.8 (C-9), 43.4 (C-13), 40.4 (C-12), 40.0 (C-10), 38.3 (C-8), 24.6 (C-15), 24.5  
(C-21), 24.2 (C-16), 22.1 (C-11), 18.7 (C-19), 13.1 (C-18); m/z (ESI) 371 [MH]
+
. Calcd. 
for C23H31O4: 371.2217. Found: [MH]
+
, 371.2213 (1.2 ppm error). X-Ray crystallography: 
CCDC 983154 contains the supplementary crystallographic data for this compound, see 
Appendix I. Crystals were grown by slow evaporation of EtOAc. Data consistent with 
those previously reported in the literature.
128
 
Lab. Book: LNB0107-022-02. 
 
1-dihydroxyl-20,20-ethylenedioxypregn-5-ene (99)29  
 
 
 
 
 
 
In a three-necked flask, argon was swept through the system for 15 min and NH3 (95 mL) 
was trapped in the flask at −78 °C. Lithium ribbons (1.62 g, 0.234 mol, 89.9 eq.) were cut 
into short pieces and slowly added: the reaction mixture became instantly dark blue. After 
1 h, a solution of epoxide 91 (0.970 g, 2.62 mmol, 1.0 eq.) in THF (95 mL) was added 
dropwise over 20 min. The reaction was cooled at −40 °C and stirred for 20 min. NH4Cl 
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(28.0 g, 0.524 mol, 200 eq.) was added portionwise over 1 h at reflux temperature (external 
temperature between −20 °C and −10 °C): the reaction mixture became white and pasty. 
Most of the NH3 was removed in a stream of argon. The residue was diluted with Et2O 
(100 mL) and washed with brine (2 × 100 mL). The combined organic extracts were dried 
over Na2SO4, filtered and concentrated to dryness in vacuo. The crude residue was purified 
by column chromatography on silica gel (1:1 to 4:6 heptane/EtOAc + 7.5% NEt3) to afford 
the title compound 99 (745 mg, 1.98 mmol, 76%) as a white solid: mp 201-205 °C 
decomposed (Lit.
128 
203-207 °C decomposed); Rf 0.20 (1:1 heptane/EtOAc + 1.5% NEt3); 
[α]D
23 −49.2 (c 1.0, CHCl3) (Lit.
128 [α]D
20 −47.0, c 0.5, CHCl3); υmax/cm
-1
 (neat) 3380 (O-H 
stretch), 2929 (C-H stretch), 2894 (C-H stretch), 1046 (C-O-C stretch); δH (400 MHz, 
MeOD) 5.48 (1 H, br d, J 5.5, H-6), 4.03-3.81 (5 H, m, H-3, H-22, H-23), 3.79 (1 H, br s, 
H-1), 2.32-2.21 (2 H, m, H-4), 2.09-1.92 (4 H, m, H-2a, H-7, H-12a), 1.81-1.43 (9 H, m, 
H-2b, H-8, H-9, H-11, H-15, H-16a, H-17), 1.28 (3 H, s, H-21), 1.23-1.04 (3 H, m, H-12b, 
H-14, H-16b), 1.00 (3 H, s, H-19), 0.79 (3 H, s, H-18); δC (125 MHz, MeOD) 138.0 (C-5), 
124.2 (C-6), 111.9 (C-20), 72.6 (C-1), 65.2 (C-3), 64.9 (C-23), 63.0 (C-22), 59.2 (C-17), 
57.0 (C-14), 43.6 (C-10), 42.5 (C-13), 41.9 (C-9), 41.3 (C-4), 40.4 (C-12), 38.5 (C-2), 32.6  
(C-7), 32.5 (C-8), 24.9 (C-21), 24.8 (C-15), 23.1(C-16), 20.5 (C-11), 19.0 (C-19), 12.4  
(C-18); m/z (ESI) 399 [MNa]
+
. Calcd. for C23H36NaO4: 399.2506. Found: [MNa]
+
, 
399.2507 (−0.4 ppm error). Data consistent with those previously reported in the 
literature.
128 
Lab. Book: LNB0170-082-04. 
 
 
 
 
 
 
Also isolated was 1α,3α-dihydroxyl-20,20-ethylenedioxypregn-5-ene (101) (97.6 mg, 0.259 
mmol, 10%) as an amorphous white solid: mp 147-150 °C decomposed; Rf 0.56 (6:4 
PE/EtOAc + 1.5% NEt3); [α]D
24 
47.3 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 3249 (O-H stretch), 
2928 (C-H stretch), 1055 (C-O-C stretch); δH (400 MHz, MeOD) 5.54 (1 H, br d, J 5.3, H-
6), 4.07-4.05 (1 H, m, H-3), 4.01-3.83 (4 H, m, H-22, H-23), 3.73 (1 H, br s, H-1), 2.64-
2.58 (1 H, m, H-4a), 2.23-2.18 (1 H, m, H-4b), 2.10-2.05 (1 H, dt, J 12.7, 3.3, 3.3, H-7a), 
2.02-1.42 (11 H, m, H-2, H-7b, H-8, H-9, H-11, H-15, H-16a, H-17), 1.27 (3 H, s, H-21), 
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1.23-1.06 (4 H, m, H-12, H-14, H-16b), 0.99 (3 H, s, H-19), 0.80 (3 H, s, H-18); δC (125 
MHz, MeOD) 135.7 (C-5), 125.5 (C-6), 111.8 (C-20), 73.2 (C-1), 68.1 (C-3), 64.8 (C-23), 
62.9 (C-22), 58.2 (C-17), 56.7 (C-14), 42.6 (C-10), 41.6 (C-13), 41.4 (C-9), 39.2 (C-4), 
39.0 (C-12), 32.7 (C-2), 31.7 (C-7), 31.6 (C-8), 24.0 (C-15), 23.6 (C-21), 23.0 (C-16), 20.5 
(C-11), 18.3 (C-19), 12.1 (C-18); m/z (ESI) 399 [MNa]
+
. Calcd. for C23H36NaO4: 
399.2506. Found: [MNa]
+
, 399.2499 (1.6 ppm error).  
Lab. Book: LNB0170-078-03. 
 
20,20-Ethylenedioxy-1-hydroxy-4-pregnen-3-one (100) 
 
 
 
 
 
 
 
In a three-necked flask, argon was swept through the system for 15 min and NH3 (5 mL) 
was trapped in the flask at −78 °C. Lithium ribbons (77.5 mg, 11.2 mmol, 89.3 eq.) were 
cut into short pieces and slowly added: the reaction mixture became instantly dark blue. 
After 1 h, a solution of epoxide 91 (46.3 mg, 0.125 mmol, 1.0 eq.) in THF (5 mL) was 
added dropwise over 20 min. The reaction was cooled at −40 °C and stirred for 20 min. 
The reaction was cooled back at −78 °C and NH4Cl (0.775 g, 0.014 mol, 116 eq.) was 
added portionwise over 1 h: the reaction mixture became white and pasty. Most of the NH3 
was removed in a stream of argon. The residue was diluted with Et2O (10 mL) and washed 
with brine (2 × 10 mL). The combined organic extracts were dried over Na2SO4, filtered 
and concentrated to dryness in vacuo. The crude residue was purified by column 
chromatography on silica gel (1:1 to 4:6 heptane/EtOAc + 7.5% NEt3) to afford the title 
compound 100 (26.1 mg, 0.07 mmol, 56%) as a white solid: mp 222-223 °C decomposed; 
Rf 0.41 (1:1 heptane/EtOAc + 1.5% NEt3); [α]D
24 
30.1 (c 0.93, CHCl3); υmax/cm
-1
 (neat) 
3380 (O-H stretch), 2924 (C-H stretch), 1672 (C=O stretch), 1052 (C-O-C stretch); δH 
(400 MHz, MeOD) 5.70 (1 H, br s, H-4), 4.06-4.04 (1 H, m, H-1), 3.99-3.84 (4 H, m,  
H-22, H-23), 2.80 (1 H, dd, J 16.9, 2.5, H-2a), 2.46 (1 H, dd, J 16.9, 2.5, H-2b), 2.11 (1 H, 
d, J 12.5, H-12a), 1.84-1.45 (11 H, m, H-6a, H-7, H-8, H-9, H-11, H-15a, H-16, H-17), 
1.41-1.38 (1 H, m, H-6b), 1.30-1.27 (2 H, m, H-12b, H-15b), 1.29 (3 H, s, H-21), 1.22  
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(3 H, s, H-19), 1.15-1.11 (1 H, m, H-14), 0.85 (3 H, s, H-18); δC (125 MHz, MeOD) 199.5 
(C-3), 140.2 (C-5), 123.4 (C-4), 112.7 (C-20), 71.6 (C-1), 63.3 (C-23), 63.0 (C-22), 59.1 
(C-17), 56.3 (C-14), 45.2 (C-9), 43.6 (C-10), 43.4 (C-13), 42.4 (C-2), 40.1 (C-12), 33.1  
(C-6), 31.8 (C-8), 31.4 (C-7), 30.1 (C-21), 23.7 (C-15), 22.2 (C-16), 19.9 (C-11), 18.1  
(C-19), 12.4 (C-18); m/z (ESI) 375 [MH]
+
. Calcd. for C23H35O4: 375.2530. Found: [MH]
+
, 
375.2510 (5.3 ppm error).  
Lab. Book: LNB0084-121-02. 
 
1-Dihydroxy-5-pregnen-20-one (61)52 
 
 
 
 
 
 
 
A solution of ketal 99 (65.0 mg, 0.172 mmol, 1.0 eq.) in AcOH/H2O/THF (65:35:10,  
33 mL) was stirred overnight at room temperature. The reaction mixture was diluted with 
EtOAc (50 mL) and slowly quenched with sat. aq. NaHCO3 (20 mL). The organic phase 
was adjusted to pH 8 by washing with sat. aq. NaHCO3. The organic extract was dried over 
Na2SO4, filtered and concentrated to dryness in vacuo to give the title compound 61  
(57.2 mg, 0.172 mmol, 100%) as white solid which required no further purification:  
mp 222-225 °C decomposed (Lit.
133 
232-236 °C decomposed); Rf 0.05 (1:1 
heptane/EtOAc); [α]D
23 
46.3 (c 1.0, CHCl3) (Lit.
128
 [α]D
20 
49.2, c 0.16, CHCl3); υmax/cm
-1
 
(neat) 3337 (O-H stretch), 2894 (C-H stretch), 1671 (C=O stretch); δH (400 MHz, MeOD) 
5.49 (1 H, br d, J 5.2, H-6), 3.90-3.87 (1 H, m, H-3), 3.80 (1 H, br s, H-1), 2.64 (1 H, dd,  
J 9.2, 9.1, H-17), 2.29-2.15 (3 H, m, H-4, H-16a), 2.12 (3 H, s, H-21), 2.03-1.21 (14 H, m, 
H-2, H-7, H-8, H-9, H-11, H-12, H-14, H-15, H-16b), 1.01 (3 H, s, H-19), 0.62 (3 H, s,  
H-18); δC (125 MHz, MeOD) 209.9 (C-20), 137.6 (C-5), 125.8 (C-6), 73.2 (C-1), 66.9  
(C-3), 64.0 (C-17), 57.2 (C-14), 44.1 (C-13), 42.0 (C-10), 41.5 (C-9), 41.4 (C-4), 38.9  
(C-12), 38.6 (C-2), 32.0 (C-7), 31.8 (C-8), 31.6 (C-21), 24.5 (C-15), 23.2 (C-16), 20.3  
(C-11), 19.7 (C-19), 13.5 (C-18); m/z (ESI) 333 [MH]
+
. Calcd. for C21H33O3: 333.2424. 
Found: [MH]
+
, 333.2422 (0.8 ppm error). X-Ray crystallography: CCDC 983153 contains 
the supplementary crystallographic data for this compound, see Appendix I. Crystals were 
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grown by slow evaporation of CH2Cl2. Data consistent with those previously reported in 
the literature.
128 
Lab. Book: LNB0107-018-01. 
 
1α-Dihydroxy-5-pregnen-20-one (102)  
 
 
 
 
 
 
A solution of ketal 101 (50.0 mg, 0.133 mmol, 1.0 eq.) in AcOH/H2O/THF (65:35:10)  
(3 mL) was stirred overnight at room temperature. The reaction mixture was diluted with 
EtOAc (10 mL) and slowly quenched with sat. aq. NaHCO3 (10 mL). The organic phase 
was adjusted to pH 8 by washing with sat. aq. NaHCO3. The organic extract was dried over 
Na2SO4, filtered and concentrated to dryness in vacuo to give the title compound 102  
(44.2 mg, 0.133 mmol, 100%) as a yellow solid which required no further purification:  
mp 147-150 °C decomposed; Rf 0.21 (1:1 heptane/EtOAc); [α]D
23 
36.7 (c 1.0, CHCl3); 
(Found: C, 75.67; H, 9.73; C27H44O6 requires C, 75.86; H, 9.70%); υmax/cm
-1
 (neat) 3317 
(O-H stretch), 2925 (C-H stretch), 1706 (C=O stretch); δH (400 MHz, CDCl3) 5.57 (1 H, 
br d, J 5.4, H-6), 4.16 (1 H, br s, H-3), 3.75 (1 H, br s, H-1), 2.64 (1 H, ddd, J 15.0, 4.9, 
2.7, H-4a), 2.54 (1 H, dd, J 9.3, 9.0, H-17), 2.23-2.19 (1 H, m, H-4b), 2.11 (3 H, s, H-21), 
2.06-1.88 (5 H, m, H-2, H-7a, H-9, H-12a), 1.72-1.33 (8 H, m, H-7b, H-8, H-11, H-12b, 
H-15a, H-16), 1.23-1.21 (2 H, m, H-14, H-15b), 0.96 (3 H, s, H-19), 0.61 (3 H, s, H-18); 
δC (100 MHz, CDCl3) 209.8 (C-20), 135.2 (C-5), 126.3 (C-6), 73.2 (C-1), 68.5 (C-3), 63.7 
(C-17), 56.7 (C-14), 44.0 (C-13), 42.8 (C-10), 41.3 (C-9), 39.7 (C-4), 38.5 (C-12), 33.5  
(C-2), 31.9 (C-7), 31.8 (C-8), 31.7 (C-21), 24.5 (C-15), 22.8 (C-16), 19.9 (C-11), 19.2  
(C-19), 13.2 (C-18); m/z (ESI) 355 [MNa]
+
. Calcd. for C21H32NaO3: 355.2244. Found: 
[MNa]
+
, 355.2230 (3.9 ppm error).  
Lab. Book: LNB0189-009-01. 
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1-Dihydroxy-(20R)-20-hydroxydithianepregn-5-ene (111) 
 
 
 
 
 
 
 To a solution of 1,3-dithiane (696  mg, 5.79 mmol, 5.0 eq.) in THF (8 mL) was added 
nBuLi (1.6 M in hexane, 3.62 mL, 5.79 mmol, 5.0 eq.) at −5 °C under argon. To the 
resulting solution was added dropwise a solution of ketone 61 (385 mg, 1.16 mmol,  
1.0 eq.) in THF (8 mL). The reaction mixture was stirred for 5 h at −5 °C, diluted with 
Et2O (20 mL) and quenched with sat. aq. NH4Cl (10 mL). The organic phase was adjusted 
to pH 7 by washing with H2O, dried over Na2SO4, filtered and concentrated to dryness in 
vacuo. The crude residue was purified by column chromatography on silica gel (2:8 
heptane/EtOAc) to afford the title compound 111 (230 mg, 0.506 mmol, 44%) as a white 
solid as a mixture of two diastereoisomers at C-20 in a 6:1 ratio in favor of the C-20β 
diastereoisomer: mp 148-151 °C decomposed; Rf 0.11 (1:1 heptane/EtOAc + 1.5% Et3N); 
[α]D
23 −57.0 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 3338 (O-H stretch), 2890 (C-H stretch), 2856 
(S-H stretch); δH (400 MHz, MeOD) 5.48 (1 H, br d, J 4.8, H-6), 4.35 (1 H, s, H-22*), 
4.19 (1 H, s, H-22), 3.91-3.85 (1 H, m, H-3), 3.78 (1 H, br s, H-1), 2.92-2.79 (4 H, m,  
H-23, H-25), 2.30-2.20 (2 H, m, H-4), 2.09-2.04 (1 H, m, H-2a), 1.96-1.47 (13 H, m, H-2b, 
H-7, H-9, H-11, H-12a, H-15, H-16a, H-17, H-24), 1.40 (3 H, s, H-21*), 1.39 (3 H, s,  
H-21), 1.24-1.03 (4 H, m, H-8, H-12b, H-14, H-16b), 1.00 (3 H, s, H-19), 0.88 (3 H, s,  
H-18), 0.83 (3 H, s, H-18*); δC (125 MHz, MeOD) 138.4 (C-5), 124.2 (C-6), 76.8 (C-20), 
72.4 (C-1), 60.7 (C-22), 60.0 (C-3), 57.3 (C-14), 55.4 (C-17), 42.7 (C-13), 41.4 (C-4), 41.1 
(C-9), 40.9 (C-10), 40.2 (C-12), 38.4 (C-2), 31.8 (C-7), 31.5 (C-8), 31.0 (C-23, C-25), 26.4 
(C-24), 24.9 (C-15), 23.0 (C-21*), 22.8 (C-21), 21.2 (C-16), 20.0 (C-11), 18.9 (C-19), 13.5 
(C-18*), 12.9 (C-18); m/z (ESI) 475 [MNa]
+
. Calcd. For C25H40NaO3S2: 475.2311.  
Found: [MNa]
+
, 475.2304 (1.6 ppm error). *: signals of the other diastereoisomer. 
Lab. Book: LNB0170-048-01 
. 
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20,20-Ethylenedioxy-1-bismethoxymethylenoxypregn-5-ene (113) 
 
 
 
 
 
 
To a solution of diol 99 (2.90 g, 7.70 mmol, 1.0 eq.) in 1,4-dioxane (65 mL) were added 
Hünig’s base (10.1 mL, 0.058 mmol, 7.6 eq.) and chloromethyl methyl ether (4.30 mL, 
0.057 mmol, 7.4 eq.) and the resulting mixture was stirred overnight at reflux temperature. 
After cooling to room temperature, the reaction mixture was diluted with EtOAc (50 mL), 
quenched with sat. aq. NH4Cl (30 mL) and stirred vigorously for 5 min. The organic phase 
was washed with H2O (30 mL) and brine (30 mL). The combined organic extracts were 
dried over MgSO4, filtered and concentrated to dryness in vacuo. The crude residue was 
purified by column chromatography on silica gel (8:2 heptane/EtOAc + 7.5% NEt3) to 
afford the title compound 113 (3.31 g, 7.12 mmol, 92%) as a white solid: mp 84-87 °C 
decomposed; Rf 0.50 (7:3 heptane/EtOAc + 1.5% NEt3); [α]D
23 −9.6 (c 1.0, CHCl3); 
(Found: C, 69.64; H, 9.51; C27H44O6 requires C, 69.79; H, 9.54%); υmax/cm
-1
 (neat) 3368 
(O-H stretch), 2881 (C-H stretch), 1614 (C=C stretch), 1025 (C-O-C stretch); δH  
(400 MHz, MeOD) 5.46 (1 H, br d, J 5.2, H-6), 4.72 (1 H, d, J 7.0, H-24a), 4.66 (1 H, d,  
J 6.7, H-26a), 4.63 (1 H, d, J 6.7, H-26b), 4.56 (1 H, d, J 7.0, H-24b), 4.00-3.76 (5 H, m, 
H-3, H-22, H-23), 3.71 (1 H, br s, H-1), 3.37 (3 H, s, H-25), 3.34 (3 H, s, H-27), 2.40-1.44 
(16 H, m, H-2, H-4, H-7, H-8, H-9, H-12a, H-11, H-14, H-15, H-16a, H-17), 1.27 (3 H, s, 
H-21), 1.20-1.15 (2 H, m, H-12b, H-16b), 1.03 (3 H, s, H-19), 0.81 (3 H, s, H-18); δC  
(125 MHz, MeOD) 138.3 (C-5), 124.0 (C-6), 111.8 (C-20), 95.8 (C-24), 94.8 (C-26), 79.5 
(C-1), 72.7 (C-3), 65.1 (C-23), 63.1 (C-22), 58.6 (C-8), 58.5 (C-17), 57.1 (C-14), 55.2  
(C-25), 54.2 (C-27), 41.8 (C-13), 41.3 (C-10), 41.1 (C-9), 39.9 (C-12), 39.0 (C-4), 32.7  
(C-2), 31.9 (C-15), 31.6 (C-7), 23.8 (C-21), 23.6 (C-16), 19.9 (C-11), 19.1 (C-19), 12.4  
(C-18); m/z (ESI) 487 [MNa]
+
. Calcd. for C27H44NaO6: 487.3030. Found: [MNa]
+
, 
487.3032 (−0.4 ppm error). 
Lab. Book: LNB0170-120-02. 
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1-Bismethoxymethylenoxypregn-5-en-20-one (38)52  
 
 
 
 
 
 
A solution of ketal 113 (267 mg, 0.575 mmol, 1.0 eq.) in AcOH/H2O/THF (65:35:10)  
(18 mL) was stirred overnight at room temperature. The reaction mixture was diluted with 
EtOAc (40 mL) and slowly quenched with sat. aq. NaHCO3 (20 mL). The organic phase 
was adjusted to pH 8 by washing with sat. aq. NaHCO3. The organic extract was dried over 
Na2SO4, filtered and concentrated to dryness in vacuo to give the title compound 38  
(247 mg, 0.575 mmol, 100%) as an orange solid which required no further purification: 
mp 125-127 °C decomposed (Lit.
29 
128-129 °C decomposed); Rf 0.44 (1:1 
heptane/EtOAc); [α]D
23 
48.0 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 2901 (C-H stretch), 1706 
(C=O stretch), 1042 (C-O-C stretch); δH (400 MHz, MeOD) 5.48 (1 H, br d, J 5.4, H-6), 
4.74 (1 H, d, J 7.0, H-22a), 4.66 (1 H, d, J 6.7, H-24a), 4.63 (1 H, d, J 6.7, H-24b), 4.58  
(1 H, d, J 7.0, H-22b), 3.85-3.78 (1 H, m H-3), 3.73 (1 H, br s, H-1), 3.40 (3 H, s, H-23), 
3.34 (3 H, s, H-25), 2.64 (1 H, dd, J 9.1, 9.1, H-17), 2.42-2.24 (3 H, m, H-2a, H-4), 2.12  
(3 H, s, H-21), 2.09-1.24 (14 H, m, H-2b, H-7, H-8, H-9, H-11, H-12, H-14, H-15, H-16), 
1.04 (3 H, s, H-19), 0.64 (3 H, s, H-18); δC (125 MHz, MeOD) 210.2 (C-20), 138.7 (C-5), 
124.4 (C-6), 96.9 (C-22), 95.8 (C-24), 80.2 (C-1), 73.3 (C-3), 64.7 (C-17), 58.3 (C-8), 57.9 
(C-14), 56.4 (C-23), 55.2 (C-25), 44.7 (C-13), 42.3 (C-10), 42.2 (C-9), 39.9 (C-4), 39.5  
(C-12), 33.3 (C-2), 32.4 (C-7), 31.3 (C-21), 25.2 (C-16), 20.9 (C-11), 20.8 (C-15), 19.9  
(C-19), 13.4 (C-18); m/z (ESI) 443 [MNa]
+
. Calcd. for C25H40NaO5: 443.2768.  
Found: [MNa]
+
, 443.2763 (1.1 ppm error). Data consistent with those previously reported 
in the literature.
29
 
Lab. Book: LNB0107-010-01. 
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1-Bismethoxymethylenoxy-(20R)-20-hydroxydithianepregn-5-ene (39)29 
 
 
 
 
 
 
To a solution of 1,3-dithiane (8.23 g, 0.069 mol, 10.0 eq.) in THF (30 mL) was added 
nBuLi (1.6 M in hexane, 42.8 mL, 0.069 mol, 10.0 eq.) at −20 °C under argon. To the 
resulting solution was added dropwise a solution of ketone 38 (2.88 g, 6.85 mol, 1.0 eq.) in 
THF (30 mL). The reaction mixture was stirred for 7 h at −20 °C, diluted with Et2O  
(60 mL) and quenched with sat. aq. NH4Cl (60 mL). The organic phase was adjusted to  
pH 7 by washing with H2O (4 × 15 mL), dried over Na2SO4, filtered and concentrated in 
vacuo to dryness. The crude residue was purified by column chromatography on silica gel 
(8:2 heptane/EtOAc) to afford the title compound 39 (2.63 g, 4.86 mmol, 71%) as a white 
solid: mp 150-153 °C decomposed (Lit.
29 
154-156 °C decomposed); Rf 0.68 (1:1 
heptane/EtOAc + 1.5% Et3N); [α]D
23 −27.8 (c 0.5, CHCl3); υmax/cm
-1
 (neat) 3480  
(O-H stretch), 2931 (C-H stretch), 2843 (S-H stretch), 1037 (C-O-C stretch); δH  
(400 MHz, CDCl3) 5.54 (1 H, br d, J 4.9, H-6), 4.73 (1 H, d, J 6.7, H-26a), 4.66 (1 H, d,  
J 6.9, H-28a), 4.63 (1 H, d, J 6.9, H-28b), 4.58 (1 H, d, J 6.7, H-26b), 4.13 (1 H, s, H-22), 
3.86-3.82 (1 H, m, H-3), 3.72 (1 H, br s, H-1), 3.38 (3 H, s, H-27), 3.34 (3 H, s, H-29), 
2.97-2.81 (4 H, m, H-23, H-25), 2.44 (1 H, ddd, J 13.5, 5.0, 1.6, H-4a), 2.36-2.31 (1 H, m, 
H-4b), 2.22 (1 H, br d, J 13.4, H-2a), 2.10-2.07 (1 H, m, H-12a), 1.95 (1 H, dd, J 17.7, 2.4, 
H-7a), 1.91-1.47 (13 H, m, H-2b, H-7b, H-8, H-9, H-11, H-15, H-16, H-17, H-24), 1.42  
(3 H, s, H-21), 1.24-1.13 (2 H, m, H-12b, H-14), 1.02 (3 H, s, H-19), 0.88 (3 H, s, H-18); 
δC (125 MHz, CDCl3) 137.9 (C-5), 124.1 (C-6), 95.6 (C-26), 95.1 (C-28), 78.7 (C-1), 77.0 
(C-20), 72.5 (C-3), 61.2 (C-22), 56.9 (C-14), 56.2 (C-29), 55.2 (C-17), 55.1 (C-27), 43.0 
(C-13), 41.6 (C-9), 41.1 (C-10), 40.0 (C-12), 38.9 (C-4), 32.5 (C-2), 31.6 (C-7), 31.5 (C-8), 
31.3 (C-23), 30.9 (C-25), 26.0 (C-24), 24.2 (C-15), 23.8 (C-21), 21.7 (C-16), 20.2 (C-11), 
19.7 (C-19), 13.5 (C-18); m/z (ESI) 563 [MNa]
+
. Calcd. for C29H48NaO5S2: 563.2835. 
Found: [MNa]
+
, 563.2820 (2.8 ppm error). Data consistent with those previously reported 
in the literature.
29
 
Lab. Book: LNB0170-123-02. 
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Further elution gave 1-bismethoxymethylenoxy-(20S)-20-hydroxydithianepregn-5-ene 
(114)  (16.0 mg, 0.030 mmol, 4%) as a white solid: mp 142-146 °C decomposed (Lit.
29 
148-150 °C decomposed); Rf 0.60 (1:1 heptane/EtOAc + 1.5% Et3N); [α]D
23 −29.4 (c 1.0, 
CHCl3); υmax/cm
-1
 (neat) 3472 (O-H stretch), 2928 (C-H stretch), 2853 (S-H stretch), 1040 
(C-O-C stretch); δH (400 MHz, CDCl3) 5.54 (1 H, br d, J 5.5, H-6), 4.73 (1 H, d, J 7.3,  
H-26a), 4.66 (1 H, d, J 7.1, H-28a), 4.63 (1 H, d, J 7.1, H-28b), 4.59 (1 H, d, J 7.3, H-26b), 
4.33 (1 H, s, H-22), 3.88-3.81 (1 H, m, H-3), 3.71 (1 H, br s, H-1), 3.38 (3 H, s, H-29), 
3.34 (3 H, s, H-27), 2.96-2.80 (4 H, m, H-23, H-25), 2.43 (1 H, ddd, J 13.9, 5.3, 2.0, H-4a), 
2.35-2.29 (1 H, m, H-4b), 2.21 (1 H, br d, J 14.0, H-2a), 2.08-1.41 (14 H, m, H-2b, H-7,  
H-9, H-11, H-12a, H-15, H-16, H-17, H-24), 1.32 (3 H, s, H-21), 1.21-1.08 (3 H, m, H-8, 
H-12b, H-14), 1.01 (3 H, s, H-19), 0.89 (3 H, s, H-18); δC (125 MHz, CDCl3) 137.8 (C-5), 
124.1 (C-6), 95.9 (C-26), 95.1 (C-28), 79.0 (C-1), 77.7 (C-20), 72.5 (C-3), 61.1 (C-22), 
56.6 (C-14), 56.1 (C-29), 55.1 (C-17), 55.0 (C-27), 43.4 (C-13), 41.6 (C-10), 41.1 (C-9), 
39.7 (C-12), 38.9 (C-4), 32.8 (C-2), 31.5 (C-7), 31.3 (C-8), 31.2 (C-23), 30.8 (C-25), 29.7 
(C-24), 25.9 (C-15), 25.0 (C-21), 23.9 (C-16), 20.3 (C-11), 19.7 (C-19), 13.9 (C-18);  
m/z (ESI) 563 [MNa]
+
. Calcd. for C29H48NaO5S2: 563.2835. Found: [MNa]
+
, 563.2843 
(−1.4 ppm error). Data consistent with those previously reported in the literature.29 
Lab. Book: LNB0170-115-04. 

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(20R)-20-Dithiane-120R-trismethoxymethylenoxy-pregn-5-ene (112) 
 
 
 
 
 
 
 
To a solution of alcohol 39 (1.12 g, 2.07 mmol, 1.0 eq.) in 1,4-dioxane (55 mL) were 
added Hünig’s base (2.74 mL, 0.016 mol, 7.6 eq.) and chloromethyl methyl ether  
(1.16 mL, 0.015 mol, 7.4 eq.). The resulting mixture was stirred overnight at 80 °C. After 
cooling to room temperature, the reaction mixture was diluted with EtOAc (50 mL), 
quenched with sat. aq. NH4Cl (20 mL) and stirred vigorously for 5 min. The organic phase 
was washed with H2O (20 mL) and brine (20 mL). The organic extract was dried over 
MgSO4, filtered and concentrated to dryness in vacuo. The crude residue was purified by 
column chromatography on silica gel (7:3 PE/EtOAc) to afford the title compound 112 
(1.03 g, 1.76 mmol, 85%) as a yellow solid: mp 188-191 °C decomposed; Rf 0.84  
(1:1 PE/EtOAc); (Found: C, 63.69; H, 8.92; C31H52O6S2 requires C, 63.66; H, 8.96%); 
[α]D
22 –49.0 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 3361 (O-H stretch), 2894 (C-H stretch), 2849 
(S-H stretch), 1020 (C-O-C stretch); δH (400 MHz, MeOD) 5.48 (1 H, br d, J 4.8, H-6), 
4.93 (1 H, d, J 6.6, H-30a), 4.72 (1 H, d, J 7.3, H-26a), 4.70 (1 H, d, J 6.6, H-30b), 4.66  
(1 H, d, J 6.8, H-28a), 4.64 (1 H, d, J 6.8, H-28b), 4.57 (1 H, d, J 7.3, H-26b), 4.37 (1 H, s, 
H-22), 3.84-3.79 (1 H, m, H-3), 3.71 (1 H, br s, H-1), 3.40 (3 H, s, H-27), 3.38 (3 H, s,  
H-29), 3.34 (3 H, s, H-31), 2.91-2.82 (4 H, m, H-23, H-25), 2.40 (1 H, ddd, J 13.4, 5.5, 2.1, 
H-4a), 2.33-2.22 (2 H, m, H-2a, H-4b), 2.11-1.46 (15 H, m, H-2b, H-7, H-8, H-9, H-12a, 
H-11, H-14, H-15, H-16, H-17, H-24), 1.56 (3 H, s, H-21), 1.28-1.19 (2 H, m, H-12b,  
H-16), 1.03 (3 H, s, H-19), 0.90 (3 H, s, H-18); δC (100 MHz, MeOD) 137.8 (C-5), 123.8 
(C-6), 111.8 (C-20), 95.6 (C-26), 94.6 (C-28), 91.8 (C-30), 79.1 (C-1), 72.2 (C-3), 61.5  
(C-22), 56.8 (C-14), 55.5 (C-17), 55.5 (C-27), 55.2 (C-29), 54.1 (C-31), 41.3 (C-13), 41.3 
(C-9), 41.1 (C-10), 40.2 (C-12), 39.0 (C-4), 32.5 (C-2), 31.8 (C-8), 31.3 (C-7), 31.3 (C-23, 
C-25), 26.5 (C-24), 23.8 (C-15), 22.1 (C-16), 21.8 (C-21), 21.2 (C-11), 18.8 (C-19), 12.8 
(C-18); m/z (ESI) 607 [MNa]
+
. Calcd. for C31H52NaO6S2: 607.3098. Found: [MNa]
+
, 
607.3086 (1.9 ppm error). Lab. Book: LNB0149-116-03. 
 128 
 
-Methoxymethylenoxypregn-5-ene (115)29 
 
 
 
 
 
 
To a solution of pregnenolone (36) (1.00 g, 3.16 mmol, 1.0 eq.) in 1,4-dioxane (20 mL) 
were added Hünig’s base (4.17 mL, 24.0 mmol, 7.6 eq.) and chloromethyl methyl ether 
(1.76 mL, 23.4 mmol, 7.4 eq.). The resulting mixture was stirred overnight at reflux 
temperature. After cooling to room temperature, the reaction mixture was diluted with 
EtOAc (20 mL), quenched with sat. aq. NH4Cl (10 mL) and stirred vigorously for 5 min. 
The organic phase was washed with H2O (10 mL) and brine (10 mL). The organic extract 
was dried over MgSO4, filtered and concentrated to dryness in vacuo to afford the title 
compound 115 which required no further purification (1.00 g, 2.77 mmol, 88%) as an 
amorphous orange solid: mp 105-107 °C decomposed (Lit.
134
 109-111 °C decomposed);  
Rf 0.74 (8:2 PE/EtOAc); [α]D
23 
15.0 (c 1.0, CHCl3) (Lit.
134
 [α]D
 
13.0, c 0.254); υmax/cm
-1
 
(neat) 3375 (O-H stretch), 2894 (C-H stretch), 1679 (C=O stretch), 1028 (C-O-C stretch); 
δH (400 MHz, CDCl3) 5.36 (1 H, br d, J 5.3, H-6), 4.69 (2 H, s, H-22), 3.47-3.39 (1 H, m, 
H-3), 3.37 (3 H, s, H-23), 2.53 (1 H, dd, J 9.2, 9.2, H-17), 2.38-2.19 (3 H, m, H-2, H-4), 
2.13 (3 H, s, H-21), 2.06-1.04 (15 H, m, H-1, H-2, H-7, H-8, H-9, H-11, H-12, H-15,  
H-16), 1.01 (3 H, s, H-19), 0.99-0.97 (1 H, m, H-14), 0.63 (3 H, s, H-18); δC (100 MHz, 
CDCl3) 209.6 (C-20), 140.7 (C-5), 121.3 (C-6), 95.3 (C-22), 76.3 (C-3), 63.8 (C-17), 56.9 
(C-14), 55.4 (C-23), 50.1 (C-9), 44.1 (C-13), 39.6 (C-12), 38.8 (C-4), 37.3 (C-1), 36.8  
(C-10), 31.9 (C-7), 31.8 (C-21), 31.5 (C-8), 28.9 (C-2), 24.6 (C-15), 22.9 (C-16), 21.1  
(C-11), 19.5 (C-19), 13.2 (C-18); m/z (ESI) 361 [MH]
+
. Calcd. for C23H37O3: 361.2737. 
Found: [MH]
+
, 361.2728 (2.6 ppm error). Data consistent with those previously reported in 
the literature.
134
 
Lab. Book: LNB0107-142-01. 
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(20R)-20-Hydroxydithiane-3β-methoxymethylenoxypregna-5-ene (116) 
 
 
 
 
 
 
To a solution of 1,3-dithiane (1.67 g, 13.9 mmol, 5.0 eq.) in THF (5 mL) was added 
n
BuLi 
(1.6 M in hexane, 8.67 mL, 13.9 mmol, 5.0 eq.) at −5 °C under argon. To the resulting 
solution was added dropwise a solution of ketone 115 (1.00 g, 2.77 mmol, 1.0 eq.) in THF 
(15 mL). The reaction mixture was stirred for 6 h at −5 °C, diluted with Et2O (15 mL) and 
quenched with sat. aq. NH4Cl (10 mL). The organic phase was adjusted to pH 7 by 
washing with H2O (4 × 10 mL), dried over Na2SO4, filtered and concentrated in vacuo to 
dryness. The crude residue was purified by column chromatography on silica gel (90:10 to 
85:15 PE/EtOAc): the product containing fractions were concentrated and dried in vacuo to 
afford the title compound 116 (1.04 g, 2.16 mmol, 78%) as a mixture of diastereoisomers 
at C-20 in a 6:1 ratio as a white solid: mp 190-194 °C; Rf 0.50 (8:2 PE/EtOAc);  
(Found: C, 66.63; H, 9.16; C27H44O3S2 requires C, 67.45; H, 9.22%);  [α]D
24
 −51.7 (c 1.0, 
CHCl3); υmax/cm
-1
 (neat) 3422 (O-H stretch), 2931 (C-H stretch), 2888 (S-H stretch), 1032 
(C-O-C stretch); δH (400 MHz, CDCl3) 5.36 (1 H, br d, J 5.2, H-6), 4.69 (2 H, s, H-26), 
4.36 (1 H, s, H-22*), 4.15 (1 H, s, H-22), 3.44-3.40 (1 H, m, H-3), 3.38 (3 H, s, H-27), 
3.00-2.82 (4 H, m, H-23, H-25), 2.38-2.27 (2 H, m, H-4), 2.12-1.50 (16 H, m, H-1, H-2,  
H-7, H-9, H-11, H-15, H-16, H-17, H-24), 1.44 (3 H, s, H-21), 1.33 (3 H, s, H-21*),  
1.34-1.06 (4 H, m, H-8, H-12, H-14), 1.02 (3 H, s, H-19), 0.89 (3 H, s, H-18); δC  
(100 MHz, CDCl3) 140.8 (C-5), 121.6 (C-6), 94.4 (C-26), 77.3 (C-20), 77.0 (C-3), 60.8 
(C-22), 56.8 (C-14), 55.4 (C-27), 55.2 (C-17), 50.1 (C-9), 43.0 (C-13), 40.0 (C-12), 39.5 
(C-4), 37.3 (C-1), 36.8 (C-10), 31.8 (C-7), 31.6 (C-23), 31.5 (C-25), 31.4 (C-8), 31.0  
(C-24), 28.8 (C-2), 24.4 (C-21), 23.8 (C-15), 21.7 (C-16), 21.0 (C-11), 19.4 (C-19), 13.4 
(C-18); m/z (ESI) 463 [M−H2O]
+
. Calcd. for C27H43O2S2: 463.2699. Found: [M−H2O]
+
, 
463.2706 (−1.4 ppm error). *: signals of the other diastereoisomer. 
Lab. Book: LNB0107-144-04. 
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(20R)-20-Dithiane-3β,20R-bismethoxymethylenoxypregn-5-ene (117) 
 
 
 
 
 
 
To a solution of alcohol 116 (3.00 g, 6.25 mmol, 1.0 eq.) in 1,4-dioxane (90 mL) were 
added Hünig’s base (8.26 mL, 0.047 mol, 7.6 eq.) and chloromethyl methyl ether  
(3.49 mL, 0.046 mol, 7.4 eq.) and the resulting mixture was stirred overnight at reflux. 
After cooling to room temperature, the reaction mixture was diluted with EtOAc (40 mL), 
quenched with sat. aq. NH4Cl (20 mL) and stirred vigorously for 5 min. The organic phase 
was washed with H2O (20 mL) and brine (20 mL). The organic extract was dried over 
MgSO4, filtered and concentrated to dryness in vacuo. The crude residue was purified by 
column chromatography on silica gel (9:1 PE/Et2O) to afford the title compound 117  
(3.00 g, 5.72 mmol, 92%) as an amorphous orange solid: mp 108-110 °C; Rf 0.34 (8:2 
PE/Et2O); (Found: C, 66.04; H, 9.12; C29H48O4S2 requires C, 66.37; H, 9.22%);  
[α]D
23
 –24.5 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 3345 (O-H stretch), 2889 (C-H stretch), 2849 
(S-H stretch), 1022 (C-O-C stretch); δH (400 MHz, CDCl3) 5.34 (1 H, br d, J 5.2, H-6), 
4.92 (1 H, d, J 6.8, H-28a), 4.75 (1 H, d, J 6.8, H-28b), 4.69 (2 H, s, H-26), 4.27 (1 H, s,  
H-22), 3.45-3.40 (1 H, m, H-3), 3.42 (3 H, s, H-29), 3.37 (3 H, s, H-27), 2.90-2.80 (4 H, m, 
H-23, H-25), 2.36 (1 H, ddd, J 13.0, 6.6, 1.8, H-4a), 2.29-2.24 (1 H, m, H-4b), 2.10-1.44 
(18 H, m, H-1, H-2, H-7, H-8, H-9, H-12a, H-11, H-14, H-15, H-16a, H-17, H-24), 1.57  
(3 H, s, H-21), 1.32-1.28 (2 H, m, H-12b, H-16b), 1.00 (3 H, s, H-19), 0.87 (3 H, s, H-18); 
δC (100 MHz, CDCl3) 140.7 (C-5), 121.7 (C-6), 94.7 (C-26), 92.3 (C-28), 81.8 (C-20), 
77.0 (C-3), 61.7 (C-22), 56.8 (C-17), 56.6 (C-14), 56.7 (C-29), 55.1 (C-27), 50.1 (C-9), 
43.1 (C-13), 40.2 (C-12), 39.6 (C-4), 37.3 (C-1), 36.7 (C-10), 32.4 (C-23), 31.8 (C-7), 31.8 
(C-25), 31.4 (C-8), 28.9 (C-2), 26.5 (C-24), 24.0 (C-15), 22.5 (C-16), 21.0 (C-11), 21.9  
(C-21), 19.5 (C-19), 13.5 (C-18); m/z (ESI) 547 [MNa]
+
. Calcd. for C29H48NaO4S2: 
547.2886. Found: [MNa]
+
, 547.2878 (1.5 ppm error). X-Ray crystallography: CCDC 
983152 contains the supplementary crystallographic data for this compound, see Appendix 
I. Crystals were grown by slow evaporation of PE. 
Lab. Book: LNB0107-145-03. 
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-(20R)-20-Bismethoxymethylenoxy-22-oxopregn-5-ene (118) 
 
 
 
 
 
 
 
To a solution of dithiane adduct 117 (30.0 mg, 0.057 mmol, 1.0 eq.) in CH3CN/H2O  
(4:1, 3.3 mL) was added a solution of AgNO3 (42.7 mg, 0.252 mmol, 4.4 eq.) and NCS 
(30.5 mg, 0.229 mmol, 4.0 eq.) in CH3CN/H2O (4:1, 1.4 mL) at 0 °C. The reaction mixture 
was protected from light and stirred for 30 min. After warming to room temperature, the 
reaction mixture was quenched with sat. aq. Na2SO3 (1 mL) then with sat. aq. NaHCO3  
(1 mL) and with brine (1 mL). The reaction mixture was stirred vigorously for 5 min and 
filtered through Celite
®
. The aqueous layer was extracted with Et2O (3 × 20 mL). The 
combined organic phases were dried over MgSO4, filtered and concentrated to dryness  
in vacuo. The crude residue was purified by column chromatography on silica gel  
(8:2 PE/Et2O) to afford the title compound 118 (19.0 mg, 0.044 mmol, 77%) as a white 
amorphous solid: mp 106-107 °C; Rf 0.52 (7:3 PE/Et2O); [α]D
23
 −17.5 (c 1.0, CHCl3); 
υmax/cm
-1
 (neat) 3350 (O-H stretch), 2895 (C-H stretch), 1693 (C=O stretch), 1019 (C-O-C 
stretch); δH (400 MHz, CDCl3) 9.70 (1 H, s, H-22), 5.35 (1 H, br d, J 5.2, H-6), 4.85 (1 H, 
d, J 7.5, H-25a), 4.69 (2 H, s, H-23), 4.62 (1 H, d, J 7.5, H-25b), 3.45-3.40 (1 H, m, H-3), 
3.42 (3 H, s, H-26), 3.37 (3 H, s, H-24), 2.35 (1 H, ddd, J 13.2, 5.0, 2.0, H-4a), 2.28-2.22 
(1 H, m, H-4b), 2.21-2.18 (2 H, m, H-2), 1.98-1.39 (13 H, m, H-1, H-7, H-8, H-11, H-12a, 
H-15, H-16, H-17), 1.37 (3 H, s, H-21), 1.24-1.19 (1 H, m, H-9), 1.06-1.01 (2 H, m, H-12b, 
H-14), 1.01 (3 H, s, H-19), 0.78 (3 H, s, H-18); δC (100 MHz, CDCl3) 205.4 (C-22), 140.8 
(C-5), 121.6 (C-6), 94.8 (C-23), 91.9 (C-25), 85.7 (C-20), 77.0 (C-3), 58.5 (C-17), 56.1  
(C-14), 56.1 (C-26), 55.3 (C-24), 50.1 (C-9), 43.4 (C-13), 40.1 (C-12), 39.6 (C-4), 37.3  
(C-1), 36.8 (C-10), 31.8 (C-7), 31.7 (C-8), 29.0 (C-2), 24.0 (C-15), 22.0 (C-16), 20.9  
(C-11), 19.4 (C-19), 18.9 (C-21), 14.8 (C-18); m/z (ESI) 457 [MNa]
+
. Calcd. for 
C26H42NaO5: 457.2924. Found: [MNa]
+
, 457.2920 (0.9 ppm error).  
Lab. Book: LNB0107-158-03. 
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(20R)-20-Hydroxyformyl-3β-methoxymethylenoxypregn-5-ene (119) 
 
 
 
 
 
 
A solution of dithiane adduct 117 (100 mg, 0.191 mmol, 1.0 eq.) in THF (1 mL) was added 
dropwise to a suspension of HgO (90.7 mg, 0.419 mmol, 2.2 eq.) and BF3•Et2O (0.052 mL, 
0.419 mmol, 2.2 eq.) in THF/H2O (1:1, 1.3 mL). The reaction was stirred at reflux for 4 h. 
The reaction mixture was cooled to room temperature and filtered through Celite
®
 and 
washed with Et2O (5 mL). The organic phase was washed with sat. aq. NaHCO3 (2 ×  
5 mL). The organic phase was dried over MgSO4, filtered and concentrated in vacuo. The 
crude residue was purified by column chromatography on silica gel (7:3 to 1:1 PE/EtOAc) 
to afford the title compound 119 (20.0 mg, 0.051 mmol, 27%) as a white amorphous solid: 
mp 125-127 °C; Rf 0.33 (7:3 PE/Et2O); [α]D
24
 −77.2 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 3409 
(O-H stretch), 2889 (C-H stretch), 1698 (C=O stretch), 1024 (C-O-C stretch); δH  
(400 MHz, CDCl3) 9.57 (1 H, s, H-22), 5.35 (1 H, br d, J 5.2, H-6), 4.69 (2 H, s, H-23), 
3.47-3.40 (1 H, m, H-3), 3.38 (3 H, s, H-24), 2.36 (1 H, ddd, J 12.8, 4.6, 1.5, H-4a),  
2.30-2.24 (1 H, m, H-4b), 1.98-1.34 (16 H, m, H-1, H-2, H-7, H-9, H-11, H-12a, H-14,  
H-15, H-16, H-17), 1.36 (3 H, s, H-21), 1.27-1.03 (2 H, m, H-8, H-12b), 1.02 (3 H, s,  
H-19), 0.80 (3 H, s, H-18); δC (100 MHz, CDCl3) 203.6 (C-22), 140.9 (C-5), 121.5 (C-6), 
94.8 (C-23), 79.6 (C-20), 77.0 (C-3), 56.6 (C-17), 55.5 (C-24), 55.3 (C-14), 50.2 (C-9), 
43.4 (C-13), 40.1 (C-12), 39.6 (C-4), 37.3 (C-1), 36.8 (C-10), 31.8 (C-7), 31.4 (C-8), 29.0 
(C-2), 24.2 (C-15), 23.1 (C-21), 22.2 (C-16), 21.0 (C-11), 19.5 (C-19), 13.9 (C-18);  
m/z (ESI) 413 [MNa]
+
. Calcd. for C24H38NaO4: 413.2662. Found: [MNa]
+
, 413.2674  
(−2.8 ppm error).  
Lab. Book: LNB0107-148-04. 
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Further elution gave (20R)-20-formyl-3β-hydroxyl-20-methoxymethylenoxypregn-5-ene 
(120) (36.3 mg, 0.093 mmol, 49%) as a white amorphous solid: mp 118-120 °C 
decomposed; Rf 0.16 (6:4 PE/Et2O); υmax/cm
-1
 (neat) 3345 (O-H stretch), 2889 (C-H 
stretch), 1700 (C=O stretch), 1013 (C-O-C stretch); δH (400 MHz, CDCl3) 9.70 (1 H, s,  
H-22), 5.35 (1 H, br d, J 5.5, H-6), 4.85 (1 H, d, J 7.2, H-23a), 4.62 (1 H, d, J 7.2, H-23b), 
3.51-3.46 (1 H, m, H-3), 3.42 (3 H, s, H-24), 2.33-2.23 (2 H, m, H-4), 2.00-1.94 (1 H, m, 
H-7), 1.89-1.46 (16 H, m, H-1, H-2, H-7, H-9, H-11, H-12a, H-14, H-15, H-16, H-17), 
1.37 (3 H, s, H-21), 1.27-1.03 (2 H, m, H-8, H-12b), 1.01 (3 H, s, H-19), 0.79 (3 H, s,  
H-18); δC (100 MHz, CDCl3) 205.4 (C-22), 140.9 (C-5), 121.6 (C-6), 92.0 (C-23), 85.7 
(C-20), 71.8 (C-3), 58.5 (C-17), 56.1 (C-14), 55.9 (C-24), 50.1 (C-9), 43.5 (C-13), 42.3  
(C-12), 40.0 (C-4), 37.3 (C-1), 36.6 (C-10), 31.7 (C-7), 31.6 (C-2), 31.5 (C-8), 23.9 (C-15), 
21.9 (C-16), 20.9 (C-11), 19.5 (C-19), 18.8 (C-21), 14.7 (C-18); m/z (ESI) 391 [MH]
+
. 
Calcd. for C24H39O4: 391.2843. Found: [MH]
+, 391.2858 (−3.9 ppm error).  
Lab. Book: LNB0107-148-05. 
 
-(20R)-20-Bismethoxymethylenoxy-22-dimethoxypregn-5-ene (121) 
 
 
 
 
 
 
 
To a solution of AgNO3 (72.8 mg, 0.429 mmol, 4.5 eq.) in MeOH (0.61 mL) was added 
NCS (50.9 mg, 0.381 mmol, 4.0 eq.) and 2,6-lutidine (0.111 mL, 0.952 mmol, 10 eq.) at 
room temperature. The reaction mixture was protected from light. After 30 min, a solution 
of dithiane adduct 117 (50 mg, 0.095 mmol, 1.0 eq.) in THF (0.61 mL) was added 
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dropwise and the reaction mixture was stirred overnight. After cooling to 0 °C, the reaction 
mixture was quenched with sat. aq. Na2SO3 (1 mL) then with sat. aq. NaHCO3 (1 mL) and 
with H2O (1 mL). The reaction mixture was stirred vigorously for 5 min and diluted with 
Et2O (1 mL). The aqueous layer was extracted with Et2O (2 × 1 mL). The combined 
organic phases were dried over MgSO4, filtered and concentrated to dryness in vacuo. The 
crude residue was purified by column chromatography on silica gel (8:2 PE/Et2O) to afford 
the title compound 121 (31.3 mg, 0.065 mmol, 68%) as a white solid: mp 103-105 °C;  
Rf 0.53 (7:3 PE/Et2O); [α]D
24 −26.6 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 3387 (O-H stretch), 
2891 (C-H stretch), 1702 (C=O stretch), 1022 (C-O-C stretch); δH (400 MHz, CDCl3) 5.35 
(1 H, br d, J 5.3, H-6), 4.99 (1 H, d, J 6.6, H-27a), 4.69 (2 H, s, H-25), 4.66 (1 H, d, J 6.6, 
H-27b), 4.02 (1 H, s, H-22), 3.53 (3 H, s, H-24), 3.46 (3 H, s, H-23), 3.45-3.41 (1 H, m,  
H-3), 3.41 (3 H, s, H-28), 3.38 (3 H, s, H-26), 2.36 (1 H, ddd, J 13.2, 4.9, 1.6, H-4a),  
2.30-2.23 (1 H, m, H-4b), 2.07-1.41 (15 H, m, H-1, H-2, H-7, H-8, H-11, H-12a, H-15,  
H-16, H-17), 1.33 (3 H, s, H-21), 1.25-1.01 (2 H, m, H-12b, H-14), 1.01 (3 H, s, H-19), 
0.92-0.88 (1 H, m, H-9), 0.88 (3 H, s, H-18); δC (100 MHz, CDCl3) 140.9 (C-5), 121.8  
(C-6), 111.2 (C-22), 94.8 (C-25), 92.5 (C-27), 81.0 (C-20), 77.0 (C-3), 59.0 (C-24), 57.5 
(C-23), 56.7 (C-14), 56.4 (C-28), 55.3 (C-26), 55.1 (C-17), 50.2 (C-9), 42.8 (C-13), 40.3 
(C-12), 39.6 (C-4), 37.1 (C-1), 36.8 (C-10), 31.8 (C-7), 31.3 (C-8), 28.9 (C-2), 23.9 (C-15), 
21.7 (C-16), 20.8 (C-11), 19.4 (C-19), 15.9 (C-21), 13.5 (C-18); m/z (ESI) 503 [MNa]
+
. 
Calcd. for C28H48NaO6: 503.3346. Found: [MNa]
+
, 503.3336 (1.3 ppm error).  
Lab. Book: LNB0107-156-03. 
 
(20R)-20-Formyl-1,20-trismethoxymethylenoxypregn-5-ene (40)65 
 
 
 
 
 
 
 
To a solution of dithiane adduct 112 (500 mg, 0.855 mmol, 1.0 eq.) in CH3CN/H2O (4:1, 
54 mL) was added a solution of AgNO3 (644 mg, 3.79 mmol, 4.4 eq.) and NCS (451 mg, 
3.38 mmol, 4.0 eq.) in CH3CN/H2O (4:1, 22 mL) at 0 °C. The reaction mixture was 
protected from light and stirred for 30 min. After warming to room temperature, the 
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reaction mixture was quenched with sat. aq. Na2SO3 (5 mL) then with sat. aq. NaHCO3  
(5 mL) and with brine (5 mL). The reaction mixture was stirred vigorously for 5 min and 
filtered through Celite
®
. The aqueous layer was extracted with Et2O (3 × 50 mL). The 
combined organic phases were dried over MgSO4, filtered and concentrated to dryness in 
vacuo. The crude residue was purified by column chromatography on silica gel  
(8:2 PE/Et2O) to afford the title compound 40 (358 mg, 0.724 mmol, 85%) as an 
amorphous yellow solid: mp 115-117 °C decomposed (Lit.
29 
118-120 °C decomposed);  
Rf 0.69 (7:3 PE/EtOAc); [α] D
23
 –18.8 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 3389 (O-H stretch), 
2889 (C-H stretch), 1701 (C=O stretch), 1025 (C-O-C stretch); δH (400 MHz, CDCl3) 9.68 
(1 H, s, H-22), 5.54 (1 H, br d, J 5.2, H-6), 4.83 (1 H, d, J 7.2, H-27a), 4.73 (1 H, d, J 7.1, 
H-23a), 4.66 (1 H, d, J 7.0, H-25a), 4.64 (1 H, d, J 7.0, H-25b), 4.60 (1 H, d, J 7.1, H-23b), 
4.56 (1 H, d, J 7.2, H-27b), 3.87-3.78 (1 H, m, H-3), 3.72 (1 H, br s, H-1), 3.39 (3 H, s,  
H-24), 3.38 (3 H, s, H-26), 3.33 (3 H, s, H-28), 2.43 (1 H, ddd, J 13.6, 5.3, 1.8, H-4a), 
2.35-2.29 (1 H, m, H-4b), 2.25-2.20 (1 H, m, H-2a), 1.98-1.90 (1 H, m, H-7a), 1.74-1.39 
(11 H, m, H-2b, H-7b, H-8, H-9, H-11, H-12a, H-15a, H-16, H-17), 1.34 (3 H, s, H-21), 
1.24-1.03 (3 H, m, H-12b, H-14, H-15b), 1.01 (3 H, s, H-19), 0.77 (3 H, s, H-18); δC  
(100 MHz, CDCl3) 205.4 (C-22), 138.0 (C-5), 124.1 (C-6), 95.7 (C-23), 95.2 (C-25), 92.0 
(C-27), 85.7 (C-20), 78.8 (C-1), 72.6 (C-3), 58.6 (C-17), 56.3 (C-26), 56.2 (C-14), 55.9  
(C-28), 55.2 (C-24), 43.5 (C-13), 41.6 (C-10), 41.2 (C-9), 39.9 (C-12), 39.0 (C-4), 32.6  
(C-2), 31.5 (C-7), 31.5 (C-8), 24.0 (C-15), 21.9 (C-16), 20.2 (C-11), 19.8 (C-19), 18.8  
(C-21), 14.8 (C-18); m/z (ESI) 517 [MNa]
+
. Calcd. for C28H46NaO7: 517.3136.  
Found: [MNa]
+
, 517.3121 (2.8 ppm error). Data consistent with those previously reported 
in the literature.
29 
Lab. Book: LNB0170-148-02/03. 
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6.2.2. Chapter 3. Construction of the δ-lactone side chain  
2,3-Dimethyl-2-butenoic acid (172)
80 
 
 
 
 
To a suspension of lithium (32.6 mg, 4.70 mmol, 2.8 eq.) in THF (0.5 mL) was added 
dropwise a solution of 2-bromo-3-methyl-2-butene (171) (250 mg, 1.68 mmol, 1.0 eq.) in 
THF (0.5 mL) over 5 min at –30 °C. The reaction mixture was warmed to –5 °C and stirred 
for 5 min. The reaction mixture was cooled down to –78 °C and an excess of CO2 was 
added (bubbling through the reaction mixture). After 30 min, the reaction mixture was 
warmed to 0 °C, quenched with ice-cold water (1 mL) and diluted with heptane (3 mL). 
The aqueous phase was acidified with 1 M aq. HCl (1 mL) and extracted with heptane  
(5 mL). The organic phase was separated, dried over Na2SO4, filtered and concentrated to 
dryness in vacuo to afford the title compound 172 (69.7 mg, 0.611 mmol, 36%) as yellow 
needdles: mp 70-74 °C decomposed (Lit.
80 
71 °C decomposed); Rf 0.70 (15:1 PE/EtOAc); 
υmax/cm
-1
 (neat) 2822 (O-H stretch), 1670 (C=O stretch), 1655 (C=C stretch); δH  
(400 MHz, CDCl3) 2.11 (3 H, s, H-5), 1.88 (3 H, s, H-6), 1.86 (3 H, s, H-4); δC  
(100 MHz, CDCl3) 174.9 (C-1), 148.4 (C-3), 121.5 (C-2), 23.5 (C-5), 23.4 (C-4), 15.7  
(C-6); m/z (ESI) 115 [MH]
+
. Calcd. for C6H11O2: 115.0754. Found: [MH]
+
, 115.0754 
(−0.5 ppm error). Data consistent with those previously reported in the literature.80 
Lab. Book: LNB0149-047-01. 
 
Ethyl 2-methyl-3-trifluorosulfonatebut-2-enoate (175)
82 
 
 
 
 
 
To a solution of ethyl 2-methylacetoacetate (174) (0.580 mL, 0.004 mol, 1.0 eq.) in toluene 
(20 mL) was added 5 M aq. LiOH (6.0 mL, 0.030 mol, 7.5 eq.) at 10 °C and the reaction 
mixture was stirred vigorously for 5 min. Triflic anhydride (1.7 mL, 0.010 mol, 2.5 eq.) 
was added dropwise maintaining the temperature of the reaction between 5 °C and 15 °C. 
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After 30 min, the biphasic solution was diluted with H2O (15 mL) and the layers were 
separated. The aqueous layer was extracted with EtOAc (20 mL). The combined organic 
layers were washed with H2O (15 mL) and brine (15 mL). The organic layer was dried 
over MgSO4, filtered and concentrated to dryness in vacuo to give the title compound 175 
(1.15 g, 0.004 mol, 100%) as an orange liquid which required no further purification: Rf 
0.42 (15:1 PE/EtOAc); δH (400 MHz, CDCl3) 4.28 (2 H, q, J 7.2, H-6), 2.15-2.13 (3 H, m, 
H-5), 1.98 (3 H, q, J 1.2, H-4), 1.34 (3 H, t, J 7.2, H-7); δC (100 MHz, CDCl3) 165.3 (C-
1), 147.6 (C-3), 121.8 (C-2), 118.3 (q, JCF 319, C-8), 61.7 (C-6), 17.6 (C-5), 15.2 (C-4), 
13.8 (C-7); m/z (ESI) 277 [MH]
+
. Calcd. for C8H12F3O5S: 277.0352. Found: [MH]
+
, 
277.0350 (0.7 ppm error). Data consistent with those previously reported in the literature.
83 
Lab. Book: LNB0107-104-01. 
 
Ethyl 2,3-dimethylbutenoate (122)
135 
 
 
 
To a suspension of CuI (2.76 g, 0.015 mol, 1.0 eq.) in Et2O (65 mL) was added MeLi  
(1.6 M in Et2O, 18.0 mL, 0.029 mol, 2.0 eq.) at 0 °C and the reaction mixture was stirred 
for 5 min to give a clear solution. A solution of the (Z)-enol triflate 175 (4.00 g, 0.015 mol, 
1.0 eq.) in Et2O (65 mL) was added to the cuprate solution at −78 °C. After 1 h, a solution 
of NH4Cl/NH3 (50 mL), prepared by mixing a sat. aq. solution of NH4Cl (15 mL), MeOH 
(10 mL) and 25% aq. NH3 (4 mL) was poured into the reaction mixture at −78 °C. The 
reaction mixture was then poured into a separating funnel, the reaction flask was washed 
consecutively with NH4Cl/NH3 (50 mL) and Et2O (50 mL). The aqueous layer was 
extracted with Et2O (3 × 50 mL), the combined organic layers were washed with H2O (50 
mL), dried over MgSO4, filtered and concentrated to dryness in vacuo to give the title 
compound 122 (1.80 g, 0.013 mol, 87%) as a yellow liquid: Rf 0.70 (15:1 PE/EtOAc); 
υmax/cm
-1
 (neat) 2944 (O-H stretch), 1670 (C=O stretch), 1618 (C=C stretch); δH (400 
MHz, CDCl3) 4.19 (2 H, q, J 7.1, H-2), 2.02-2.00 (3 H, m, H-6), 1.88-1.86 (3 H, m, H-8), 
1.82-1.80 (3 H, m, H-7), 1.30 (3 H, t, J 7.1, H-1); δC (100 MHz, CDCl3) 169.9 (C-3), 
142.8 (C-5), 122.7 (C-4), 60.1 (C-2), 22.9 (C-6), 22.4 (C-7), 15.7 (C-8), 14.4 (C-1). Data 
consistent with those previously reported in the literature.
136
 
Lab. Book: LNB0149-123-07. 
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2,2-(Dimethyl)-2-phenylacetaldehyde (177)
85 
 
 
 
 
 
To a solution of aldehyde 176 (250 mg, 1.86 mmol, 1.0 eq.) in THF (0.8 mL) was added a 
solution of NaH (49.2 mg, 2.05 mmol, 1.1 eq.) in THF (0.8 mL) dropwise over 5 min at  
0 °C. After 10 min, MeI (0.233 mL, 3.77 mmol, 2.2 eq.) was added carefully maintaining 
the temperature around 0 °C. After 1 h, the reaction was quenched with sat. aq. NaHCO3  
(2 mL) and extracted with Et2O (3 × 2 mL). The combined organic phases were dried over 
MgSO4, filtered and concentrated to dryness in vacuo to afford the title compound 177 
(240 mg, 1.62 mmol, 87%) as a yellow oil which required no further purification: Rf 0.86 
(8:2 PE/EtOAc); υmax/cm
-1
 (neat) 2986 (C-H stretch), 1722 (C=O stretch), 1420 (C=C 
stretch), 1393 (CH3 bend); δH (400 MHz, CDCl3) 9.51 (1 H, s, H-8), 7.41-7.37 (3 H, m,  
H-2, H-3, H-5), 7.31-7.27 (2 H, m, H-1, H-4), 1.47 (6 H, s, H-9, H-10); δC (100 MHz, 
CDCl3) 202.4 (C-8), 141.3 (C-6), 129.0 (C-2, C-3, C-5), 126.8 (C-1, C-4), 50.6 (C-7), 22.6 
(C-9, C-10); m/z (ESI) 149 [MH]
+
. Calcd. for C10H13O: 149.0961. Found: [MH]
+
, 
149.0961 (−0.2 ppm error). Data consistent with those previously reported in the 
literature.
137 
Lab. Book: LNB0107-109-01. 
 
(6S)-4-Methyl-6-phenyl-5,6-dihydro-2H-pyran-2-one (181)
30 
 
 
 
 
 
To a solution of 
i
Pr2NH (0.632 mL, 4.50 mmol, 2.4 eq.) in THF (10 mL) was added 
n
BuLi 
(1.6 M in hexane, 2.59 mL, 4.15 mmol, 2.2 eq.) dropwise at  
–78 °C and the resulting mixture was stirred for 30 min. A solution of  
3,3-dimethylbutenoate (178) (507 mg, 3.96 mmol, 2.1 eq.) in THF/DMPU (9:1, 6 mL) was 
added dropwise and stirred for 1 h. A solution of benzaldehyde (180) (200 mg, 1.88 mmol, 
1.0 eq.) in THF (10 mL) was added dropwise at –78 °C and the reaction mixture was 
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stirred for 5.5 h. The reaction mixture was warmed to room temperature, quenched with 
sat. aq. NH4Cl (10 mL) and extracted with Et2O (15 mL). The combined organic phases 
were washed with brine (10 mL), dried over MgSO4, filtered and concentrated to dryness 
in vacuo. The crude residue was purified by column chromatography on silica gel (9:1 to 
7:3 PE/EtOAc) to afford the title compound 181 (277 mg, 1.47 mmol, 78%) as a yellow 
amorphous solid: mp 73-75 °C decomposed; Rf 0.38 (7:3 PE/EtOAc); υmax/cm
-1
 (neat) 
3000 (C-H stretch), 1689 (C=O stretch), 1655 (C=C stretch), 1039 (C-O-C stretch); δH 
(400 MHz, CDCl3) 7.35-7.25 (5 H, m, H-1, H-2, H-3, H-4, H-5), 5.82-5.81 (1 H, m, H-
10), 4.91 (1 H, dd, J 12.2, 4.1, H-7), 2.55 (1 H, ddq, J 17.9, 12.2, 0.9, H-8b), 2.38 (1 H, dd, 
J 17.9, 4.1, H-8a), 1.94 (3 H, d, J 1.1, H-12); δC (100 MHz, CDCl3) 164.6 (C-11), 157.2 
(C-9), 138.4 (C-6), 128.3 (C-2, C-5), 128.2 (C-3), 125.7 (C-1, C-4), 116.2 (C-10), 78.3  
(C-7), 36.4 (C-8), 22.6 (C-12); m/z (ESI) 189 [MH]
+
. Calcd. for C12H13O2: 189.0910. 
Found: [MH]
+, 189.0915 (−2.9 ppm error). Data consistent with those previously reported 
in the literature.
86
 
Lab. Book: LNB0149-004-03. 
 
 
 
 
 
Also isolated was ethyl 5-hydroxy-3-methyl-5-phenylpent-2-enoate (182) (34.0 mg,  
0.145 mmol, 8%) as an orange oil: Rf 0.93 (7:3 PE/EtOAc); δH (400 MHz, CDCl3)  
7.37-7.28 (5 H, m, H-1, H-2, H-3, H-4, H-5), 5.78 (1 H, dd, J 2.3, 1.2, H-10), 4.91 (1 H, 
dd, J 8.7, 5.0, H-7), 4.15 (2 H, q, J 7.3, H-12), 2.57 (1 H, dd, J 14.0, 8.7, H-8a), 2.51 (1 H, 
dd, J 14.0, 5.0, H-8b), 2.23 (3 H, d, J 1.2, H-14), 1.28 (3 H, t, J 7.3, H-13); δC (100 MHz, 
CDCl3) 166.4 (C-11), 155.6 (C-9), 143.7 (C-6), 128.6 (C-2, C-5), 127.8 (C-3), 125.6 (C-1, 
C-4), 118.5 (C-10), 72.1 (C-7), 59.7 (C-12), 50.7 (C-8), 19.0 (C-14), 14.4 (C-13); m/z 
(ESI) 257 [MNa]
+
. Calcd. for C14H18NaO3: 257.1148. Found: [MNa]
+
, 257.1140 (2.4 ppm 
error). Data consistent with those previously reported in the literature.
87 
Lab. Book: LNB0149-004-02. 
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,20R-Bismethoxymethylenoxy-1,14,17-trisdeoxy-17-epi-25-desmethyl-withanolide F 
(183)
 
 
 
 
 
 
 
To a solution of LiHMDS (1.0 M in toluene, 1.38 mL, 1.38 mmol, 3.0 eq.) in THF  
(1.2 mL) was added a solution of 3,3-dimethylbutenoate (178) (0.174 mL, 1.24 mmol,  
2.7 eq.) in THF/DMPU (1:1, 1.2 mL) dropwise at −78 °C and the resulting mixture was 
stirred for 1 h. A solution of aldehyde 118 (200 mg, 0.460 mmol, 1.0 eq.) in THF (2 mL) 
was added dropwise and the reaction mixture was stirred for 6 h at −78 °C. The reaction 
mixture was stirred overnight allowing the temperature to reach room temperature, 
quenched with sat. aq. NH4Cl (5 mL) and extracted with Et2O (3 × 5 mL). The combined 
organic phases were washed with brine (5 mL), dried over MgSO4, filtered and 
concentrated to dryness in vacuo. The crude residue was purified by column 
chromatography on silica gel (8:2 to 1:1 PE/Et2O) to afford the title compound 183  
(22.0 mg, 0.043 mmol, 9%) as a mixture of diastereoisomers at C-22 in a 1:1 ratio and as a 
yellow oil: Rf 0.22 (4:6 PE/Et2O); δH (400 MHz, CDCl3) 5.80 (1 H, s, H-25), 5.35 (1 H,  
br d, J 4.6, H-6), 4.98 (1 H, d, J 6.7, H-28a), 4.81 (1 H, d, J 6.7, H-28b), 4.80 (1 H, d,  
J 7.8, H-28a*), 4.69 (2 H, s, H-30), 4.68 (3 H, br s, H-30*, H 28b*), 4.32 (1 H, dt, J 13.1, 
3.3, H-22), 3.46-3.19 (1 H, m, H-3), 3.39 (6 H, s, H-29, H-31), 2.51-2.42 (1 H, m, H-23a), 
2.36-2.32 (1 H, m, H-23b), 2.30-2.22 (3 H, m, H-2a, H-4), 1.99 (3 H, br d, J 3.6, H-27), 
1.89-1.45 (14 H, m, H-1, H-2b, H-7, H-8, H-11, H-12a, H-15, H-16, H-17), 1.42 (3 H, s, 
H-21*), 1.40 (3 H, s, H-21), 1.30-1.28 (1 H, m, H-12b), 1.06-1.04 (1 H, m, H-14), 1.00  
(3 H, s, H-19), 0.94-0.89 (1 H, m, H-9), 0.86 (3 H, s, H-18*), 0.81 (3 H, s, H-18); δC  
(100 MHz, CDCl3) 165.2 (C-26), 158.4 (C-24), 140.9 (C-5), 120.6 (C-6), 116.4 (C-25), 
94.8 (C-28), 92.8 (C-30), 91.8 (C-28*), 83.2 (C-22), 80.7 (C-20), 77.0 (C-3), 56.8 (C-14), 
55.5 (C-17), 55.3 (C-29, C-31), 50.1 (C-9), 43.1 (C-13), 40.2 (C-12), 39.6 (C-4), 37.3  
(C-1), 36.8 (C-10), 31.8 (C-7), 31.3 (C-8), 30.8 (C-23), 28.9 (C-2), 23.9 (C-15), 23.2  
(C-27), 22.0 (C-16), 20.8 (C-11), 19.4 (C-19), 18.0 (C-21), 16.9 (C-21*), 13.9 (C-18*), 
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13.7 (C-18); m/z (ESI) 539 [MNa]
+
. Calcd. for C31H48NaO6: 539.3343. Found: [MNa]
+
, 
539.3345 (−0.4 ppm error). *: signals of the other diastereoisomer. 
Lab. Book: LNB0149-025-09. 
 
 
 
 
 
 
 
Also isolated was ,20R-bismethoxymethylenoxy-22-(3’-carboxy-2’-methylpropenylenyl)-
pregn-5-ene (184) (60.0 mg, 0.116 mmol, 25%) as an amorphous yellow solid:  
mp 132-134 °C decomposed; Rf 0.35 (4:6 PE/Et2O); [α]D
23 
15.7 (c 0.5, CHCl3);  
υmax/cm
-1
 (neat) 2934 (O-H stretch), 1714 (C=O stretch), 1682 (C=C stretch), 1599 (C=C 
stretch), 1449 (O-H bend), 1252 (C-O stretch), 1032 (C-O-C stretch); δH (400 MHz, 
CDCl3) 7.55 (1 H, d, J 16.4, H-23), 6.26 (1 H, d, J 16.4, H-22), 5.68 (1 H, s, H-25), 5.33  
(1 H, br s, H-6), 4.67 (2 H, s, H-28), 4.63 (2 H, s, H-30), 3.44-3.39 (1 H, m, H-3), 3.37  
(3 H, s, H-31), 3.35 (3 H, s, H-29), 2.35-2.25 (2 H, m, H-4), 2.00 (3 H, br d, J 1.1, H-27), 
1.91-1.47 (15 H, m, H-1, H-2, H-7, H-8, H-11, H-12a, H-15, H-16, H-17), 1.44 (3 H, s,  
H-21), 1.18-1.04 (2 H, m, H-12b, H-14), 0.98 (3 H, s, H-19), 0.93-0.87 (1 H, m, H-9), 0.80 
(3 H, s, H-18); δC (100 MHz, CDCl3) 170.8 (C-26), 153.1 (C-24), 144.1 (C-22), 140.8  
(C-5), 125.9 (C-23), 121.7 (C-6), 116.6 (C-25), 94.7 (C-28), 91.8 (C-30), 81.7 (C-20), 77.0 
(C-3), 60.6 (C-17), 56.6 (C-14), 55.6 (C-31), 55.3 (C-29), 50.2 (C-9), 43.2 (C-13), 40.2  
(C-12), 39.6 (C-4), 37.3 (C-1), 36.8 (C-10), 31.9 (C-7), 31.5 (C-8), 29.1 (C-2), 23.9 (C-15), 
23.5 (C-21), 22.5 (C-16), 21.4 (C-27), 21.0 (C-11), 19.4 (C-19), 14.3 (C-18); m/z (ESI) 
539 [MNa]
+
. Calcd. for C31H48NaO6: 539.3343. Found: [MNa]
+
, 539.3327 (3.0 ppm error).
 
Lab. Book: LNB0149-025-02. 
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,20R-Bismethoxymethylenoxy-1,14,17-trisdeoxy-17-epi-withanolide F (185) 
 
 
 
 
 
 
 
To a solution of LiHMDS (1.0 M in THF, 0.359 mL, 0.359 mmol, 3.0 eq.) in THF  
(0.417 mL) was added a solution of ethyl-2,3-dimethylbutenoate (122) (45.9 mg,  
0.323 mmol, 2.7 eq.) in THF/DMPU (1:1, 0.834 mL) dropwise at −78 °C and the resulting 
mixture was stirred for 1.5 h. This reaction mixture was canulated dropwise to a solution of 
aldehyde 118 (52.0 mg, 0.120 mmol, 1.0 eq.) in THF (0.834 mL) and the reaction mixture 
was stirred for 5 h at −78 °C. The reaction mixture warmed to room temperature, quenched 
with sat. aq. NH4Cl (3 mL), extracted with Et2O (3 × 3 mL). The combined organic phases 
were washed with brine (3 mL), dried over MgSO4, filtered and concentrated to dryness  
in vacuo. The crude residue was purified by column chromatography on silica gel (85:15 
heptane/EtOAc) to afford the title compound 185 (46.6 mg, 0.088 mmol, 73%) as a white 
solid: mp 80-83 °C decomposed; Rf 0.29 (7:3 heptane/EtOAc); (Found: C, 72.23; H, 9.56; 
C32H50O6 requires C, 72.42; H, 9.50%);  [α]D
23 
20.8 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 2932 
(C-H stretch), 1709 (C=O stretch), 1034 (C-O-C stretch); δH (400 MHz, CDCl3) 5.33  
(1 H, br d, J 4.3, H-6), 4.96 (1 H, d, J 6.7, H-29a), 4.81 (1 H, d, J 6.7, H-29b), 4.66 (2 H, s, 
H-31), 4.23 (1 H, dd, J 13.1, 3.4, H-22), 3.42-3.38 (1 H, m, H-3), 3.35 (3 H, s, H-32), 3.34 
(3 H, s, H-30), 2.46 (1 H, br dd, J 15.9, 15.2, H-23a), 2.32 (1 H, br dd, J 12.7, 3.0, H-4a), 
2.24 (1 H, br dd, J 12.7, 11.4, H-4b), 2.12 (1 H, br d, J 15.8, 1.96, H-23b), 1.99-1.95 (2 H, 
m, H-7a, H-16a), 1.91 (3 H, s, H-28), 1.89-1.86 (1 H, m, H-2a), 1.85 (3 H, s, H-27),  
1.72-1.46 (10 H, m, H-1, H-2b, H-7b, H-8, H-11, H-12a, H-15a, H-16b), 1.57 (1 H, br dd, 
J 9.7, 9.5, H-17), 1.38 (3 H, s, H-21), 1.33-1.28 (1 H, m, H-12b), 1.17-1.10 (1 H, m,  
H-15b), 0.98 (3 H, s, H-19), 0.90-0.86 (2 H, m, H-9, H-14), 0.85 (3 H, s, H-18); δC  
(125 MHz, CDCl3) 166.1 (C-26), 148.7 (C-24), 138.0 (C-5), 121.8 (C-25), 121.5 (C-6), 
94.6 (C-29), 92.7 (C-31), 82.1 (C-22), 79.8 (C-20), 76.7 (C-3), 56.3 (C-14), 56.2 (C-32), 
55.2 (C-30), 54.4 (C-17), 50.0 (C-9), 42.9 (C-13), 42.4 (C-10), 40.1 (C-12), 39.5 (C-4), 
37.1 (C-1), 32.0 (C-23), 31.8 (C-7), 31.3 (C-8), 28.8 (C-2), 23.9 (C-15), 21.8 (C-16), 20.8 
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(C-11), 20.4 (C-28), 19.3 (C-19), 17.8 (C-21), 13.8 (C-18), 12.4 (C-27); m/z (ESI) 553 
[MNa]+. Calcd. for C32H50NaO6: 553.3500. Found: [MNa]+, 553.3481 (3.4 ppm error). 
Lab. Book: LNB0170-018-05. 
 
,20R-Trismethoxymethylenoxy-14,17-dideoxy-17-epi-withanolide F (41)35 
 
 
 
 
 
 
 
To a solution of LiHMDS (1.0 M in THF, 1.09 mL, 1.09 mmol, 3.0 eq.) in THF (1.27 mL) 
was added a solution of ethyl-2,3-dimethylbutenoate (122) (140 mg, 0.982 mmol, 2.7 eq.) 
in THF/DMPU (1:1, 2.54 mL) dropwise at −78 °C and the resulting mixture was stirred for 
1.5 h. This reaction mixture was canulated dropwise to a solution of aldehyde 40 (180 mg, 
0.364 mmol, 1.0 eq.) in THF (2.54 mL), the reaction mixture was stirred for 5 h at −78 °C. 
The reaction mixture was quenched with sat. aq. NH4Cl (5 mL), extracted with Et2O (3 ×  
5 mL). The combined organic phases were washed with brine (5 mL), dried over MgSO4, 
filtered and concentrated to dryness in vacuo. The crude residue was purified by column 
chromatography on silica gel (9:1 to 8:2 heptane/EtOAc) to afford the title compound 41 
(145 mg, 0.245 mmol, 67%) as a white solid: mp 215-218 °C decomposed (Lit.
29  
220-222 °C decomposed); Rf 0.40 (1:1 heptane/EtOAc); [α]D
23 
30.4 (c 0.1, CHCl3); 
υmax/cm
-1
 (neat) 2932 (C-H stretch), 1710 (C=O stretch), 1027 (C-O-C stretch); δH  
(400 MHz, CDCl3) 5.54 (1 H, br d, J 4.9, H-6), 4.98 (1 H, d, J 6.5, H-33a), 4.81 (1 H, d,  
J 6.5, H-33b), 4.73 (1 H, d, J 7.1, H-29a), 4.66 (2 H, br s, H-31), 4.58 (1 H, d, J 7.1,  
H-29b), 4.23 (1 H, dd, J 13.3, 3.2, H-22), 3.86-3.83 (1 H, m, H-3), 3.72 (1 H, br s, H-1), 
3.39 (3 H, s, H-30), 3.37 (3 H, s, H-34), 3.34 (3 H, s, H-32), 2.48-2.42 (2 H, m, H-4a,  
H-23a), 2.35-2.31 (1 H, m, H-4b), 2.22 (1 H, br d, J 13.0, H-2a), 2.12 (1 H, br d, J 17.2, 
2.3, H-23b), 1.98-1.95 (2 H, m, H-7a, H-16a), 1.92 (3 H, s, H-28), 1.87 (3 H, s, H-27), 
1.72-1.47 (8 H, m, H-2b, H-7b, H-8, H-9, H-11a, H-12a, H-15a, H-16b), 1.64 (1 H, br dd, 
J 10.7, 9.0, H-17), 1.40 (3 H, s, H-21), 1.30-1.27 (1 H, m, H-12b), 1.19-1.14 (2 H, m,  
H-11b, H-15b), 1.07-1.05 (1 H, m, H-14), 1.01 (3 H, s, H-19), 0.87 (3 H, s, H-18); δC  
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(100 MHz, CDCl3) 166.1 (C-26), 148.7 (C-24), 138.0 (C-5), 124.1 (C-6), 121.1 (C-25), 
95.6 (C-29), 95.1 (C-31), 92.8 (C-33), 82.3 (C-22), 79.8 (C-20), 78.7 (C-1), 72.5 (C-3), 
56.7 (C-14), 56.3 (C-30), 56.2 (C-34), 55.1 (C-32), 54.6 (C-17), 43.8 (C-13), 41.8 (C-10), 
41.1 (C-9), 40.2 (C-12), 38.9 (C-4), 32.5 (C-23), 32.2 (C-2), 31.5 (C-7), 31.2 (C-8), 24.0 
(C-15), 21.7 (C-16), 20.5 (C-11), 20.1 (C-28), 19.7 (C-19), 17.9 (C-21), 13.8 (C-18), 12.4 
(C-27); m/z (ESI) 613 [MNa]+. Calcd. for C34H54NaO8: 613.3711. Found: [MNa]+, 
613.3690 (3.4 ppm error). Data consistent with those previously reported in the literature.
29 
Lab. Book: LNB0170-126-02. 
 
 
 
 
 
 
 
Also isolated was 1α,,20R-trismethoxymethylenoxy-22-hydroxy-(2’,3’-
dimethylbutenoate)-pregn-5-ene (186) (7.10 mg, 0.011 mmol, 3%) as a yellow oil: Rf 0.42 
(1:1 heptane/EtOAc); [α]D
23 −32.9 (c 0.44, CHCl3); υmax/cm
-1
 (neat) 3429 (O-H stretch), 
2932 (C-H stretch), 1709 (C=O stretch), 1027 (C-O-C stretch); δH (400 MHz, CDCl3) 5.58  
(1 H, br d, J 4.6, H-6), 4.87 (1 H, d, J 7.1, H-35a), 4.73 (1 H, d, J 7.0, H-31a), 4.65 (2 H, 
br s, H-33), 4.58 (1 H, d, J 7.0, H-31b), 4.52 (1 H, d, J 7.1, H-35b), 4.16 (2 H, br q, J 7.1, 
H-27), 3.84-3.82 (1 H, m, H-3), 3.72-3.69 (2 H, m, H-1, H-22), 3.38 (6 H, s, H-32, H-36), 
3.34 (3 H, s, H-34), 2.44 (1 H, dd, J 13.1, 4.2, H-4a), 2.40-2.35 (1 H, m, H-4b), 2.29-2.10 
(4 H, m, H-2, H-23),  2.03 (3 H, s, H-29), 2.02-1.99 (1 H, m, H-12a), 1.96-1.93 (1 H, m, 
H-7a),  1.90 (3 H, s,  H-30), 1.71-1.39 (9 H, m, H-7b, H-8, H-9, H-11, H-15a, H-16, H-17), 
1.29 (3 H, s, H-21), 1.25 (3 H, t, J 7.1 H-28), 1.21-1.14 (2 H, m, H-12b, H-15b), 1.02 (3 H, 
s, H-19), 1.01-0.98 (1 H, m, H-14), 0.78 (3 H, s, H-18); δC (125 MHz, CDCl3) 169.8  
(C-26), 143.9 (C-24), 137.9 (C-5), 124.4 (C-6), 124.1 (C-25), 95.6 (C-31), 95.2 (C-33), 
91.0 (C-35), 84.7 (C-20), 78.7 (C-1), 74.0 (C-22), 72.5 (C-3), 60.0 (C-27), 57.7 (C-14), 
56.4 (C-32), 56.3 (C-34), 56.0 (C-36), 54.2 (C-17), 43.4 (C-13), 41.6 (C-10), 41.2 (C-9), 
39.7 (C-12), 38.9 (C-4), 38.0 (C-23), 32.5 (C-2), 31.5 (C-8), 31.1 (C-7), 24.1 (C-15), 21.4 
(C-16), 20.4 (C-29), 20.2 (C-11), 19.7 (C-19), 15.8 (C-21), 15.4 (C-30), 14.6 (C-28), 13.6 
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(C-18); m/z (ESI) 659 [MNa]
+
. Calcd. for C36H60NaO9: 659.4130. Found: [MNa]
+
, 
659.4122 (1.2 ppm error). 
 Lab. Book: LNB0170-126-05. 
 
,20R-Bishydroxy-1,14,17-trisdeoxy-17-epi-withanolide F (56)29 
 
 
 
 
 
 
To a solution of MOM protected diol 185 (39.0 mg, 0.074 mmol, 1.0 eq.) in THF (1 mL) 
was added 6 M aq. HCl (0.94 mL). The reaction was stirred at room temperature for 3 h, 
quenched with sat. aq. NaHCO3 (1 mL) and extracted with EtOAc (5 mL). The organic 
phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo. The crude 
residue was purified by column chromatography on silica gel (7:3 heptane/EtOAc) to 
afford the title compound 56 (32.8 mg, 0.074 mmol, 100%) as an amorphous white solid: 
mp 240-244 °C decomposed (Lit.
35 
243-245 °C decomposed); Rf 0.25 (7:3 
heptane/EtOAc); [α]D
23 
18.7 (c 1.0, CHCl3) (Lit.
35
 [α]D
20 
16.7, c 0.62, CHCl3); υmax/cm
-1
 
(neat) 3396 (O-H stretch), 2926 (C-H stretch), 1694 (C=O stretch), 1058 (C-O-C stretch); 
δH (400 MHz, CDCl3) 5.33 (1 H, br d, J 4.4, H-6), 4.21 (1 H, dd, J 13.3, 3.2, H-22),  
3.53-3.49 (1 H, m, H-3), 2.47-2.40 (1 H, m, H-23a), 2.28 (1 H, br dd, J 12.7, 3.7, H-4a), 
2.22 (1 H, br dd, J 12.7, 11.6, H-4b), 2.11 (1 H, br dd, J 15.4, 3.2, H-23b), 2.04-2.00 (1 H, 
m, H-12a), 1.97-1.95 (2 H, m, H-7a, H-11a), 1.94 (3 H, s, H-28), 1.87 (3 H, s, H-27),  
1.83-1.81 (2 H, m, H-1a, H-2a), 1.62-1.41 (7 H, m, H-2a, H-7b, H-8, H-11b, H-15a,  
H-16a, H-17), 1.27 (3 H, s, H-21), 1.25-1.20 (3 H, m, H-12b, H-15b, H-16b), 1.07-1.03  
(1 H, m, H-1b), 0.99 (3 H, s, H-19), 0.98-0.96 (1 H, m, H-14), 0.91-0.89 (1 H, m, H-9), 
0.85 (3 H, s, H-18); δC (100 MHz, CDCl3) 166.1 (C-26), 148.9 (C-24), 140.8 (C-5), 122.0 
(C-6), 121.5 (C-25), 80.9 (C-22), 75.2 (C-20), 71.7 (C-3), 56.8 (C-14), 54.7 (C-17), 50.5 
(C-9), 43.0 (C-13), 42.3 (C-4), 40.1 (C-12), 37.2 (C-1), 36.5 (C-10), 31.9 (C-2), 31.8 (C-8), 
31.6 (C-7), 31.3 (C-23), 23.8 (C-15), 22.0 (C-16), 20.9 (C-21), 20.8 (C-11), 20.6 (C-28), 
19.4 (C-19), 13.6 (C-18), 12.5 (C-27); m/z (ESI) 465 [MNa]
+
. Calcd. for C28H42NaO4: 
465.2975. Found: [MNa]
+
, 465.2974 (0.3 ppm error). Data consistent with those previously 
reported in the literature.
35
 Lab. Book: LNB0189-007-02. 
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,20R-Trihydroxy-14,17-dideoxy-17-epi-withanolide F (21)29 
 
 
 
 
 
 
 
To a solution of MOM protected triol 41 (11.8 mg, 0.020 mmol, 1.0 eq.) in THF (0.5 mL) 
was added 6 M aq. HCl (0.40 mL). The reaction was stirred at room temperature for 7 h, 
quenched with sat. aq. NaHCO3 (1 mL) and extracted with EtOAc (5 mL). The organic 
phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo. The crude 
residue was purified by column chromatography on silica gel (15:85 heptane/EtOAc) to 
afford the title compound 21 (10.2 mg, 0.022 mmol, 100%) as an amorphous pale pink 
solid: mp 264-269 °C decomposed (Lit.
29 
270-272 °C decomposed); Rf 0.13 (2:8 
heptane/EtOAc); [α]D
23 
17.3 (c 1.0, CHCl3) (Lit.
29
 [α]D
 
19.4, c 0.14); υmax/cm
-1
 (neat) 3396 
(O-H stretch), 2926 (C-H stretch), 1692 (C=O stretch), 1052 (C-O-C stretch); δH  
(400 MHz, CDCl3) 5.58 (1 H, br d, J 4.8, H-6), 4.21 (1 H, dd, J 13.3, 3.3, H-22), 4.01-3.94 
(1 H, m, H-3), 3.84 (1 H, br s, H-1), 2.43 (1 H, br d, J 15.9, H-23a), 2.37 (1 H, br dd,  
J 13.7, 3.2, H-4a), 2.28 (1 H, br dd, J 13.7, 12.1, H-4b), 2.13-2.00 (2 H, m, H-2a, H-23b), 
2.00-1.97 (2 H, m, H-7a, H-16a), 1.94 (3 H, s, H-28), 1.87 (3 H, s, H-27), 1.73 (1 H,  
br ddd, J 12.4, 12.0, 2.3, H-2b), 1.66-1.45 (6 H, m, H-7b, H-11a, H-12a, H-15a, H-16b,  
H-17), 1.30-1.28 (2 H, m, H-8, H-12b), 1.27 (3 H, s, H-21), 1.20-1.14 (2 H, H-9, H-15b), 
1.08-1.06 (2 H, m, H-11b, H-14), 1.02 (3 H, s, H-19), 0.86 (3 H, s, H-18); δC (125 MHz, 
CDCl3) 166.1 (C-26), 148.9 (C-24), 137.4 (C-5), 125.4 (C-6), 122.0 (C-25), 81.0 (C-22), 
75.2 (C-20), 72.1 (C-1), 66.4 (C-3), 56.7 (C-14), 54.7 (C-17), 43.0 (C-13), 41.7 (C-10), 
41.5 (C-9), 41.4 (C-4), 39.8 (C-12), 38.3 (C-2), 31.6 (C-23), 31.5 (C-7), 31.3 (C-8), 23.9 
(C-15), 22.7 (C-16), 20.8 (C-21), 20.5 (C-11), 20.1 (C-28), 19.4 (C-19), 13.6 (C-18), 12.4 
(C-27); m/z (ESI) 459 [MH]
+
. Calcd. for C28H43O5: 459.3105. Found: [MH]
+
, 459.3117 
(−2.6 ppm error). Data consistent with those previously reported in the literature.29 
Lab. Book: LNB0149-125-03. 
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6.2.3. Chapter 4. A/B-ring functionalisation: the synthesis of 14,17-dideoxy-17-epi-
withanoldie F (24) 
3-Acetate1-hydroxy-5-pregnen-20-one (203) 
 
 
 
 
 
 
To a solution of diol 61 (30.0 mg, 0.090 mmol, 1.0 eq.) in CH2Cl2 (5 mL) was added NEt3 
(50% in CH2Cl2, 37.8 L, 0.237 mmol, 2.6 eq.), DMAP (0.500 mg, 0.008 mmol, 0.05 eq.) 
and Ac2O (30.9 μL, 0.328 mmol, 3.6 eq.). The reaction was stirred at room temperature 
overnight, quenched with 0.1 M aq. HCl (2 mL) and extracted with CH2Cl2 (5 mL). The 
organic phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo. The 
crude residue was purified by column chromatography on silica gel (7:3 heptane/EtOAc) to 
afford the title compound 203 (21.9 mg, 0.059 mmol, 65%) as an amorphous white solid: 
mp 175-179 °C decomposed; Rf 0.34 (1:1 heptane/EtOAc); [α]D
23 
13.6 (c 1.0, CHCl3); 
υmax/cm
-1
 (neat) 3444 (O-H stretch), 2931 (C-H stretch), 1742 (C=O stretch), 1706 (C=O 
stretch), 1035 (C-O-C stretch); δH (400 MHz, CDCl3) 5.59 (1 H, br d, J 5.2, H-6),  
5.05-4.98 (1 H, m, H-3), 3.85 (1 H, br s, H-1), 2.52 (1 H, t, J 8.9, H-17), 2.42 (1 H, ddd,  
J 13.2, 5.3, 1.9, H-4a), 2.33 (1 H, br dd, J 13.2, 11.9, H-4b), 2.18-2.14 (1 H, m, H-16a), 
2.10 (3 H, s, H-21), 2.08-2.05 (1 H, m, H-2a), 2.04-2.01 (1 H, m, H-12a), 2.01 (3 H, s,  
H-23), 1.98-1.95 (1 H, m, H-7a), 1.85 (1 H, td, J 11.6, 1.9, H-2b), 1.72-1.56 (5 H, m, H-7b, 
H-9, H-11a, H-15a, H-16b), 1.50-1.39 (3 H, m, H-8, H-11b, H-12b), 1.21-1.17 (2 H, m,  
H-15b, H-14), 1.02 (3 H, s, H-19), 0.61 (3 H, s, H-18); δC (125 MHz, CDCl3) 209.5  
(C-20), 170.5 (C-22), 136.3 (C-5), 126.1 (C-6), 72.4 (C-1), 69.4 (C-3), 63.5 (C-17), 56.6 
(C-14), 43.9 (C-13), 41.7 (C-10), 41.3 (C-9), 38.5 (C-12), 37.2 (C-4), 34.6 (C-2), 31.7  
(C-21), 31.6 (C-7), 31.5 (C-8), 24.5 (C-15), 22.8 (C-16), 21.3 (C-23), 20.2 (C-11), 19.3  
(C-19), 13.2 (C-18); m/z (ESI) 397 [MNa]
+
. Calcd. for C23H34NaO4: 397.2349. Found: 
[MNa]
+
, 397.2343 (1.6 ppm error).   
Lab. Book: LNB0170-079-03. 
 
 
 148 
 
1,3-Bisacetate-5-pregnen-20-one (204)35 
 
 
 
 
 
 
To a solution of diol 61 (30.0 mg, 0.090 mmol, 1.0 eq.) in CH2Cl2 (5 mL) was added NEt3 
(50% in CH2Cl2, 37.8 L, 0.237 mmol, 2.6 eq.), DMAP (1.10 mg, 9.02 μmol,  
0.10 eq.) and Ac2O (30.9 μL, 0.328 mmol, 3.6 eq.). The reaction was stirred at room 
temperature overnight, quenched with 0.1 M aq. HCl (2 mL) and extracted with CH2Cl2  
(5 mL). The organic phase was dried over Na2SO4, filtered and concentrated to dryness in 
vacuo. The crude residue was purified by column chromatography on silica gel (7:3 
heptane/EtOAc) to afford the title compound 204 (25.0 mg, 0.060 mmol, 67%) as an 
amorphous white solid: mp 155-159 °C decomposed (Lit.
91 
141-142 °C decomposed);  
Rf 0.50 (1:1 heptane/EtOAc); [α]D
23 
27.1 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 2940 (C-H 
stretch), 1733 (C=O stretch), 1703 (C=O stretch); δH (400 MHz, CDCl3) 5.51 (1 H, br d,  
J 5.0, H-6), 5.04 (1 H, br s, H-1), 4.92-4.86 (1 H, m, H-3), 2.51 (1 H, t, J 9.0, H-17),  2.46 
(1 H, ddd, J 13.2, 4.8, 2.0, H-4a), 2.32 (1 H, br dd, J 12.0, 11.2, H-4b), 2.19-2.12 (1 H, m, 
H-16a), 2.08 (3 H, s, H-21), 2.07-2.05 (1 H, m, H-2a), 2.04 (3 H, s, H-25), 1.99 (3 H, s,  
H-23), 1.98-1.95 (2 H, m, H-7a, H-12a), 1.80 (1 H, td, J 11.9, 2.0, H-2b), 1.69-1.55 (3 H, 
m, H-7b, H-15a, H-16b), 1.48-1.31 (5 H, m, H-8, H-9, H-11, H-12b), 1.19-1.14 (2 H, m, 
H-14, H-15b), 1.05 (3 H, s, H-19), 0.58 (3 H, s, H-18); δC (125 MHz, CDCl3) 209.3  
(C-20), 170.3 (C-24), 170.2 (C-22), 136.0 (C-5), 124.8 (C-6), 74.5 (C-1), 69.2 (C-3), 63.5 
(C-17), 56.8 (C-14), 43.8 (C-13), 42.0 (C-9), 40.4 (C-10), 38.6 (C-12), 37.2 (C-4), 31.9  
(C-2), 31.6 (C-8), 31.5 (C-21), 31.4 (C-7), 24.4 (C-15), 22.7 (C-16), 21.3 (C-25), 21.1  
(C-23), 20.4 (C-11), 19.3 (C-19), 13.2 (C-18); m/z (ESI) 417 [MH]
+
. Calcd. for C25H37O5: 
417.2636. Found: [MH]
+
, 417.2633 (0.6 ppm error). Data consistent with those previously 
reported in the literature.
91
 
Lab. Book: LNB0170-065-02. 
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3-Benzoyl1-hydroxy-5-pregnen-20-one (205) 
 
 
 
 
 
 
To a solution of diol 61 (20.0 mg, 0.060 mmol, 1.0 eq.) in CH2Cl2 (0.5 mL) was added 
pyridine (24.2 L, 0.301 mmol, 5.0 eq.) and BzCl (15.4 μL, 0.132 mmol, 2.2 eq.) at 0 °C. 
The reaction was stirred at room temperature overnight, quenched with sat. aq. NaHCO3  
(1 mL) and extracted with EtOAc (5 mL). The organic phase was dried over Na2SO4, 
filtered and concentrated to dryness in vacuo. The crude residue was purified by column 
chromatography on silica gel (8:2 to 7:3 heptane/EtOAc) to afford the title compound 205 
(17.7 mg, 0.041 mmol, 68%) as an amorphous white solid: mp 228-230 °C decomposed; 
Rf 0.27 (1:1 heptane/EtOAc); [α]D
23 
18.6 (c 1.0, CHCl3); υmax/cm
-1
 (neat) 3483 (O-H 
stretch), 2967 (C-H stretch), 1714 (C=O stretch), 1684 (C=O stretch), 1453 (C=C stretch), 
711 (C-H bend); δH (400 MHz, CDCl3) 8.02 (2 H, d, J 7.3, H-24, H-28), 7.54 (1 H, t,  
J 7.0, H-26), 7.42 (2 H, t, J 7.6, H-25, H-27), 5.64 (1 H, br d, J 4.8, H-6), 5.30-5.26 (1 H, 
m, H-3), 3.93 (1 H, br s, H-1), 2.58-2.49 (3 H, m, H-4, H-17), 2.25 (1 H, br d, J 12.3,  
H-2a), 2.18-2.16 (1 H, m, H-16a),  2.12 (3 H, s, H-21), 2.04-1.98 (3 H, m, H-2a, H-7a,  
H-12a), 1.77-1.47 (8 H, m, H-7b, H-8, H-9, H-11, H-12b, H-15a, H-16b), 1.32-1.24 (2 H, 
m, H-14, H-15b), 1.08 (3 H, s, H-19), 0.64 (3 H, s, H-18); δC (125 MHz, CDCl3) 209.5  
(C-20), 170.5 (C-22), 136.3 (C-5), 132.8 (C-26), 130.6 (C-23),  129.5 (C-25, C-27), 128.3 
(C-24, C-28), 126.1 (C-6), 72.4 (C-1), 69.4 (C-3), 63.5 (C-17), 56.6 (C-14), 43.9 (C-13), 
41.7 (C-10), 41.3 (C-9), 38.5 (C-12), 37.2 (C-4), 34.6 (C-2), 31.7 (C-21), 31.6 (C-7), 31.5 
(C-8), 24.5 (C-15), 22.8 (C-16), 20.2 (C-11), 19.3 (C-19), 13.2 (C-18); m/z (ESI) 459 
[MNa]
+
. Calcd. for C28H36NaO4: 459.2506. Found: [MNa]
+
, 459.2508 (−0.4 ppm error).  
Lab. Book: LNB0170-089-03. 
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Also isolated was 1α,3-bisbenzoyl-5-pregnen-20-one (206) (6.30 mg, 0.012 mmol, 19%) 
as a white solid: mp 234-236 °C decomposed; Rf 0.45 (1:1 heptane/EtOAc); [α]D
23 
50.3  
(c 0.8, CHCl3); υmax/cm
-1
 (neat) 2939 (C-H stretch), 1713 (C=O stretch), 1450 (C=C 
stretch), 709 (C-H bend); δH (400 MHz, CDCl3) 8.05 (2 H, d, J 7.3, H-24, H-28), 7.99  
(2 H, d, J 7.2, H-31, H-35), 7.57 (1 H, t, J 7.4, H-26), 7.53 (1 H, t, J 7.4, H-33), 7.47 (2 H, 
t, J 7.7, H-25, H-27), 7.41 (2 H, t, J 7.7, H-32, H-34), 5.68 (1 H, br d, J 5.2, H-6), 5.40  
(1 H, br s, H-1), 5.28-5.25 (1 H, m, H-3), 2.73 (1 H, br ddd, J 13.5, 5.6, 1.8, H-4a),  
2.58-2.54 (1 H, m, H-4b), 2.45 (1 H, br t, J 9.1, H-17), 2.38-2.35 (1 H, m, H-2a), 2.19-2.07 
(2 H, m, H-2b, H-16a), 2.05 (3 H, s, H-21), 2.05-2.03 (1 H, m, H-7a), 1.98-1.96 (1 H, m, 
H-12a), 1.68-1.32 (8 H, m, H-7b, H-8, H-9, H-11, H-12b, H-15a, H-16b), 1.14-1.09 (2 H, 
m, H-14, H-15b), 1.21 (3 H, s, H-19), 0.61 (3 H, s, H-18); δC (125 MHz, CDCl3) 209.4  
(C-20), 165.8 (C-22), 165.5 (C-29), 136.1 (C-5), 133.1 (C-26), 132.9 (C-33), 130.4 (C-23), 
130.2 (C-30), 129.7 (C-25, C-27), 129.5 (C-32, C-34), 128.6 (C-24, C-28), 128.3 (C-31,  
C-35), 125.2 (C-6), 74.9 (C-1), 70.3 (C-3), 63.5 (C-17), 56.7 (C-14), 43.9 (C-13), 42.3  
(C-10), 41.0 (C-9), 38.5 (C-12), 37.4 (C-4), 32.1 (C-2), 31.8 (C-21), 31.7 (C-7), 31.5 (C-8), 
24.8 (C-15), 22.7 (C-16), 20.9 (C-11), 19.5 (C-19), 13.3 (C-18); m/z (ESI) 563 [MNa]
+
. 
Calcd. for C35H40NaO5: 536.2768. Found: [MNa]
+
, 563.2779 (−1.9 ppm error).   
Lab. Book: LNB0170-089-02. 
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1-Hydroxy-3-pivaloyl 5-pregnen-20-one (207) 
 
 
 
 
 
 
To a solution of diol 61 (20.0 mg, 0.060 mmol, 1.0 eq.) in CH2Cl2 (0.5 mL) was added 
pyridine (24.2 L, 0.301 mmol, 5.0 eq.) and PvCl (16.3 μL, 0.132 mmol, 2.2 eq.) at 0 °C. 
The reaction was stirred at room temperature overnight, quenched with sat. aq. NaHCO3  
(2 mL) and extracted with EtOAc (5 mL). The organic phase was dried over Na2SO4, 
filtered and concentrated to dryness in vacuo. The crude residue was purified by column 
chromatography on silica gel (7:3 heptane/EtOAc) to afford the title compound 207  
(3.40 mg, 8.16 μmol, 14%) as an amorphous white solid: mp 222-225 °C decomposed;  
Rf 0.30 (1:1 heptane/EtOAc); [α]D
22 
24.7 (c 0.19, CHCl3); υmax/cm
-1
 (neat) 3383 (O-H 
stretch), 2923 (C-H stretch), 1723 (C=O stretch), 1700 (C=O stretch); δH (400 MHz, 
CDCl3) 5.60 (1 H, br d, J 5.1, H-6), 5.00-4.97 (1 H, m, H-3), 3.87 (1 H, br s, H-1), 2.53  
(1 H, t, J 9.1, H-17), 2.42 (1 H, ddd, J 13.4, 5.3, 1.7, H-4a), 2.31 (1 H, br dd, J 13.4, 12.8, 
H-4b), 2.20-2.15 (1 H, m, H-16a), 2.11 (3 H, s, H-21), 2.05-1.98 (3 H, m, H-2a, H-7a,  
H-12a), 1.83 (1 H, td, J 12.3, 1.8, H-2b), 1.70-1.41 (5 H, m, H-7b, H-9, H-11a, H-15a,  
H-16b), 1.32-1.17 (5 H, m, H-8, H-11b, H-12b, H-14, H-15b), 1.17 (9 H, s, H-24, H-25,  
H-26), 1.04 (3 H, s, H-19), 0.62 (3 H, s, H-18); δC (125 MHz, CDCl3) 209.6 (C-20), 178.3 
(C-22), 136.0 (C-5), 126.2 (C-6), 72.6 (C-1), 69.2 (C-3), 63.6 (C-17), 56.7 (C-14), 43.8  
(C-13), 41.8 (C-10), 41.4 (C-9), 38.5 (C-12), 38.1 (C-23), 37.2 (C-4), 34.0 (C-2), 31.7  
(C-7), 31.6 (C-21), 31.5 (C-8), 27.2 (C-24, C-25, C-26), 23.2 (C-15), 22.6 (C-16), 20.3  
(C-11), 19.4 (C-19), 13.2 (C-18); m/z (ESI) 439 [MNa]
+
. Calcd. for C26H40NaO4: 
439.2819. Found: [MNa]
+
, 439.2830 (−2.7 ppm error).   
Lab. Book: LNB0170-090-02. 
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3-Benzoyl-1-xo 5-pregnen-20-one (208) 
 
 
 
 
 
 
 
To a solution of alcohol 205 (13.6 mg, 0.031 mmol, 1.0 eq.) in CH2Cl2 (0.5 mL) was added 
DMP (39.6 mg, 0.094 mmol, 3.0 eq.). The reaction was stirred at room temperature 
overnight, quenched with 1 M aq. Na2CO3 (2 mL) and extracted with CH2Cl2 (5 mL). The 
organic phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo.  The 
crude residue was purified by column chromatography on silica gel (7:3 heptane/EtOAc) to 
afford the title compound 208 (4.36 mg, 0.010 mmol, 32%) as an amorphous white solid: 
mp 242-243 °C decomposed; Rf 0.40 (1:1 heptane/EtOAc); [α]D
23 
25.0 (c 0.28, CHCl3); 
υmax/cm
-1
 (neat) 2918 (C-H stretch), 1702 (C=O stretch), 1113 (C-O-C stretch); δH  
(400 MHz, CDCl3) 8.02 (2 H, d, J 7.2, H-24, H-28), 7.57 (1 H, t, J 7.4, H-26), 7.44 (2 H, t, 
J 7.7, H-25, H-27), 5.71 (1 H, br d, J 5.4, H-6), 5.21-5.13 (1 H, m, H-3), 2.86-2.76 (4 H, m, 
H-2, H-4), 2.56 (1 H, t, J 9.1, H-17), 2.13 (3 H, s, H-21), 2.03-2.00 (2 H, m, H-7a, H-12a), 
1.85-1.81 (1 H, m, H-16a), 1.72-1.44 (8 H, m, H-7b, H-8, H-9, H-11, H-12b, H-15a,  
H-16b), 1.28-1.21 (2 H, m, H-15b, H-14), 1.33 (3 H, s, H-19), 0.64 (3 H, s, H-18); δC  
(125 MHz, CDCl3) 210.1 (C-1), 209.5 (C-20), 165.7 (C-22), 134.5 (C-5), 133.3 (C-26), 
130.6 (C-23),  129.7 (C-25, C-27), 128.5 (C-24, C-28), 126.8 (C-6), 70.6 (C-3), 63.7  
(C-17), 58.6 (C-14), 52.8 (C-10), 44.1 (C-2), 44.0 (C-13), 42.7 (C-9), 38.7 (C-12), 37.4  
(C-4), 31.9 (C-21), 31.7 (C-8), 31.2 (C-7), 24.5 (C-15), 22.8 (C-16), 22.5 (C-11), 18.9  
(C-19), 13.5 (C-18); m/z (ESI) 457 [MNa]
+
. Calcd. For C28H34NaO4: 457.2349. Found: 
[MNa]
+
, 457.2351 (−0.3 ppm error).   
Lab. Book: LNB0170-097-02. 
 
 
 
 
 
 
 153 
 
3-Acetate-1-xo 5-pregnen-20-one (210) 
 
 
 
 
 
To a solution of alcohol 203 (50.0 mg, 0.134 mmol, 1.0 eq.) in CH2Cl2 (1.25 mL) was 
added DMP (113 mg, 0.267 mmol, 2.0 eq.). The reaction was stirred at room temperature 
overnight, quenched with 1 M aq. Na2CO3 (2 mL) and extracted with CH2Cl2 (5 mL). The 
organic phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo. The 
crude residue was purified by column chromatography on silica gel (7:3 heptane/EtOAc) to 
afford the title compound 210 (50 mg, 0.134 mmol, 100%) as an amorphous yellow solid: 
mp 146-150 °C decomposed (Lit.
138 
154-156 °C decomposed); Rf 0.45 (1:1 
heptane/EtOAc); [α]D
23 
65.6 (c 0.68, CHCl3) (Lit.
138
 [α]D
 
73.5, CHCl3); 2922 (C-H stretch), 
1739 (C=O stretch), 1703 (C=O stretch), 1032 (C-O-C stretch); δH (400 MHz, CDCl3) 
5.65 (1 H, br d, J 5.4, H-6), 4.92-4.86 (1 H, m, H-3), 2.73-2.61 (3 H, m, H-2, H-4a), 2.54 
(1 H, t, J 8.9, H-17), 2.50-2.47 (1 H, m, H-4b), 2.11 (3 H, s, H-21), 2.03 (3 H, s, H-23), 
2.02-1.98 (1 H, m, H-12a), 1.78 (1 H, dd, J 13.1, 3.4, H-16a), 1.70-1.41 (7 H, m, H-7a,  
H-8, H-9, H-11a, H-12b, H-15a, H-16b), 1.26 (3 H, s, H-19), 1.25-1.22 (4 H, m, H-7b,  
H-11b, H-14, H-15b), 0.62 (3 H, s, H-18); δC (125 MHz, CDCl3) 210.0 (C-1), 209.4  
(C-20), 170.1 (C-22), 134.4 (C-5), 126.5 (C-6), 70.0 (C-3), 63.6 (C-17), 56.7 (C-14), 52.7 
(C-10), 43.9 (C-2), 43.9 (C-13), 42.5 (C-9), 38.6 (C-12), 37.2 (C-4), 31.8 (C-8), 31.5  
(C-21), 31.0 (C-7), 24.4 (C-15), 22.7 (C-16), 22.4 (C-11), 21.1 (C-23), 18.7 (C-19), 13.3 
(C-18); m/z (ESI) 373 [MH]
+
. Calcd. for C23H33O4: 373.2373. Found: [MH]
+
, 373.2358 
(4.0 ppm error). Data consistent with those previously reported in the literature.
138
 
Lab. Book: LNB0170-100-03. 
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2,5-Pregnen-1,20-dione (209)  
 
 
 
 
 
To a solution of acetate 210 (17.6 mg, 0.047 mmol, 1.0 eq.) in benzene (0.5 mL) was 
added Al2O3 (120 mg, 1.18 mmol, 25.0 eq.) at room temperature. The reaction was heated 
at 55 °C, stirred for 5 h, filtered through Celite
®
 and washed with EtOAc (5 mL). The 
filtrate was concentrated to dryness in vacuo. The crude residue was purified by column 
chromatography on silica gel (7:3 heptane/EtOAc) to afford the title compound 209  
(14.0 mg, 0.045 mmol, 95%) as an amorphous white solid: mp 132-136 °C decomposed  
Rf 0.58 (1:1 heptane/EtOAc); [α]D
23 
27.5 (c 0.71, CHCl3); υmax/cm
-1
 (neat) 2965 (C-H 
stretch), 1701 (C=O stretch), 1682 (C=O stretch), 1665 (C=C stretch); δH (400 MHz, 
CDCl3) 6.78-6.75 (1 H, ddd, J  10.0, 4.9, 2.5, H-3), 5.87 (1 H, dd, J 10.0, 2.1, H-2), 5.56  
(1 H, br d, J 6.1, H-6), 3.27 (1 H, dd, J 21.4, 2.4, H-4a), 2.82 (1 H, dd, J 21.4, 4.9, H-4b), 
2.57 (1 H, t, J 9.2, H-17), 2.29 (1 H, dd, J 13.4, 3.1, H-16a), 2.19-2.15 (1 H, m, H-11a), 
2.12 (3 H, s, H-21), 2.03-1.95 (2 H, m, H-7a, H-12a), 1.72-1.41 (7 H, m, H-9, H-7b, H-8, 
H-11b, H-12b, H-15a, H-16b), 1.28-1.24 (2 H, m, H-14, H-15b), 1.22 (3 H, s, H-19), 0.63 
(3 H, s, H-18); δC (125 MHz, CDCl3) 209.6 (C-20), 204.4 (C-1), 145.2 (C-3), 135.9 (C-5), 
127.9 (C-2), 124.6 (C-6), 63.8 (C-17), 56.8 (C-14), 50.5 (C-10), 43.8 (C-13), 42.8 (C-9), 
38.9 (C-12), 33.5 (C-8), 33.2 (C-4), 31.6 (C-21), 30.7 (C-7), 24.5 (C-15), 23.7 (C-16), 22.5 
(C-11), 19.0 (C-19), 13.4 (C-18); m/z (ESI) 313 [MH]
+
. Calcd. for C21H29O2: 313.2162. 
Found: [MH]
+
, 313.2151 (3.5 ppm error).  
Lab. Book: LNB0170-114-01. 
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3,5-Pregnen-1,20-dione (211)  
 
 
 
 
 
To a solution of acetate 210 (14.3 mg, 0.038 mmol, 1.0 eq.) in CH2Cl2 (0.5 mL) was added 
DBN (9.49 L, 0.077 mmol, 2.0 eq.). The reaction was stirred at room temperature for  
40 min, quenched with sat. aq. NH4Cl (2 mL) and extracted with CH2Cl2 (5 mL).  
The organic phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo. 
The crude residue was purified by column chromatography on silica gel (7:3 
heptane/EtOAc) to afford the title compound 211 (10.7 mg, 0.034 mmol, 89%) and as an 
amorphous white solid: mp 150-153 °C decomposed; Rf 0.58 (1:1 heptane/EtOAc);  
[α]D
23 
90.9 (c 0.6, CHCl3); υmax/cm
-1
 (neat) 2930 (C-H stretch), 1721 (C=O stretch), 1702 
(C=O stretch), 1690 (C=C stretch); δH (400 MHz, CDCl3) 6.03 (1 H, br d, J 9.3, H-4), 
5.63 (1 H, dd, J 5.8, 2.3, H-6), 5.61-5.59 (1 H, m, H-3), 3.29 (1 H, br d, J 19.5, H-2a), 2.74 
(1 H, dd, J 19.8, 4.6, H-2b), 2.57 (1 H, t, J 9.2, H-17), 2.21-2.14 (2 H, m, H-7a, H-11a), 
2.12 (3 H, s, H-21), 1.98 (1 H, dt, J 12.2, 3.6, H-12a), 1.91-1.85 (1 H, m, H-11b), 1.82  
(1 H, dd, J 11.9, 4.0, H-9), 1.71-1.50 (5 H, m, H-7b, H-8, H-12b, H-15a, H-16a), 1.35  
(3 H, s, H-19), 1.34-1.32 (1 H, m, H-16b), 1.28-1.22 (2 H, m, H-14, H-15b), 0.63 (3 H, s, 
H-18); δC (125 MHz, CDCl3) 210.8 (C-20), 209.4 (C-1), 141.0 (C-5), 129.4 (C-4), 126.9 
(C-6), 121.6 (C-3), 63.7 (C-17), 56.7 (C-14), 52.1 (C-10), 44.1 (C-13), 40.9 (C-9), 39.8  
(C-2), 38.7 (C-12), 31.7 (C-8), 31.6 (C-21), 30.9 (C-7), 24.4 (C-15), 22.6 (C-16), 22.5  
(C-11), 20.4 (C-19), 13.4 (C-18); m/z (ESI) 313 [MH]
+
. Calcd. for C21H29O2: 313.2162. 
Found: [MH]
+
, 313.2153 (2.8 ppm error).  
Lab. Book: LNB0170-093-02. 
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3-Acetate-1,20R-bishydroxy-14,17-dideoxy-17-epi-withanolide F (22)35 
 
 
 
 
 
 
To a solution of triol 21 (100 mg, 0.218 mmol, 1.0 eq.) in CH2Cl2 (11 mL) was added NEt3 
(50% in CH2Cl2, 80.0 μL, 0.574 mmol, 2.6 eq.), Ac2O (74.9 μL, 0.792 mmol, 3.6 eq.) and 
DMAP (1.33 mg, 0.011 mmol, 0.05 eq.). The reaction was stirred at room temperature for 
6 h, quenched with 0.1 M aq. HCl (1 mL) and extracted with CH2Cl2 (10 mL). The organic 
phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo. The crude 
residue was purified by column chromatography on silica gel (2:8 heptane/EtOAc) to 
afford the title compound 22 (78.4 mg, 0.157 mmol, 72%) as an amorphous white solid: 
mp 144-147 °C decomposed (Lit.
25 
144-146 °C decomposed); Rf 0.63 (1:9 
heptane/EtOAc); [α]D
23 
5.3 (c 1.0, CHCl3) (Lit.
139
 [α]D
23 
6.9, c 0.44, CHCl3); υmax/cm
-1
 
(neat) 3481 (O-H stretch), 2928 (C-H stretch), 1709 (C=O stretch); δH (400 MHz, CDCl3) 
5.60 (1 H, br d, J 5.4, H-6), 5.05-4.99 (1 H, m, H-3), 4.21 (1 H, dd, J 13.3, 3.3, H-22), 3.85 
(1 H, s, H-1), 2.45-2.41 (1 H, m, H-23a), 2.37-2.30 (2 H, m, H-4), 2.13-2.00 (3 H, m,  
H-2a, H-12a, H-23b), 2.02 (3 H, s, H-30), 1.96-1.94 (1 H, m, H-16a), 1.94 (3 H, s, H-28), 
1.93-1.90 (1 H, m, H-7a), 1.87 (3 H, s, H-27), 1.65-1.40 (8 H, m, H-2b, H-7b, H-8, H-9,  
H-11a, H-15a, H-16b, H-17), 1.29-1.27 (1 H, m, H-12b), 1.28 (3 H, s, H-21), 1.08-1.05  
(3 H, m, H-11b,  H-14, H-15b), 1.03 (3 H, s, H-19), 0.87 (3 H, s, H-18); δC (125 MHz, 
CDCl3) 170.4 (C-29), 166.1 (C-26), 148.9 (C-24), 136.3 (C-5), 126.2 (C-6), 122.0 (C-25), 
81.0 (C-22), 75.2 (C-20), 72.5 (C-1), 69.4 (C-3), 56.6 (C-14), 54.6 (C-17), 43.0 (C-13), 
41.7 (C-10), 41.7 (C-9), 39.8 (C-12), 37.2 (C-4), 34.5 (C-2), 31.8 (C-7), 31.6 (C-23), 31.2 
(C-8), 23.9 (C-15), 21.9 (C-16), 21.4 (C-11), 20.9 (C-30), 20.5 (C-21), 20.1 (C-28), 19.3 
(C-19), 13.5 (C-18), 12.4 (C-27); m/z (ESI) 501 [MH]
+
. Calcd. for C30H45O6: 501.3211. 
Found: [MH]
+, 530.3218 (−1.6 ppm error). Data consistent with those previously reported 
in the literature.
25 
Lab. Book: LNB0170-133-03. 
 
 
 157 
 
 
 
 
 
 
 
Also isolated was -bisacetate-20R-hydroxy-14,17-dideoxy-17-epi-withanolide F 
(212) (19.8 mg, 0.037 mmol, 17%) as a white solid: mp 140-142 °C decomposed (Lit.
140 
135 °C decomposed); Rf 0.72 (1:9 heptane/EtOAc); [α]D
23 
16.2 (c 0.96, CHCl3) (Lit.
25
 
[α]D
25 
17.6, c 0.11, CHCl3); υmax/cm
-1
 (neat) 3489 (O-H stretch), 2941 (C-H stretch), 1713 
(C=O stretch); δH (400 MHz, CDCl3) 5.53 (1 H, br d, J 4.9, H-6), 5.05 (1 H, br s, H-3), 
4.93-4.89 (1 H, m, H-1), 4.21 (1 H, dd, J 13.3, 3.3, H-22), 2.46 (1 H, br ddd, J 13.4, 5.0, 
1.8, H-4a), 2.43-2.30 (3 H, m, H-4b, H-23), 2.11-2.06 (1 H, m, H-2a), 2.04 (3 H, s, H-30), 
2.02 (3 H, s, H-32), 1.95-1.93 (2 H, m, H-7a, H-12a), 1.93 (3 H, s, H-28), 1.88 (3 H, s,  
H-27), 1.63-1.29 (11 H, m, H-2b, H-7b, H-8, H-9, H-11, H-15, H-16, H-17), 1.28 (3 H, s, 
H-21), 1.19-1.11 (1 H, m, H-12b), 1.08 (3 H, s, H-19), 1.03-0.99 (1 H, m, H-14), 0.85  
(3 H, s, H-18); δC (125 MHz, CDCl3) 170.4 (C-31), 170.3 (C-29), 166.0 (C-26), 148.7  
(C-24), 136.1 (C-5), 125.0 (C-6), 122.0 (C-25), 80.9 (C-22), 75.1 (C-20), 74.6 (C-3), 69.3 
(C-1), 56.7 (C-14), 54.5 (C-17), 43.0 (C-13), 42.0 (C-10), 40.4 (C-9), 39.9 (C-12), 37.3  
(C-4), 31.9 (C-8), 31.6 (C-2), 31.5 (C-7), 31.1 (C-23), 23.8 (C-15), 21.9 (C-16), 21.3  
(C-32), 21.1 (C-30), 20.8 (C-21), 20.5 (C-11), 20.2 (C-28), 19.4 (C-19), 13.6 (C-18), 12.4 
(C-27); m/z (ESI) 565 [MNa]
+
. Calcd. for C32H46NaO6: 565.3136. Found: [MH]
+
, 
565.3142 (−1.1 ppm error). Data consistent with those previously reported in the 
literature.
25 
Lab. Book: LNB0170-133-02.
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3-Acetate20R-hydroxy-1-oxo-14,17-dideoxy-17-epi-withanolide F (23) 
  
 
 
 
 
 
To a solution of diol 22 (78.0 mg, 0.156 mmol, 1.0 eq.) in CH2Cl2 (1.5 mL) was added 
DMP (132 mg, 0.312 mmol, 2.0 eq.). The reaction was stirred at room temperature for 2 h, 
quenched with 1 M aq. Na2CO3 (5 mL) and extracted with CH2Cl2 (10 mL). The organic 
phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo. The crude 
residue was purified by column chromatography on silica gel (4:6 heptane/EtOAc) to 
afford the title compound 23 (65.0 mg, 0.130 mmol, 84%) as an amorphous yellow solid: 
mp 166-168 °C decomposed (Lit.
25 
169-171 °C decomposed); Rf 0.44 (1:1 
heptane/EtOAc); [α]D
23 
34.5 (c 1.0, CHCl3) (Lit.
25
 [α]D
  
29.8, c 0.13); υmax/cm
-1
 (neat) 3500 
(O-H stretch), 2927 (C-H stretch), 1708 (C=O stretch); δH (400 MHz, CDCl3) 5.63 (1 H, 
br d, J 5.1, H-6), 4.94-4.86 (1 H, m, H-3), 4.20 (1 H, dd, J 13.3, 3.3, H-22), 2.70 (1 H, dd,  
J 13.2, 6.3, H-2a), 2.69-2.60 (2 H, m, H-2b, H-4a), 2.49 (1 H, br dd, J 12.5, 11.7, H-4b), 
2.40 (1 H, br dd, J 16.0, 13.3, H-23a), 2.10 (1 H, dd, J 16.0, 3.3, H-23b), 2.05-2.03 (2 H, 
m, H-7a, H-12a), 2.03 (3 H, s, H-30), 1.94 (3 H, s, H-28), 1.88 (3 H, s, H-27), 1.70-1.44  
(7 H, m, H-7b, H-9, H-11a, H-15a, H-16, H-17), 1.35-1.32 (1 H, m, H-12b), 1.28 (3 H, s, 
H-21), 1.27 (3 H, s, H-19), 1.27-1.25 (1 H, m, H-8), 1.20-1.15 (1 H, m, H-15b), 1.08-1.03 
(2 H, m, H-11b, H-14), 0.88 (3 H, s, H-18); δC (125 MHz, CDCl3) 210.1 (C-1), 170.1  
(C-29), 165.9 (C-26), 148.8 (C-24), 134.4 (C-5), 126.5 (C-6), 122.0 (C-25), 81.0 (C-22), 
75.2 (C-20), 70.0 (C-3), 56.7 (C-14), 54.8 (C-17), 52.7 (C-10), 43.9 (C-2), 43.1 (C-9), 42.6 
(C-13), 39.9 (C-12), 37.2 (C-4), 31.8 (C-8), 31.6 (C-7), 31.1 (C-23), 23.8 (C-15), 21.9  
(C-16), 21.5 (C-30), 21.2 (C-11), 20.9 (C-21), 20.5 (C-28), 18.7 (C-19), 13.6 (C-18), 12.5 
(C-27); m/z (ESI) 521 [MNa]
+
. Calcd. for C30H42NaO6: 521.2874. Found: [MNa]
+
, 
521.2874 (−0.1 ppm error). Data consistent with those previously reported in the 
literature.
25 
Lab. Book: LNB0149-131-03. 
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14,17-Dideoxy--epi-withanolide F (24)89 
 
 
 
 
 
 
 To a solution of acetate 23 (40 mg, 0.080 mmol, 1.0 eq.) in benzene (1 mL) was added 
Al2O3 (205 mg, 2.01 mmol, 25.0 eq.). The reaction was stirred at 50 °C for 4 h, filtered 
through Celite
®
 and washed with EtOAc (10 mL). The filtrate was concentrated to dryness 
in vacuo. The crude residue was purified by column chromatography on silica gel (75:25 
heptane/EtOAc) to afford the title compound 24 (31.5 mg, 0.072 mmol, 90%) as an 
amorphous white solid: mp 194-195 °C decomposed; Rf 0.30 (6:4 heptane/EtOAc);  
[α]D
23 
18.6 (c 1.0, CHCl3) (Lit.
40
 [α]D
20 
34.0, c 0.0053, CHCl3); UV λmax (MeOH) 222 nm 
(Lit.
40
 UV λmax (MeOH) 218 nm); υmax/cm
-1
 (neat) 3463 (O-H stretch), 2926 (C-H stretch), 
1705 (C=O stretch), 1682 (C=O stretch), 1666 (C=C stretch); δH (400 MHz, CDCl3) 6.75 
(1 H, ddd, J  9.9, 4.6, 3.0, H-3), 5.87 (1 H, dd, J 9.9, 3.0, H-2), 5.55 (1 H, br d, J 6.1, H-6), 
4.20 (1 H, dd, J 13.4, 3.3, H-22), 3.27 (1 H, dd, J 21.4, 3.0, H-4a), 2.85 (1 H, dd, J 21.4, 
4.6, H-4b), 2.39 (1 H, br dd, J 15.6, 15.0, H-23a), 2.18 (1 H, br dd, J 13.1, 3.4, H-11a), 
2.11 (1 H, br dd, J 17.4, 2.8, H-23b), 2.04 (1 H, br d, J 12.8, H-12a), 1.98-1.95 (2 H, m,  
H-7a, H-16a), 1.97 (3 H, s, H-28), 1.87 (3 H, s, H-27), 1.64-1.34 (8 H, m, H-7b, H-8, H-9, 
H-11b, H-12b, H-15a, H-16b, H-17), 1.29 (3 H, s, H-21), 1.21 (3 H, s, H-19), 1.17-1.04  
(2 H, m, H-14, H-15b), 0.89 (3 H, s, H-18); δC (125 MHz, CDCl3) 204.4 (C-1), 166.0  
(C-26), 148.8 (C-24), 145.1 (C-3), 135.9 (C-5), 127.9 (C-2), 124.7 (C-6), 122.0 (C-25), 
81.0 (C-22), 75.2 (C-20), 56.7 (C-14), 54.7 (C-17), 50.5 (C-10), 42.9 (C-13), 42.8 (C-9), 
40.2 (C-12), 33.5 (C-4), 32.6 (C-8), 31.6 (C-23), 30.7 (C-7), 23.9 (C-15), 23.4 (C-11), 21.8 
(C-16), 21.0 (C-21), 20.5 (C-28), 19.0 (C-19), 13.6 (C-18), 12.4 (C-27); m/z (ESI) 461 
[MNa]
+
. Calcd. for C28H38NaO4: 461.2662. Found: [MNa]
+, 461.2666 (−0.7 ppm error). 
Data consistent with those previously reported in the literature.
40 
Lab. Book: LNB0170-138-02. 



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3,4-Dihydro-Δ3,4-14,17-dideoxy-epi-withanolide F (213) 
 
 
 
 
 
 
To a solution of 2,5-dienone 24 (20.0 mg, 0.046 mmol, 1.0 eq.) in CH2Cl2 (0.5 mL) was 
added DBN (11.3 μL, 0.091 mmol, 2.0 eq.). The reaction was stirred at room temperature 
for 3 h, quenched with sat. aq. NH4Cl (2 mL) and extracted with CH2Cl2 (5 mL). The 
organic phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo. The 
crude residue was purified by column chromatography on silica gel (75:25 heptane/EtOAc) 
to afford the title compound 213 (19.5 mg, 0.044 mmol, 98%) as an amorphous white 
solid: mp 215-218 °C decomposed; Rf 0.30 (6:4 heptane/EtOAc); [α]D
23 
64.4 (c 0.5, 
CHCl3); UV λmax (MeOH) 225 nm; υmax/cm
-1
 (neat) 3483 (O-H stretch), 2942 (C-H 
stretch), 1713 (C=O stretch), 1660 (C=C stretch); δH (400 MHz, CDCl3) 6.03 (1 H, d,  
J 9.2, H-4), 5.63 (1 H, br d, J 3.1, H-6), 5.60-5.58 (1 H, m, H-3), 4.20 (1 H, dd, J 13.4, 3.7, 
H-22), 3.28 (1 H, br d, J 19.5, H-2a), 2.73 (1 H, dd, J 19.5, 4.3, H-2b), 2.43-2.36 (1 H, m, 
H-23a), 2.16-2.10 (3 H, m, H-7a, H-23b), 2.04-2.00 (1 H, m, H-12a), 1.95 (3 H, s, H-28), 
1.88 (3 H, s, H-27), 1.81-1.38 (10 H, m, H-7b, H-8, H-9, H-11, H-12b, H-15a, H-16,  
H-17), 1.35 (3 H, s, H-19), 1.30 (3 H, s, H-21), 1.15-1.09 (2 H, m, H-14, H-15b), 0.90  
(3 H, s, H-18); δC (125 MHz, CDCl3) 209.3 (C-1), 166.5 (C-26), 149.2 (C-24), 141.5  
(C-5), 129.7 (C-4), 127.4 (C-6), 122.2 (C-25), 122.0 (C-3), 80.6 (C-22), 75.4 (C-20), 57.0 
(C-14), 55.0 (C-17), 52.7 (C-10), 43.3 (C-13), 41.1 (C-9), 40.1 (C-12), 39.6 (C-2), 31.6  
(C-7), 31.1 (C-8), 30.9 (C-23), 23.8 (C-15), 22.3 (C-11), 21.8 (C-16), 21.4 (C-19), 20.9  
(C-28), 20.6 (C-21), 14.3 (C-18), 12.8 (C-27); m/z (ESI) 461 [MNa]
+
. Calcd. for 
C28H38NaO4: 461.2662. Found: [MNa]
+, 461.2663 (−0.0 ppm error). 
Lab. Book: LNB0170-157-02. 
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,20R-Bishydroxy--tetrahydropyranyloxy-14,17-dideoxy-17-epi-withanolide F 
(217)
 
 
 
 
 
 
 
To a solution of triol 21 (38.8 mg, 0.085 mmol, 1.0 eq.) in CH2Cl2 (2.5 mL) was added 
DHP (5.76 μL, 0.064 mmol, 0.75 eq.) and p-TsOH (cat.) at 0 °C. The reaction was stirred 
for 3 h, quenched with sat. aq. NaHCO3 (3 mL) and extracted with CH2Cl2 (10 mL). The 
organic phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo. The 
crude residue was purified by column chromatography on silica gel (7:3 heptane/EtOAc) to 
afford the title compound 217 (26.0 mg, 0.048 mmol, 57%) as an inseparable mixture of 
two diastereoisomers at C-29 in a 1:1 ratio and as an amorphous white solid: Rf 0.19 (1:1 
heptane/EtOAc); δH (400 MHz, CDCl3) 5.58 (1 H, br d, J 6.1, H-6), 4.68 (1 H, br d,  
J 12.7, H-29), 4.21 (1 H, dd, J 13.2, 2.9, H-22), 3.99-3.94 (1 H, m, H-3), 3.91-3.88 (1 H, 
m, H-33a), 3.83-3.80 (1 H, m, H-1), 3.51-3.46 (1 H, m, H-33b), 2.44-2.25 (4 H, m, H-2a, 
H-4, H-23a), 2.12-1.98 (4 H, m, H-2b, H-7a, H-12a, H-23b), 1.94 (3 H, s, H-28), 1.87  
(3 H, s, H-27), 1.85-1.32 (17 H, m, H-7b, H-8, H-9, H-11, H-12b, H-15, H-16, H-17, H-30, 
H-31, H-32), 1.27 (3 H, s, H-21), 1.09-1.04 (1 H, m, H-14), 1.02 (3 H, s, H-19), 0.86 (3 H, 
s, H-18); δC (125 MHz, CDCl3) 166.5 (C-26), 148.5 (C-24), 137.8 (C-5), 125.6 (C-6), 
121.6 (C-25), 97.3 (C-29), 81.1 (C-22), 75.2 (C-20), 73.1 (C-1), 70.9 (C-3), 63.1 (C-33), 
57.3 (C-14), 54.9 (C-17), 43.3 (C-13), 41.8 (C-10), 41.6 (C-9), 39.8 (C-12), 39.6 (C-2), 
37.5 (C-4), 31.5 (C-7), 31.3 (C-8), 31.2 (C-30, C-31, C-32), 31.1 (C-23), 24.4 (C-15), 22.1 
(C-16), 21.4 (C-28), 21.1 (C-21), 20.5 (C-11), 19.3 (C-19), 13.9 (C-18), 12.9 (C-27);  
m/z (ESI) 565 [MNa]
+
. Calcd. for C33H50NaO6: 565.3500. Found: [MNa]
+
, 565.3502  
(−0.5 ppm error). 
Lab. Book: LNB0189-002-04. 
 
 
 
 
 162 
 
 
 
 
 
 
 
Also isolated was α-bistetrahydropyranyloxy-20R-hydroxy-14,17-dideoxy-17-epi-
withanolide F (218) (9.05 mg, 0.014 mmol, 19%) as an inseparable mixture of four 
diastereoisomers at C-29 and C-34 and as an amorphous white solid: Rf 0.49 (1:1 
heptane/EtOAc); δH (400 MHz, CDCl3) 5.45 (1 H, br d, J 5.3, H-6), 4.72-4.56 (4 H, m,  
H-29, H-29*, H-34, H-34*), 4.19 (1 H, dd, J 13.2, 3.0, H-22), 4.07-3.99 (1 H, m, H-3), 
3.92-3.81 (5 H, m, H-3, H-33a, H-33a*, H-38a,  H-38a*), 3.78 (1 H, br s, H-1), 3.64 (1 H, 
br s, H-1*), 3.52-3.43 (4 H, m, H-33b, H-33b*, H-38b, H-38b*), 2.42-2.36 (3 H, m, H-2a, 
H-4a, H-23a), 2.25-2.18 (2 H, m, H-2b, H-4b), 2.13-2.10 (1 H, m, H-23b), 2.04-2.02 (1 H, 
m, H-12a), 1.92 (3 H, s, H-28), 1.90-1.88 (1 H, m, H-7a), 1.86 (3 H, s, H-27), 1.80-1.30 
(23 H, m, H-7b, H-8, H-9, H-11, H-12b, H-15, H-16, H-17, H-30, H-31, H-32, H-35, H-36, 
H-37), 1.27 (3 H, s, H-21), 1.09-1.04 (1 H, m, H-14), 1.00 (3 H, s, H-19*), 0.97 (3 H, s,  
H-19), 0.86 (3 H, s, H-18); δC (125 MHz, CDCl3) 166.7 (C-26), 148.8 (C-24), 138.2  
(C-5), 123.4 (C-6), 122.2 (C-25), 101.1 (C-29), 98.3 (C-29*), 96.2 (C-34), 95.1 (C-34*), 
81.8 (C-1), 80.7 (C-22), 76.2 (C-1*), 75.7 (C-20), 71.7 (C-3), 70.6 (C-3*), 62.5 (C-33,  
C-33*), 61.7 (C-38, C-38*), 56.8 (C-14), 54.3 (C-17), 43.4 (C-13), 42.8 (C-10), 41.2 (C-9), 
40.0 (C-12), 39.5 (C-2), 39.3 (C-4), 32.1-30.1 (C-30, C-31, C-32, C-35, C-36, C-37), 31.5 
(C-7), 31.2 (C-8), 31.1 (C-23), 24.5 (C-15), 22.2 (C-16), 21.4 (C-21), 21.0 (C-28), 20.4  
(C-11), 20.3 (C-19*), 19.3 (C-19), 13.9 (C-18), 12.7 (C-27); m/z (ESI) 649 [MNa]
+
. Calcd. 
for C38H58NaO7: 649.4075. Found: [MNa]
+, 649.4076 (−0.3 ppm error). *: signal of other 
diastereoisomers.
 
Lab. Book: LNB0170-158-02. 
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-Tetrahydropyranyl-20R-hydroxy--oxo-14,17-dideoxy-17-epi-withanolide F (219) 
 
 
 
 
 
 
To a solution of hydroxyl 217 (27.0 mg, 0.050 mmol, 1.0 eq.) in CH2Cl2 (1 mL) was added 
DMP (42.2 mg, 0.100 mmol, 2.0 eq.). The reaction was stirred at room temperature 
overnight, quenched with 1 M aq. Na2CO3 (2 mL) and extracted with CH2Cl2 (5 mL).  
The organic phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo. 
The crude residue was purified by column chromatography on silica gel (75:25 
heptane/EtOAc) to afford the title compound 219 (16.4 mg, 0.030 mmol, 61%) as an 
inseparable mixture of two diastereoisomers at C-29 in a 1:1 ratio and as an amorphous 
white solid: Rf 0.58 (1:1 heptane/EtOAc); δH (400 MHz, CDCl3) 5.59 (1 H, br d, J 5.6,  
H-6), 4.72 (1 H, br s, H-29), 4.63 (1 H, br s, H-29*), 4.20 (1 H, dd, J 13.3, 3.0, H-22), 
3.89-3.84 (1 H, m, H-33a), 3.83-3.77 (1 H, m, H-3), 3.49-3.46 (1 H, m, H-33b), 2.83-2.78 
(1 H, m, H-2a), 2.72-2.52 (3 H, m, H-2b, H-4), 2.43-2.37 (1 H, m, H-23a), 2.16-1.99 (3 H, 
m, H-7a, H-12a, H-23b), 1.94 (3 H, s, H-28), 1.87 (3 H, s, H-27), 1.81-1.32 (17 H, m,  
H-7b, H-8, H-9, H-11, H-12b, H-15, H-16, H-17, H-30, H-31, H-32), 1.28 (6 H, s, H-19, 
H-21), 1.09-1.03 (1 H, m, H-14), 0.87 (3 H, s, H-18); δC (125 MHz, CDCl3) 210.7 (C-1), 
166.0 (C-26), 148.8 (C-24), 135.1 (C-5), 125.9 (C-6), 122.0 (C-25), 97.2 (C-29, C-29*), 
81.0 (C-22), 75.2 (C-20), 73.1 (C-3), 62.5 (C-33), 56.7 (C-14), 54.7 (C-17), 52.6 (C-10), 
46.4 (C-2), 43.1 (C-13), 42.4 (C-9), 40.0 (C-12), 38.2 (C-4), 31.6 (C-8), 31.4 (C-30), 31.3  
(C-32), 31.1 (C-23), 31.0 (C-7), 29.7 (C-31), 23.9 (C-15), 21.9 (C-16), 21.0 (C-11), 20.5 
(C-28), 19.4 (C-19, C-21), 13.6 (C-18), 12.5 (C-27); m/z (ESI) 563 [MNa]
+
. Calcd. for 
C33H48NaO6: 563.3343. Found: [MNa]
+, 563.3358 (−2.6 ppm error). *: signal of other 
diastereoisomers.
 
Lab. Book: LNB0170-160-02. 
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20R-Dihydroxy--oxo-14,17-dideoxy-17-epi-withanolide F (220)29 
 
 
 
 
 
 
To a solution of THP protected alcohol 219 (15.6 mg, 0.029 mmol, 1.0 eq.) in MeOH  
(0.5 mL) was added 2 M aq. HCl (0.1 mL). The reaction was stirred at room temperature 
for 1 h, quenched with sat. aq. NaHCO3 (2 mL) and extracted with EtOAc (5 mL). The 
organic phase was dried over Na2SO4, filtered and concentrated to dryness in vacuo. The 
crude residue was purified by column chromatography on silica gel (7:3 heptane/EtOAc) to 
afford the title compound 220 (14.0 mg, 0.031 mmol, 100%) as an amorphous pale pink 
solid: mp 184-187 °C decomposed (Lit.
29 
189-190 °C decomposed); Rf 0.55 (9:1 
heptane/EtOAc); [α]D
23 
25.6 (c 0.28, CHCl3) (Lit.
25
 [α]D
24 
30.0, c 0.13, CHCl3); υmax/cm
-1
 
(neat) 3429 (O-H stretch), 2981 (C-H stretch), 1709 (C=O stretch); δH (400 MHz, CDCl3) 
5.60 (1 H, br d, J 4.4, H-6), 4.19 (1 H, dd, J 13.2, 2.9, H-22), 3.85-3.82 (1 H, m, H-3), 
2.73-2.70 (1 H, m, H-2a), 2.63 (1 H, dd, J 12.4, 5.3, H-2b), 2.54-2.50 (2 H, m, H-4),  
2.43-2.37 (1 H, m, H-23a), 2.10 (1 H, br d, J 15.9, H-23b), 1.99-1.96 (2 H, m, H-7a,  
H-12a), 1.94 (3 H, s, H-28), 1.87 (3 H, s, H-27), 1.62-1.31 (10 H, m, H-7b, H-8, H-9,  
H-11, H-12b, H-15a, H-16, H-17), 1.30 (3 H, s, H-19), 1.29 (3 H, s, H-21), 1.19-1.15 (1 H, 
m, H-15b), 1.08-1.02 (1 H, m, H-14), 0.87 (3 H, s, H-18); δC (125 MHz, CDCl3) 210.6  
(C-1), 166.1 (C-26), 148.9 (C-24), 135.1 (C-5), 126.0 (C-6), 122.0 (C-25), 81.0 (C-22), 
75.2 (C-20), 69.1 (C-3), 56.6 (C-14), 54.5 (C-17), 52.4 (C-10), 48.0 (C-2), 43.1 (C-13), 
42.4 (C-9), 41.2 (C-4), 39.9 (C-12), 31.6 (C-7), 31.3 (C-23), 31.1 (C-8), 23.9 (C-15), 22.3 
(C-16), 21.8 (C-21), 20.9 (C-28), 20.5 (C-11), 19.3 (C-19), 13.7 (C-18), 12.5 (C-27);  
m/z (ESI) 479 [MNa]
+
. Calcd. for C28H40NaO5: 479.2768. Found: [MNa]
+
, 479.2759  
(1.9 ppm error). Data consistent with those previously reported in the literature.
29 
Lab. Book: LNB0189-001-01. 
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6.2.4. Chapter 5. Methodology towards the construction of δ-lactones 
Methallyl sulfide (243)
108 
 
 
 
 
To a solution of Na2S (2.00 g, 8.33 mmol, 1.0 eq.) in MeOH/H2O (1:1, 11.0 mL) was 
added 3-chloro-2-methylpropene (243) (2.04 mL, 0.021 mol, 2.5 eq.) and the solution was 
vigorously stirred at room temperature for 1 h. The reaction mixture was stirred overnight 
at reflux temperature, quenched with sat. aq. NH4Cl (10 mL) and extracted with Et2O  
(10 mL). The organic phase was adjusted to pH 7 by washing with H2O (5 × 5 mL), dried 
over MgSO4, filtered and concentrated in vacuo to give the title compound 244 (1.19 g, 
8.37 mmol, 100%) as a colourless liquid which required no further purification: Rf 0.73 
(100% PE); δH (400 MHz, CDCl3) 4.87-4.85 (2 H, m, H-7a, H-8a), 4.82-4.80 (2 H, m,  
H-7b, H-8b), 3.04-3.02 (4 H, m, H-3, H-4), 1.83-1.80 (6 H, m, H-1, H-6); δC (100 MHz, 
CDCl3) 141.1 (C-2, C-5), 113.5 (C-7, C-8), 38.0 (C-3, C-4), 20.9 (C-1, C-6); m/z (ESI) 
143 [MH]
+
. Calcd. for C8H15S: 143.0889 Found: [MH]
+, 143.0898 (−6.3 ppm error). Data 
consistent with those previously reported in the literature.
110
 
Lab. Book: LNB0107-139-01. 
 
Methallyl sulfoxide (246)
110 
 
 
 
 
To a solution of methallyl sulfide 244 (119 mg, 0.838 mmol, 1.0 eq.) in glacial acetic acid 
(1.4 mL) was added dropwise H2O2 (30% w/w, 0.150 mL, 5.02 mmol, 6.0 eq.) at 0 °C and 
the reaction mixture was stirred overnight. Upon completion of the reaction, the reaction 
mixture was quenched with sat. aq. NaHCO3 (2 mL) and diluted with CH2Cl2 (2 mL). The 
organic layer was washed with sat. aq. NaHCO3 (2 mL), dried over MgSO4, filtered and 
concentrated to dryness in vacuo. The crude residue was purified by column 
chromatography on silica gel (7:3 PE/EtOAc) to afford the title compound 246 (61.2 mg, 
0.387 mmol, 46%) as colorless crystals: mp 25 °C decomposed (Lit.
110 
rt decomposed);  
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Rf 0.43 (7:3 PE/EtOAc); υmax/cm
-1
 (neat) 2973 (C-H stretch), 1650 (C=C stretch), 1378 
(CH3 bend), 1035 (S=O stretch); δH (400 MHz, CDCl3) 5.12-5.09 (2 H, m, H-7a, H-8a), 
5.03 (2 H, br s, H-7b, H-8b), 3.46-3.38 (4 H, m, H-3, H-4), 1.91-1.89 (6 H, m, H-1, H-6);  
δC (100 MHz, CDCl3) 135.8 (C-2, C-5), 118.4 (C-7, C-8), 61.5 (C-3, C-4), 23.0 (C-1,  
C-6); m/z (ESI) 159 [MH]
+
. Calcd. for C8H15OS: 159.0838. Found: [MH]
+
, 159.0837  
(0.5 ppm error). Data consistent with those previously reported in the literature.
110
 
Lab. Book: LNB0107-131-02. 
 
Methallyl sulfone (245)
108 
 
 
 
 
 
To a solution of methallyl sulfide 244 (1.19 g, 8.38 mmol, 1.0 eq.) in CH2Cl2 (10 mL) was 
added m-CPBA (4.34 g, 25.1 mmol, 3.0 eq.) portionwise over 1 h at 0 °C and stirred 
vigorously for 1 h. The reaction mixture was warmed to room temperature over 4 h, diluted 
with Et2O (20 mL) and quenched with sat. aq. Na2S2O4 (10 mL). The organic phase was 
washed with sat. aq. Na2S2O4 (5 × 10 mL) and with sat. aq. NaHCO3 (2 × 10 mL).  
The organic layer was dried over MgSO4, filtered and concentrated to dryness in vacuo. 
The crude residue was purified by column chromatography on silica gel (9:1 to 7:3 
PE/EtOAc) to afford the title compound 245 (1.18 g, 6.77 mmol, 81%) as a white 
amorphous solid: mp 29-31 °C decomposed (Lit.
110 
32 °C decomposed); Rf 0.66 (7:3 
PE/EtOAc); υmax/cm
-1
 (neat) 1405 (CH3 bend), 1304 (S=O stretch), 1118 (S=O stretch), 
820 (CH2 bend); δH (400 MHz, CDCl3) 5.24-5.22 (2 H, m, H-7a, H-8a), 5.10 (2 H, br s, 
H-7b, H-8b), 3.71 (4 H, s, H-3, H-4), 1.98-196 (6 H, m, H-1, H-6); δC (100 MHz, CDCl3) 
133.7 (C-2, C-5), 120.7 (C-7, C-8), 59.8 (C-3, C-4), 22.7 (C-1, C-6); m/z (ESI) 175 
[MH]
+
. Calcd. for C8H15O2S: 175.0787. Found: [MH]
+, 175.0789 (−1.1 ppm error). Data 
consistent with those previously reported in the literature.
110 
Lab. Book: LNB0107-141-02. 
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3,4-Dimethyl-2,5-dihydrothiophene-1,1-dioxide (240)
109 
 
 
 
 
 
To a solution of sulfone 245 (1.00 g, 5.74 mmol, 1.0 eq.) in degassed CH2Cl2 (40 mL) was 
added Grubbs second generation catalyst (388 mg, 0.459 mmol, 0.08 eq.) portionwise  
(4 × 2 mol% over 4 h, i.e. 97.2 mg added per hour). The reaction mixture was stirred 
overnight at reflux temperature, cooled to room temperature and concentrated to dryness in 
vacuo. The crude residue was purified by column chromatography on silica gel (95:5 to 7:3 
heptane/EtOAc) to afford the title compound 240 (851 mg, 5.82 mmol, 100%) as a grey 
amorphous solid: mp 109-113 °C decomposed (Lit.
141 
135 °C decomposed); Rf 0.38 (7:3 
PE/EtOAc); υmax/cm
-1
 (neat) 1404 (CH3 bend), 1289 (S=O stretch), 1107 (S=O stretch), 
719 (CH2 bend); δH (400 MHz, CDCl3) 3.73 (4 H, s, H-1, H-4), 1.78 (6 H, s, H-5, H-6);  
δC (100 MHz, CDCl3) 125.9 (C-2, C-3), 61.0 (C-4, C-1), 14.9 (C-5, C-6); m/z (ESI) 169 
[MNa]
+
. Calcd. for C6H10NaO2S: 169.0294. Found: [MNa]
+
, 169.0293 (0.3 ppm error). 
Data consistent with those previously reported in the literature.
110 
Lab. Book: LNB0149-067-03. 
 
 
3,4-Di(bromomethylene)-2,5-dihydrothiophene-1,1-dioxide (241)
106 
 
 
 
 
 
To a solution of cyclic sulfone 240 (67.0 mg, 0.458 mmol, 1.0 eq.) in chlorobenzene  
(0.48 mL) was added NBS (130 mg, 0.733 mmol, 1.6 eq.) and benzoyl peroxide (1:1 with 
plasticiser dicyclo phthalate, 11.1 mg, 0.023 mmol, 0.05 eq.). The reaction mixture was 
stirred at reflux overnight, cooled to room temperature, diluted with CH2Cl2 (5 mL) and 
concentrated to dryness in vacuo. The crude residue was purified by column 
chromatography on silica gel (9:1 to 8:2 PE/EtOAc) to afford the title compound 241  
(19.5 mg, 0.065 mmol, 14%) as a brown amorphous solid: mp 115-118 °C decomposed 
 168 
 
(Lit.
142 
118-120 °C decomposed); Rf 0.31 (7:3 PE/EtOAc); δH (400 MHz, CDCl3) 4.08  
(4 H, br s, H-5, H-6), 4.02 (4 H, br s, H-1, H-4); δC (100 MHz, CDCl3) 131.6 (C-2, C-3), 
58.8 (C-1, C-4), 24.3 (C-5, C-6); m/z (ESI) 302 [MH]
+
. Calcd. for C6H9
79
Br
79
BrO2S: 
302.8685. Found: [MH]
+, 302.8695 (−3.3 ppm error). Data consistent with those 
previously reported in the literature.
142 
Lab. Book: LNB0149-012-03. 
 
Further elution gave 3-bromomethylene-4-methyl-2,5-dihydrothiophene-1,1-dioxide (242) 
(29.8 mg, 0.133 mmol, 29%) as a brown amorphous solid. 
  
3-Bromomethylene-4-methyl-2,5-dihydrothiophene-1,1-dioxide (242)
106 
 
 
 
 
 
To a solution of cyclic sulfone 240 (100 mg, 0.680 mmol, 1.0 eq.) in CCl4 (2.5 mL) was 
added NBS (181.6 mg, 1.02 mmol, 1.5 eq.) and benzoyl peroxide (1:1 with plasticiser 
dicyclo phthalate, 8.30 mg, 0.034 mmol, 0.05 eq.). The reaction mixture was stirred at 
reflux overnight, cooled to room temperature, diluted with CH2Cl2 (10 mL) and quenched 
with H2O (10 mL). The aqueous layer was further extracted with CH2Cl2 (2 × 10 mL), the 
organic phase was washed with brine (10 mL), dried over Na2SO4, filtered and 
concentrated to dryness in vacuo to give the title compound 242 as a mixture with cyclic 
sulfone in a 6:1 ratio which was used without further purification: mp 83-85 °C 
decomposed (Lit.
107 
81-82 °C decomposed); Rf 0.29 (7:3 PE/EtOAc); υmax/cm
-1
 (neat) 
1380 (CH3 bend), 1289 (S=O stretch), 1108 (S=O stretch), 823 (CH2 bend), 564 (C-Br 
stretch); δH (400 MHz, CDCl3) 4.06 (2 H, br s, H-6), 3.95-3.93 (2 H, m, H-4), 3.84-3.82  
(2 H, m, H-1), 1.90 (3 H, s, H-5); δC (100 MHz, CDCl3) 131.9 (C-2), 126.6 (C-3), 61.2  
(C-1), 58.0 (C-4), 26.0 (C-6), 14.9 (C-5); m/z (ESI) 246 [MNa]
+
. Calcd. for 
C6H9
79
BrNaO2S: 246.9399. Found: [MNa]
+
, 246.9382 (6.9 ppm error). Data consistent 
with those previously reported in the literature.
107
 
Lab. Book: LNB0149-012-04/05. 
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3-Hydroxymethylene-4-methyl-2,5-dihydrothiophene-1,1-dioxide (256) 
 
 
 
 
 
To a solution of CF3CO2Ag (42.9 mg, 0.194 mmol, 2.0 eq.) in H2O (0.350 mL) was added 
mono-brominated compound 242 (21.8 mg, 0.097 mmol, 1.0 eq.). The reaction mixture 
was stirred at room temperature overnight. The reaction mixture was filtered through a 
PVC filter (0.45 μm), washed with EtOAC (3 mL) and the filtrate was concentrated to 
dryness in vacuo. The crude residue was purified by column chromatography on silica gel 
(2:8 heptane/EtOAc) to afford the title compound 256 (16.2 mg, 0.100 mmol, 100%) as a 
yellow oil: Rf 0.20 (2:8 heptane/EtOAc); υmax/cm
-1
 (neat) 3490 (O-H stretch), 1407 (CH3 
bend), 1294 (S=O stretch), 1253 (C=O stretch), 1160 (S=O stretch); δH (400 MHz, CDCl3) 
4.31 (2 H, br s, H-6), 3.92 (2 H, br s, H-4), 3.78 (2 H, br s, H-1), 1.84 (3 H, br s, H-5);  
δC (125 MHz, CDCl3) 128.4 (C-3), 126.6 (C-2), 60.9 (C-1), 58.3 (C-6), 57.6 (C-4), 14.7 
(C-5); m/z (ESI) 185 [MNa]
+
. Calcd. for C6H10NaO3S: 185.0243. Found: [MNa]
+
, 
185.0242 (0.6 ppm error).  
Lab. Book: LNB0149-074-03. 
 
3-Formyl-4-methyl-2,5-dihydrothiophene-1,1-dioxide (253)
 
 
 
 
 
 
To a solution of allylic alcohol 256 (10.9 mg, 0.067 mmol, 1.0 eq.) in CH2Cl2 (0.5 mL) 
was added DMP (57.0 mg, 0.134 mmol, 2.0 eq.). The reaction mixture was stirred at room 
temperature overnight, filtered through Celite
®
 and washed with Et2O (5 mL). The filtrate 
was concentrated to dryness in vacuo. The crude residue was purified by column 
chromatography on silica gel (2:3 heptane/EtOAc) to afford the title compound 253  
(5.30 mg, 0.033 mmol, 49%) as a yellow solid: mp 106-108 °C decomposed; Rf 0.31 (2:8 
heptane/EtOAc); δH (400 MHz, CDCl3) 10.1 (1 H, s, H-6), 4.03 (2 H, br s, H-4), 3.99  
 170 
 
(2 H, br s, H-1), 2.33 (3 H, br s, H-5); δC (125 MHz, CDCl3) 184.9 (C-6), 149.4 (C-2), 
131.8 (C-3), 62.5 (C-1), 54.7 (C-4), 15.1 (C-5); m/z (ESI) 183 [MNa]
+
. Calcd. for 
C6H8NaO3S: 183.0086. Found: [MNa]
+
, 183.0078 (4.5 ppm error).  
Lab. Book: LNB0189-003-02. 
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Appendix I. X-Ray Crystallography Data 
 
1-Epoxy-20,20-ethylenedioxypregn-4,6-dien-3-one (91) (CCDC 983154) 
 
 
 
Identification code   rjkt1311a 
Empirical formula   C23H30O4 
Formula weight    370.47 
Temperature/K    110.00(14) 
Crystal system    monoclinic 
Space group    C2 
a/Ǻ, b/Ǻ, c/Ǻ    19.5214(8), 7.3857(2), 28.3837(11) 
α/°, β/°, γ/°     90.00, 109.574(5), 90.00 
Volume/Ǻ3     3855.8(3) 
Z      8 
ρcalcmg/mm
3   
 1.276 
m/mm
-1
     0.086 
F(000)     1600.0 
Crystal size/mm
3
    0.2645 × 0.1023 × 0.0675 
2Θ range for data collection  5.94 to 56.28° 
Index ranges    −19 ≤ h ≤ 25, −5 ≤ k ≤ 9, −35 ≤ l ≤ 21 
Reflections collected   7868 
Independent reflections  5739[R(int) = 0.0227] 
Data/restraints/parameters  5739/1/493 
Goodness-of-fit on F
2
   1.091 
Final R indexes [I>=2σ (I)]  R1 = 0.0494, wR2 = 0.1195 
Final R indexes [all data]  R1 = 0.0569, wR2 = 0.1245 
Largest diff. peak/ hole/ e Ǻ-3 0.30/−0.25 
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1-Dihydroxy-5-pregnen-20-one (61) (CCDC 983153) 
 
 
 
Identification code   rjkt1310 
Empirical formula   C21H32O3 
Formula weight    332.47 
Temperature/K    110.05(10) 
Crystal system    tetragonal 
Space group    P43212 
a/Ǻ, b/Ǻ, c/Ǻ    11.48385(11), 11.48385(11), 27.9202(4) 
α/°, β/°, γ/°     90.00, 90.00, 90.00 
Volume/Ǻ3     3682.08(7) 
Z      8 
ρcalcmg/mm
3   
 1.199 
m/mm
-1
     0.078 
F(000)     1456.0 
Crystal size/mm
3
    0.3692 × 0.2032 × 0.1302 
2Θ range for data collection  5.8 to 64.16° 
Index ranges    −15 ≤ h ≤ 15, −16 ≤ k ≤ 13, −41 ≤ l ≤ 41 
Reflections collected   18861 
Independent reflections  5919[R(int) = 0.0343] 
Data/restraints/parameters  5919/0/228 
Goodness-of-fit on F
2
   1.095 
Final R indexes [I>=2σ (I)]  R1 = 0.0443, wR2 = 0.1142 
Final R indexes [all data]  R1 = 0.0501, wR2 = 0.1175 
Largest diff. peak/ hole/ e Ǻ-3 0.42/−0.20 
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(20R)-20-Dithiane-3β,20R-bismethoxymethylenoxypregn-5-ene (117) (CCDC 983152) 
 
 
 
Identification code   rjkt1208 
Empirical formula   C29H48O4S2 
Formula weight    524.79 
Temperature/K    110.00(10) 
Crystal system    orthorhombic 
Space group    P212121 
a/Ǻ, b/Ǻ, c/Ǻ    6.79761(16), 9.1752(3), 45.2097(12) 
α/°, β/°, γ/°     90.00, 90.00, 90.00 
Volume/Ǻ3     2819.71(14) 
Z      4 
ρcalcmg/mm
3   
 1.236 
m/mm
-1
     0.221 
F(000)     1144.0 
Crystal size/mm
3 
   0.3417 × 0.2004 × 0.0263 
2Θ range for data collection  6.06 to 60.06° 
Index ranges    −9 ≤ h ≤ 9, −8 ≤ k ≤ 12, −35 ≤ l ≤ 63 
Reflections collected   13133 
Independent reflections  8139[R(int) = 0.0474] 
Data/restraints/parameters  8139/36/321 
Goodness-of-fit on F
2
   1.146 
Final R indexes [I>=2σ (I)]  R1 = 0.1145, wR2 = 0.2431 
Final R indexes [all data]  R1 = 0.1211, wR2 = 0.2463 
Largest diff. peak/ hole/ e Ǻ-3 1.30/−0.86 
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Appendix II. nOe Spectra for 1α,3α-Dihydroxy-5-
Pregnen-20-One (102) 
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Appendix III. 
1
H- and 
13
C-NMR Spectra for  
14,17-Dideoxy-17-Epi-Withanolide F (24) 
 
1
H-NMR spectrum of 14,17-dideoxy-17-epi-withanolide F (24) 
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13
C-NMR spectrum of 14,17-dideoxy-17-epi-withanolide F (24) 
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Appendix IV. 
1
H- and 
13
C-NMR Spectra for  
3,4-Dihydro-Δ3,4-14,17-Dideoxy-17-Epi-Withanolide 
F (213) 
 
1
H-NMR spectrum of 3,4-dihydro-Δ3,4-14,17-dideoxy-17-epi-withanolide F (213) 
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13
C-NMR spectrum of 3,4-dihydro-Δ3,4-14,17-dideoxy-17-epi-withanolide F (213) 
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Abbreviations 
 
The following abbreviations are used within the dissertation: 
Ac    Acetyl 
AcOH   Acetic acid 
ADP    Allyl diethyl phosphate 
aq.    Aqueous 
br    Broad 
brsm    Based on recovered starting material 
Bz    Benzoyl 
Bu    Butyl 
°C    Degrees Celsius 
cat.    Catalytic 
CCDC   Cambridge Crystallographic Data Centre 
COSY   COrrelated SpectroscopY 
δ    Chemical shift  
d    Day  
d    Doublet 
dba    Dibenzylideneacetone 
DBDMH   Dibromodimethylhydantoin 
DBN    1,5-Diazabicyclo[4.3.0]non-5-ene 
DBU    1,8-Diazabicyclo[5.4.0]undec-7-ene 
DDQ    2,3-Dichloro-5,6-dicyano-p-benzoquinone 
DHP    Dihydropyran 
DIPEA   N,N-diisopropylethylamine 
DMAP   4-Dimethylaminopyridine 
DME   Dimethylether or Dimethoxyethane 
DMF   N,N-Dimethylformamide 
DMP   Dess-Martin periodinane 
DMPU   1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
DMSO   Dimethyl sulfoxide 
E    Entgegen, trans 
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E1CB    Unimolecular conjugate base elimination 
E2    Bimolecular elimination  
e.e.    Enantiomeric excess 
eq.    Equivalent 
ESI    Electrospray ionisation 
Et    Ethyl 
g    Gram(s) 
Glc    Glucose 
h    Hour(s) 
Hh    Hedgehog 
HMBC   Heteronuclear Multiple Bond Correlation 
HMPA   Hexamethylphosphoramide 
HRMS   High Resolution Mass Spectrometry 
HSQC   Heteronuclear Single Quantum Coherence 
HWE   Horner-Wadsworth-Emmons 
Hz    Hertz 
i    iso 
IBX    2-Iodoxybenzoic acid 
IC50    Half maximal Inhibition Concentration 
IR    Infra-red (spectroscopy) 
IUPAC   International Union of Pure and Applied Chemistry 
J    Coupling constant in Hertz 
LDA    Lithium diisopropylamide 
LiCHA   Lithium isopropyl cyclohexylamide 
LiHMDS   Lithium hexamethyldisilazane 
Lit.    Literature 
m    meta 
m    Multiplet 
M    Molarity 
m-CPBA   3-Chloroperbenzoic acid 
Me    Methyl  
mg    Milligram(s) 
MHz    Mega Hertz 
min    Minute(s) 
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mL    Milliliter(s) 
mmol   Millimole(s) 
mp    Melting point 
MPO   4-Methoxypyridine-N-oxide 
mol    Mole(s) 
MOM   Methoxymethyl ether 
Ms    Methanesulfonyl  
m/z    Mass to charge ratio 
n    Normal 
NBS    N-Bromosuccinimide 
NCS    N-Chlorosuccinimide 
nm    Nanometre 
NMO   N-Methylmorpholine N-oxide 
NMP   N-Methyl-2-pyrrolidone 
NMR   Nuclear magnetic resonance 
nOe    Nuclear Overhauser effect 
o/n    Overnight 
p    para 
PCC    Pyridinium chlorochromate  
Pd/C    Palladium on carbon 
PDC    Pyridinium dichromate 
PE    Petroleum Ether (40 - 60 °C) 
Ph    Phenyl 
PIDA   (Diacetoxyiodo)benzene 
PPh3    Triphenylphosphine 
ppm    Parts per million 
Pr    Propyl 
Pv    Pivaloyl 
p-TsOH   p-Toluenesulfonic acid 
RCM   Ring-closing metathesis 
Rf    Retention factor 
rsm    Recovered starting material 
rt    Room temperature 
s    Singlet 
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s    sec 
sat.    Saturated 
t    tert 
TBAF   Tributylammonium fluoride 
TBD    Triazabicyclodecene 
TBDMS   tert-Butyldimethylsilyl 
TBS    tert-Butyldimethylsilyl  
TBSOTf   tert-Butyldimethylsilyl- trifluoromethane sulfonate 
Tf    Trifluoromethanesulfonyl 
TFAA   Trifluoroacetic anhydride 
Tf2O    Trifluoromethanesulfonic anhydride 
THF    Tetrahydrofuran 
THP    Tetrahydropyran 
TLC    Thin Layer Chromatography 
TMSI   Trimethylsilyliodide 
(TMS)2NH  Bis(trimethylsilyl)amine 
TPAP   Tetrapropylammonium perruthenate 
TPP    meso-tetraphenylporphyrin 
Triton B   Benzyltrimethylammonium hydroxide 
Ts    Toluenesulfonyl                                      
p-TsOH.H2O  p-Toluenesulfonic acid monohydrate 
UV    Ultra-Violet 
υ    Wavenumbers 
w/w    Weight per weight 
Z    Zusammen, cis 
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